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Overview of Thesis 
 
Significant cardiovascular morbidity and mortality exists in chronic obstructive 
pulmonary disease independent of traditional risk factors.  A number of different 
hypotheses exist to explain this association including the contribution arterial stiffness 
and lung hyperinflation.  
  
Non-invasive cardiovascular imaging and assessment are ideal methods through 
which this relationship can be further studied although a number of the techniques 
have yet to be validated in COPD.   In this thesis we aimed to achieve a number of 
goals.  First, we aimed to assess the reproducibility and level of agreement between 
different measures of arterial stiffness in stable hyperinflated COPD.  Second, we 
hoped to establish the utility of 3 different measurement techniques for measuring 
intrinsic cardiac function in stable hyperinflated COPD. Third, in a case-control study 
we compared surrogates of cardiovascular risk in hyperinflated COPD patients and a 
group matched for cardiovascular risk with normal lung function.  Finally, we sought 
to understand the impact of pharmacologically reducing lung hyperinflation on 
cardiovascular structure, function and arterial stiffness. 
 
We have firstly demonstrated that non-invasive measures of arterial stiffness are 
reproducible in stable hyperinflated COPD. Secondly, we have established the level 
of agreement and reproducibility of three different CMR techniques for measuring 
intrinsic myocardial function which will provide important information for the powering 
of future CMR studies in COPD.  Thirdly, we have shown that surrogates for 
cardiovascular outcomes are adversely affected in COPD compared to a group 
matched for global cardiovascular risk, suggesting that current scoring systems may 
be suboptimal in risk prediction in COPD.  Finally, we have demonstrated that 
pharmacological lung deflation has consistent and physiologically plausible beneficial 
effects on cardiac structure, function and the pulmonary vasculature. Whether 
intrinsic myocardial function can be modulated through prolonged periods of lung 
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Chapter One:  
Chronic obstructive pulmonary disease 
 
An estimated 3 million people have chronic obstructive pulmonary disease (COPD) in 
the UK.  The prevalence of an abnormal forced expiratory volume in 1 second 
(FEV1), the hallmark of COPD, is approximately 9% in primary care.  About 900,000 
have a confirmed diagnosis of COPD, whereas an estimated 2 million people have 
COPD which remains undiagnosed.
2
 The true mortality of COPD is difficult to 
ascertain for a number of reasons: some die with the disease rather than because of 
it whereas others are misclassified at the time of death, dying of causes related to 
COPD but certified as being as a result of these associated complications.  Despite 
this COPD is the third largest cause of respiratory death in the UK, accounting for 
30,000 (23%) of respiratory deaths.
3, 4
  Furthermore COPD patients have an increase 
in all cause mortality, highlighting the co-morbid nature of the condition.
5, 6
  In men, 
age standardised mortality rates from COPD have fallen progressively since the 




Pathogenesis and pathophysiology 
 
Cigarette smoking is implicated in the pathogenesis of COPD in 90% of cases, 
although a significant genetic component also exists since only 15-20% of heavy 
smokers develop COPD.
8
  The term COPD historically has principally encompassed 
two conditions, chronic bronchitis and emphysema.   
 
Chronic bronchitis can be defined clinically based on sputum production: The 
presence of chronic cough and sputum production on most days for a minimum of 3 
months a year for two successive years.  Mucus hypersecretion takes place in the 
central airways and contributes, along with remodelling of the central airways as a 




However emphysema is based on radiological or histopathological findings and is 
characterised by irreversible damage to lung parenchyma and vasculature. 
Emphysema can be conveniently classified into 2 types, depending on how the 
acinus is destroyed: a) The most common form in smokers, centriacinar 
 21 
(centrilobular) emphysema which is characterised by focal destruction of the 
bronchioles and central portions of the acinus and surrounded by grossly normal lung 
parenchyma and b) panacinar (panlobular) emphysema in which the whole acinus is 




Pathologically, biopsy and broncho-alveolar lavage studies have found the 
predominant finding is parenchymal infiltration by CD8-lymphocytes and 
polymorphonuclear cells with destruction of the normal architecture of alveolar 
spaces and thickening of submucosal glands with intact epithelium.
11, 12
  Induced 
sputum studies confirm a predominance of neutrophils within the airways, although 
eosinophils are present in a significant proportion of patients, particularly at 
exacerbation.
9, 13-16




Figure 1 Schematic representation of the different types of emphysema in relation to the acinar 
architecture of the lung. TB: Terminal bronchiole; RB1–3: respiratory bronchioles; AD: alveolar duct; 
AS: alveolar sacs. a Normal acinus; b Centriacinar emphysema, in which the respiratory bronchioles are 
predominantly involved, whereas alveolar ducts and sacs are still normal; c Panacinar emphysema in 
which there is destructive enlargement of all air spaces distal to the terminal bronchiole and the acinus 
is more or less uniformly involved. (reproduced with permission from Turato et al
10
, published in 
Respiration by S. Karger AG) 
 
Expiratory flow limitation in the presence of airflow obstruction is a hallmark of 
COPD.  Most accepted definitions of COPD define airflow obstruction as a ratio of 
less than 70% of the FEV1 to Forced vital capacity (FVC).  Patients are said to be 
flow limited when the expiratory flow they generate during tidal respiration represents 
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the maximal possible flows that they can generate at that lung volume. Expiratory 
flow limitation can be characterised by FEV1 and is one method by which the severity 
of COPD is defined (Table 1).   
 
Table 1 Gradation of severity of airflow obstruction (adapted from Nice guidelines 20102)  
  NICE 2004 ATS/ERS 
2004 






Severity of airflow obstruction 
   Post Bronchodilator 

















Up until the most recent Global initiative for chronic lung diseases (GOLD) 
guidelines, COPD was staged exclusively based on the extent of airflow limitation 
and exacerbation frequency with pharmacological and non-pharmacological 
management largely being based on this. The dependency on FEV1 to stage the 
disease is problematic in that not all aspects of the disease are properly captured 
and large heterogeneity exists within the COPD population with respect to clinical 
course and the efficacy of interventions.  More recent guidelines have developed a 
more multi-dimensional approach, taking into account symptoms as well as exercise 
limitation, categorising patients into 4 groups A,B,C,D (see Figure 2).  Specifically, 
they recommend the employment of the Medical Research Council dyspnoea (MRC) 
score and the COPD assessment test (CAT) score, discussed in more detail below. 
The groups no longer represent a linear increase in severity since, when the MRC 
score is used as the measure of symptoms, the risk of hospitalisation and mortality 
are similar in groups B and D.  Furthermore, they do not differentiate active from 




Figure 2 Associations between symptoms, spirometric classification and risk of future 
exacerbations. CAT: COPD assessment test; mMRC: modified Medical Research Council score. 
Reprinted with permission of the American Thoracic Society. © 2015 American Thoracic Society. The 





An exacerbation of COPD is an acute event characterised by worsening of the 
patient’s respiratory symptoms that is beyond the normal day-to-day variations and 
leads to a change in medication.
17
  The manifestations of these exacerbations are 
highly variable reflecting the broad heterogeneity in the underlying pathophysiology 
of COPD as will be discussed below.  Exacerbations play a key role in the 
progression of COPD.  They accelerate the decline in lung function and impact on all 
cause mortality, which has been reported to be as high as 20% and 49% at 2 months 
and 2 years following an admission for hypercapnic respiratory failure.
18
   The impact 
on lung function, symptoms and health status persist beyond the index events; 
Seemungal and colleagues prospectively followed a cohort of 101 patients with 
moderate to severe COPD for 2.5 years.   At 35 days measures of lung function had 
returned to baseline in only 75.2% of subjects, with 14% remaining symptomatic.  At 




Prevention and early treatment play a vital role in maintaining health in COPD, where 




Dyspnoea: MRC score 
Dyspnoea is the most disabling symptom of COPD and is an important factor in the 
patient’s perception of the illness.  In the 1940’s Fletcher and co-workers devised a 
short questionnaire that allowed a numeric value to be placed on each person’s 
exercise capacity, first published in 1952.
22
  The scale is still employed today, 
consisting of a five-point scale based on the patient’s perception of dyspnoea while 
walking distances on the level or climbing.  It does not quantify breathlessness itself 
rather the disability of it.   There is good inter-observer agreement of up to 98% and it 
correlates well with other breathlessness and symptom scores, oxygen saturations, 
shuttle distance and measures of health related quality of life.
23-25
  The scale is 
sufficiently sensitive to establish a treatment response to long-acting bronchodilators 
and pulmonary rehabilitation.
26-28
  Furthermore, it predicts 5-year survival to a better 
extent than FEV1 in isolation and has been incorporated into a highly validated 




Symptom score: CAT 
The CAT test was introduced and first validated in 2009 as a simple short, patient-
completed instrument to assess symptoms and quality of life in patients with COPD.  
It comprises 8 questions, each scored between 0-5, giving a total maximum score of 
40.  Scores of 0-10, 11-20, 21-30 and 31-40 represent mild, moderate, severe and 
very severe clinical impact.  It has been shown to have good internal consistency and 
reliability.
31, 32
  It correlates well with other more established questionnaires such as 
the COPD specific St. Georges Respiratory Questionnaire (SGRQ) in the stable 
state.  Furthermore, it can differentiate between the stable and exacerbating state, 
can differentiate mild from severe exacerbations and is sufficiently sensitive to 
identify improvements post exacerbation and post pulmonary rehabilitation in the 
short term where it correlates with Chronic Respiratory Questionnaire (CRQ) and 
SGRQ.
33-35
  It shows similar changes than the more complex SGRQ and therefore 







Inhaled pharmacological treatment of COPD  
 
Inhaled bronchodilators 
Inhaled long-acting bronchodilators are central to the management of COPD and 
have been shown in large randomised controlled trials (TORCH, UPLIFT, POET, 
INSPIRE) to be effective at reducing symptoms and preventing further 
exacerbations.
17, 37-40
  Furthermore, subgroup analyses of TORCH and UPLIFT have 
shown that as well as those with severe disease this also applies to those with 
moderate disease.
41, 42
 Both long acting β2-agonists (LABA) and long-acting 
muscarinic antagonists (LAMAs) are available in once daily and twice-daily forms, 
with newer combinations presently in development.  Both classes act by relaxing 
airway smooth muscle tone. LABAs stimulate β2-adrenergic receptors and provide 
functional antagonism to bronchoconstriction, whereas LAMAs prevent acetylcholine 
binding to muscarinic receptors that are involved in smooth muscle contractions.
43
 
Evidence indicates that once daily LABA and LAMAs have superior bronchodilation 
properties and clinical efficacy.  An example of a once daily LABA or “ultra-LABA”, 
the first to be licensed in the UK, is Indacaterol.  It has shown to be efficacious 
versus placebo, and other twice-daily LABAs.  
 
Inhaled corticosteroids (ICS) and fixed dose combination inhalers  
The mechanism of action of inhaled corticosteroids is discussed on page 53 (Effects 
of inhaled COPD Therapies). Early studies looking at ICS in COPD showed no 
beneficial effect, although the studies contained small numbers of participants and 
were of short duration. The ICS in Obstructive Lung Disease in Europe (ISOLDE) 
study was the first large long-term, randomised, double-blind, placebo-controlled 
clinical trial that evaluated the effect of long term ICS on lung function, exacerbations, 
and health status in 751 patients with moderate-to-severe COPD which reported 
significant reduction in the median exacerbation rate by about 25%. A post-hoc 
analysis of ISOLDE suggested that this effect was seen predominantly in those 
patients with severe COPD (FEV1 <50%).  However, ICS reduced the percentage of 
patients who had more than one exacerbation per year, indicating that ICS are 
effective in patients with mild COPD and frequent exacerbations.
44
   
 
A number of studies have looked at fixed dose combinations (LABA and ICS) in 
 26 
COPD. TRISTAN revealed that all active treatment arms (ICS/LABA and individual 
components) improved lung function, symptoms, and health status and reduced use 
of rescue medication and frequency of exacerbations compared to placebo, however 
combination therapy with fluticasone/salmeterol proved significantly more effective 
than salmeterol alone.
45
 The TORCH study published in 2007 is the largest COPD 
trial of pharmacotherapy to-date. It randomised a total of 6112 COPD patients at 444 
centers in 42 countries and investigated the effects of fixed dose ICS/LABA and its 
components with placebo on mortality, lung function, exacerbations and quality of life 
for a period of 3 years. Patients in the ICS/LABA group demonstrated reduced 
annual rate of exacerbations (0.85 95% CI 0.80, 0.90) compared to placebo (1.13 
95% CI, 1.07, 1.20). The resulted rate ratio for exacerbations was 0.75 (95% CI, 
0.69, 0.81; P<0.001), depicting a 25% reduction compared to placebo that 
corresponded to a number needed to treat of four to prevent one exacerbation in 1 
year.  As discussed above a post-hoc analysis by Jenkins et al supported the notion 
that those patients with milder disease may also benefit from inhaled 
corticosteroids.
41
  Further evidence can be found in a recent Cochrane review and a 
meta-analysis on ICS and COPD where long-term use of ICS was found to 
significantly reduce the mean rate of exacerbations.
46, 47
  
Concerns persist related to adverse events.  Of particular concern is the number of 
the larger randomised controlled trials that report an increase risk of pneumonia, 
findings that have been confirmed in subsequent meta-analyses and Cochrane 
reviews.
26, 37, 39, 48, 49
  Furthermore, a nested case control study involving 163,514 
patients with COPD after adjustment for covariates has demonstrated that the use of 
ICS is associated with a 69% increase in the rate of serious pneumonia (RR 1.69; 
95% CI 1.63, 1.75), which disappeared within a few months of stopping the therapy. 
Despite this, international guidelines continue to recommend treatment with an 
inhaled corticosteroid (ICS) on top of long-acting bronchodilators for severe/very 
severe chronic obstructive pulmonary disease (COPD) patients with a history of 
recurrent exacerbations. A number of different ultra-LABAS are now in development, 






Fluticasone Furoate/Vilanterol (FF/VI) 
One such example is Fluticasone Furoate/Vilanterol (FF/VI). Vilanterol (VI) is an 
inhaled LABA with 24-hour activity. Fluticasone furoate (FF) is an enhanced-affinity 
ICS with a pharmacologic profile that demonstrates greater retention in the lung and 
longer duration of action than fluticasone propionate (FP).
50, 51
 In dose-ranging phase 
II studies it has shown to be effective in providing rapid and sustained improvement 
in FEV1 in subjects with moderate to severe COPD with improvements in weighted 
mean FEV1 of 173-214 ml and trough FEV1 115 - 144 ml respectively over 24 weeks. 
52, 53
 Further phase III studies have confirmed its effects are maintained throughout 
the 24-hour dosing period.
54
  It appears safe in renal impairment, with no clinically 
relevant effects on pharmacokinetic, pharmacodynamics properties or tolerability of 
FF/VI.  A 4-week study with safety among its primary endpoints has demonstrated 
that this therapy vs. placebo has no significant effects on heart rate, QTc interval, 
premature beats, ventricular ectopics or blood pressure.   However, in patients with 
moderate to severe hepatic impairment there is a suggestion of increased systemic 




The complexity of COPD 
 
 The Global initiative for chronic lung diseases (GOLD) guidelines 2011 define COPD 
as a “common preventable and treatable disease, characterised by persistent airflow 
limitation that is usually progressive and associated with an enhanced chronic 
inflammatory response in the airways and the lung to noxious particles or gases”.
17
 
This definition is broad and as a result can be broadly applied to most people with 
COPD.  However, it does not expose the complexity of the condition, which is made 
up of a number of different clinical phenotypes.  The document does however 
attempt to make a fuller, more rounded assessment of the individual compared to 
previous documents. Prior to this, it has been argued that guideline development for 
COPD has been an oversimplification of a complex reality.
56
  The one treatment fits 
all attitude led to the selection of pharmacological treatment based exclusively on the 
severity of airflow obstruction and was proposed as early as the 2001 GOLD 
guideline.   There has been a paradigm shift in this most recent document proposing 
treatment guided by severity of symptoms and exercise capacity (as assessed by the 
MRC scale and CAT score discussed above), the risk of poor outcomes (assessed 
by airflow obstruction and frequency of exacerbations) in a 3-dimensional evaluation.  
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It has become evident that not all people respond in the same way to particular 
treatments irrespective of the above subdivisions, leading to the development of the 




The term “clinical phenotype” has recently been proposed:
57
 “A single or combination 
of disease attributes that describe differences between individuals as they relate to 
clinically meaningful outcomes,  (symptoms, exacerbations, response to therapy, rate 
of disease progression, or death)”.  This definition emphasises two key aspects:  the 
attributes that define the clinical phenotype cannot occur in all patients with the 
disease of interest since they have to identify a subgroup of patients that differ in 
their prognosis or therapeutic needs; and the phenotype has to relate to clinically 
meaningful outcomes.  Therefore any potential clinical phenotype must be validated 
longitudinally and prior to this these phenotypic traits should be considered mere 
descriptors of disease complexity.
58
  Examples in COPD include the frequent 
exacerbator phenotype, defined as two or more exacerbations per year based on the 
findings of the ECLIPSE study, due to the potential for therapeutic interventions and 







A further example of a clinical phenotype is lung hyperinflation, often associated with 
emphysema, and which can develop to varying degrees as a consequence of 
expiratory flow limitation (EFL).  It impacts on mortality, was a predictor of 
exacerbations in the COPD Gene Study and the recent Spanish guidelines for COPD 
have acknowledged that these patients should follow a different treatment algorithm 




Assessment of lung volumes and the development of lung hyperinflation 
Lung volumes can be divided into several compartments defined by the normal cycle 
of tidal breathing and the maximum capacity to inhale and exhale.  During relaxed 
tidal breathing the lung tends to return to a basal level of inflation, which is termed 
the functional residual capacity (FRC) or end expiratory lung volume (EELV), which 
in normal lungs represents the point at which the outward recoil of the chest wall 
equals the inward recoil of the lungs.
65
  Once this value is known all other values can 
be determined from spirometry including the total lung capacity (TLC; the maximum 
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volume of air that can be inhaled), the residual volume (RVol; volume of air remaining 
at the end of complete exhalation) and inspiratory capacity (IC; The difference 
between EELV and TLC - see Figure 3 and Box 1).   
 
Figure 3 Diagram of lung volumes ERV: expiratory reserve volume; FRC: functional residual capacity; 
IC: inspiratory capacity; IRV: inspiratory reserve volume; RVol: residual volume TLC: total lung capacity; 
VT: tidal volume 
 
Most COPD patients have some degree of lung hyperinflation, although this can 
remain undetected.  Destruction of elastic tissue associated with emphysema alters 
the elastic recoil of the lung, adjusting the pressure volume of the curve so that a 
given lung volume produces less lung recoil than in healthy lung.  Hence, the 
reduced lung recoil requires a greater volume to balance the chest wall recoil and 
over time this results in lung over-inflation, termed static lung hyperinflation.
65
   Static 
lung hyperinflation increases functional residual capacity, RVol and TLC.   
 
Cosio et al in 1978 first demonstrated that the RVol, reflecting early airway closure, is 
the first parameter to increase, followed by FRC and eventually TLC.
66
  In this 4-year 
follow-up study they found no change in FEV1 or FEV1/FVC, most probably as a 
result of increases in TLC that allowed VC to remain the same or increase and 
prevented the fall in FEV1.   As the disease progresses airway narrowing, as a result 
of vagal tone, inflammation, mucus plugging and early collapse, causes a reduction 
in the time available for complete lung emptying during spontaneous breathing and 
insufficient lung emptying. This results in increases in (RVol) relative to the TLC with 
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a resultant fall in FEV1 and FVC.   The primary event therefore is gas trapping, the 
extent of which is a continuous variable, determined by expiratory flow limitation and 




Measuring lung hyperinflation 
The measurement of Total Lung Capacity (TLC) and its subdivisions provide detailed 
information concerning the functional status of the lung and are determined by its 
elastic properties.  The value is mainly estimated through the use of 
plethysmographic and helium dilution techniques, although more recently the use of 
CT has also been employed.  Significant differences in the measurement of TLC 
exist between these methods.
69
  Regarding CT assessment is made at maximal 
inspiration in the supine position, which is not the case for other techniques.
70
  
Measurement at full inspiration is also in conflict with the clinical definition of lung 
hyperinflation which implies an abnormal increase in the volume of gas in the lungs 





Important differences also exist between helium dilution and plethysmography.  Over-
estimation of lung volumes can occur during plethysmography when breathing 
frequencies greater than 2 Hz are employed, an error which has been shown to be 
corrected for if frequencies of less than 1 Hz are used.
72-75
  In patients with significant 
airflow obstruction and poorly communicating areas of lung, helium dilution will result 
in underestimation of lung volumes owing to the helium not mixing with gas trapped 
in these under-ventilated areas.
76
  Thus body plethysmography is considered the 
best modality for assessing patients with airflow obstruction for estimating the FRC, 
known as the thoracic gas volume TGV when calculated by this technique.  The 
resulting TGV is combined with measurements of inspiratory capacity (IC) and slow 
vital capacity (SVC) to derive values for lung hyperinflation (see page 31) . 
 
Indices used for estimating lung hyperinflation include TLC, RVol and the ratio of 
RVol/TLC.  There is no consensus as to which value is the most robust although in 
COPD TLC varies as a function of the prevalent phenotype (it is increased in 
emphysema and often normal in chronic bronchitis) and it has been shown that RVol 
and RVol/TLC were more sensitive than TLC to the degree of airway obstruction.
77
  
Furthermore, a recent study by Deesomchok et al found that the RVol was increased 
in mild, moderate, and severe obstruction, and the greatest change in percent of 
predicted values following bronchodilators, as well as the largest frequency of a 
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positive response post bronchodilators, was seen in RVol.
78
  Although there has 
been renewed interest in inspiratory capacity (IC) as a surrogate for hyperinflation, 
predominantly due to the ease at which it can be measured from simple spirometry, 
RVol is still presently considered to be the best way to evaluate therapies aimed at 
reducing air-trapping
79
.  Despite suggestions in some reviews that the current RVol 
cut-off for hyperinflation of > 120% predicted of normal actually sits within the normal 
range of some individuals, they base this on unpublished personal communications 
which have not been the subject of peer review.
79
  Accordingly for the purposes of 
this thesis we will consider an RVol value of >120% predicted as the cut-off to define 
lung hyperinflation.  
 






Slow vital capacity (SVC) 
The maximum volume of gas which can be expired from the lungs during relaxed 
expiration from a position of full inspiration. 
Inspiratory capacity (IC) 
The maximum volume of gas which can be inspired from functional residual capacity. 
Thoracic gas volume (TGV) 
The volume of gas in the thorax at the end of tidal breathing. 
 
These can be used to derive the following parameters: 
Total lung capacity (TLC) = TGV + IC (highest value) 
The volume of gas in the lungs and airways at full inspiration. 
Residual volume (RVOL) = TLC-SVC (highest value) 
The volume of gas in the lungs and airways at full expiration 
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Clinical implications of lung hyperinflation  
Lung hyperinflation has significant clinical implications.  In lung hyperinflation tidal 
breathing takes place at a position closer to TLC.  As a consequence, breathing 
takes place on a flatter part of the lung compliance curve, where progressive 
pressure increases generate smaller incremental volume changes - greater effort is 
required for a given change in volume.  Furthermore, as a result of expiratory flow 
limitation, intrapulmonary pressures are positive at the end of expiration, termed 
intrinsic end expiratory pressure, which essentially acts as an inspiratory threshold 
load that must be overcome on top of the inward recoil of the lung before inspiration 
can occur.  This has been measured to be as much as 6-9cm of H20 during quiet 
breathing in clinically stable hyperinflated COPD patients, and as a result of these 
mechanical limitations on ventilation work of breathing is increased.
80, 81
 Activity 
related dyspnoea is one of the earliest symptoms of lung hyperinflation and may 
progress over time to incapacitating levels, particularly in situations where the 
ventilation system is under more stress such as during exercise or an exacerbation, 
and the drive breathe is increased but the ability of the respiratory system to respond 
is hindered (neuro-mechanical dissociation).
82, 83
  This has a major impact on the 
wellbeing of the patient where they develop symptoms of respiratory distress or 




As well as these mechanistic and symptomatic consequences, arguably most 
importantly it is predictive of mortality in clinical trials, whether assessed 
radiologically or by residual volume.
85
   It acts as a marker of disease progression, 
where it correlates with the extent of oxygen desaturation on exercise and limitations 




 Through quantitative CT there is 
evidence that extent of emphysema may identify those whose FEV1 may rapidly 
progress due to “active disease” despite having no significant airflow limitation at 
baseline.
88
 In a prospective study by Ozgur et al lasting 47 months, lung 
hyperinflation significantly correlated with emergency visits and hospital admissions, 
although only weakly.  This finding is further supported by a retrospective cohort 
study by Zaman et al where lung hyperinflation as measured by IC/TLC was able to 






Change in paradigm  
Spirometry has been used to physiologically stage the disease.   Following seminal 
work by Fletcher and Peto an accelerated decline in FEV1 has been universally 
accepted as the paradigm for the natural history of COPD. Subsequent to this it has 
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been shown that forced expiratory volume in 1s (FEV1) strongly predicts all-cause 
and cardiovascular mortality, the need for re-hospitalisation following an exacerbation 
and the likelihood for treatment failure or intensification of drug treatment
91-93
. 
However, its use as a surrogate is far from perfect.   FEV1 has a limited application in 
the assessment of response to bronchodilators or predicting other patient centred 
outcomes in terms of exercise ability or dyspnoea.
94-96
  For example, in the National 
Emphysema Treatment Trial (NETT), a multicentre prospective randomised 
controlled trial that compared optimal medical treatment versus optimal medical 
treatment plus lung volume reduction surgery, a FEV1 of 0.75 litres resulted in 
significant variation in maximum exercise capacity of between 10-80W and no 
meaningful relationship between FEV1 and six-minute walk distance was identified.
97
 
It has become clear that the development of air trapping and dynamic hyperinflation 
through the mechanisms described above play a key role in a number of these 
processes.  Paradigms have been proposed that focus on lung volumes rather than 
simple spirometry alone in the progression of the disease, thereby focussing 
therapeutic aims towards reducing air trapping, the primary event in the development 
















Figure 4: The natural history of chronic obstructive pulmonary disease, characterised by a 
progressive increase in gas trapping measured by a progressive increase in residual volume 
(RV). A lesser increase in total lung capacity (TLC) leads to a progressive decline in vital 
capacity (VC) imposing a reduction in forced expiratory volume in 1 s (FEV1). FRC: functional 
residual capacity; IC: inspiratory capacity. (Reproduced with permission of the European Respiratory 
Society © Eur Respir J March 2010 35:676-680; doi:10.1183/09031936.00120609
68
)   
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Pharmacological treatment of lung hyperinflation: Bronchodilator 
therapy 
Bronchodilator therapy is the mainstay of treatment for lung hyperinflation.  
Improvements in resting lung hyperinflation have been demonstrated in both short 
and longer term studies using all classes of bronchodilators.
98
  A retrospective study 
of lung function databases demonstrated that the measurement of lung volumes may 
expose improvements that are not uncovered by the standard measurement of FEV1, 
with up to 75% being responsive to bronchodilator therapy, the largest difference 
being seen in RVol.
99
  These findings have been replicated elsewhere:  Tantucci et al 
conducted a single dose study using salbutamol in moderate to severe COPD and 
demonstrated improvements in IC and FRC in flow limited COPD patients despite no 
change in FEV1.  O’Donnell et al have also demonstrated that plethysmography 
increases the sensitivity for identifying people that show bronchodilator response, 
that the RVol showed the greatest response and was most sensitive for detecting a 
significant reduction in air trapping, and that IC and VC underestimated changes in 
FRC and RVol respectively in 43% of patients due to small but consistent changes in 
the TLC.  A reduction in hyperinflation post bronchodilation in both these studies 
seems to depend to some extent on the presence of expiratory flow limitation.  
Expected changes in lung volumes post bronchodilator in those considered to have 
irreversible lung function on simple spirometry have been reported as 18+/-2, -10+/-
1, 8+/-1 % predicted for RVol, functional residual capacity (FRC), inspiratory capacity 
(IC) respectively.  Long-acting bronchodilators improve dyspnoea relative to placebo 
and provide equivalent improvements in lung hyperinflation-related exercise 





Figure 5: Proposal of pharmacological treatment COPD according to clinical phenotypes 
(Reproduced with permission of the European Respiratory Society © Eur Respir J June 2013 41:1252-




Improvements in milder disease 
Improvements in lung hyperinflation are not confined to the moderately severe end of 
the spectrum.  Anticholinergic bronchodilation has also shown to have beneficial 
effects in patients with airflow obstruction and preserved FRC, IC and post-
bronchodilator FEV1.  Inhaled bronchodilation was associated with consistent 
improvements in forced expiratory flow rates, specific airways resistance and RVol, 
although to a lesser extent than the more severe patients.
102
  These findings have 
been replicated in a retrospective analysis, which confirmed that RVol, FRC and TLC 
were significantly increased in GOLD Stage 1, whereas VC and IC were largely 
preserved.
78
 It is felt that lung deflation reflects improvements in mechanical lung 
emptying through reduced airway resistance and increased functional strength of the 




Sustained improvements in lung deflation 
Initially the question remained as to whether acute volume reduction with 
SABA/SAMA could lead to sustained symptomatic and physiological benefits for 
people taking these medications on a regular basis.  Studies have looked at 
responses over 2, 4 and 6 weeks and found consistent improvements in resting as 
well as exercise parameters of hyperinflation with salmeterol and tiotropium.
104
  
Computer tomography is increasingly used to assess emphysema and has also 
demonstrated radiological improvements in lung hyperinflation following long-acting 
anticholinergics over 1 year, which correlated with improvements in residual 
volume
105-107
.  Magnussen et al have also shown that combining bronchodilating 
agents appears to have an additive effect which persist over a 2 month period 
compared to a single agent alone.  The development of “ultra-LABAs”, 24 hour  
bronchodilation with once daily dosing, has the potential to further improve the ability 
to lung deflate through what some have described as “pharmacological stenting”.
108
  
One such compound indacaterol showed significant improvement in resting IC with 
differences of 140-200ml with placebo at 3 weeks, although this may simply reflect 
the potency of the bronchodilator it is likely the sustained bronchodilator effect plays 
a part.  Surprisingly these were less than previous studies involving tiotropium 









The impact of lung deflation 
Lung deflation correlates with improvements in dyspnoea during exercise 
manoeuvres in mild to severe disease and 10% (0.39l) improvement in IC results in a 
25-32% increase in exercise endurance time.
94, 95, 112, 113
  Reduced inspiratory 
threshold load (intrinsic PEEP) as a result of lung deflation is thought to relieve 
dyspnoea by reducing the disparity between efferent motor output (sensed by 
corollary discharge) and afferent inputs from mechanosensors in the respiratory 
muscles, chest wall and lungs (improved neuro-mechanical coupling).  This improved 
dyspnoea in combination with lung deflation is thought to result in the patient being 
less vulnerable to the triggers of an exacerbation resulting in the reduced 
exacerbation frequency described above.
38, 114, 115
 Lung hyperinflation contributes to 
the co-morbidity associated with COPD and, as discussed later (page 58), its 











































Sections of this Chapter have been published in Heart Journal as part of a Review 
Article and Editorial: 
 
Chronic obstructive pulmonary disease: a modifiable risk factor for 
cardiovascular disease? Ian S Stone, Neil C Barnes, Steffen E Petersen 
Heart 2012; 98:14 1055-1062  
 
Raised troponin in COPD: clinical implications and possible mechanisms Ian S 
Stone, Steffen E Petersen, Neil C Barnes Heart 2013; 99:2 71-72  
 
Dr. Ian Stone was first author and conceived the idea of the review article and drafted 
the manuscripts. 
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The phenotypic approach to managing COPD has the advantage that these “new” 
phenotypes are based on current knowledge making implementation into practice 
more feasible.  There is however inherently a bias.  An alternative approach involves 
the use of “hypothesis generating” or “discovery driven” techniques with the use of 
cluster analysis or principal component analysis based on standardised guideline 
directed approaches.  A number of studies have begun utilising this approach 
although only one has longitudinally validated the identified “phenotypes” with 
clinically relevant outcomes such as mortality and hospitalisation.  One such group 
consisted of patients with moderate COPD (FEV1 58%) but a predominant 
metabolic/cardiovascular phenotype.  More recently Van Fleeteren et al have 
published a cluster analysis where 97.7 % of all patients had at least one co-
morbidity, which was undiagnosed in a large proportion.  They identified clusters 
which had markedly different health status despite having similar degrees of COPD 
severity where cardiovascular disease was once again found to play a key role.
116
 
These findings mirror a study by Barnett et al where multi-morbidity was found to 
predominate in a number of chronic disorders including COPD, emphasising the 
importance of multi-morbidity in COPD health-status and outcome, where 




Increased cardiovascular morbidity and mortality in COPD 
 
Reduced pulmonary function, no matter what cause, is associated with increases in 
all-cause and cardiac mortality, myocardial infarction (MI) and arrhythmia.
118-121
 
Forced expiratory volume in 1s (FEV1) is ranked second to smoking and above blood 
pressure and cholesterol as a predictor of all-cause and cardiovascular mortality.
93
   
It has been suggested that a reduction in FEV1 combined with a smoking history 




Cardiovascular mortality in COPD 
In COPD a large proportion of patients succumb to cardiovascular causes rather than 
respiratory failure, where cardiovascular causes of death have been reported in 12 
and 37% of COPD patients.
123
  Curkendall et al demonstrated a greater than two-fold 
increase in cardiovascular and all cause mortality in those with more severe COPD 
from a retrospective cohort study.
124
 The HUNT lung study recruited 10,491 adults 
between 1995-1997, who were followed up for up to 12 years.  Compared to normal 
airflow obstruction those with a FEV < 50% predicted had a HR of 3.8-6.85 for all 
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cause mortality.  Although to a lesser degree, CV mortality was also increased:  In 
men for every 10% decrease in percent predicted FEV1 the adjusted HR for CV 
mortality was 1.24 (95% CI 1.10, 1.39).
125
  Similarly the Lung Health Study revealed 
adjusted cardiovascular mortality rose by 28% for every 10% decrease in FEV1.
122
 As 
well as severity, the “activity” of the disease is associated with cardiovascular 
mortality. As part of the 29 year follow up of the Buffalo Health Study cohort 
Schunemann et al have shown the rate of FEV1 loss independently predicts coronary 
artery disease (CAD) mortality.
126
  Furthermore, in the Baltimore Longitudinal study of 
ageing, patients with the greatest decline in FEV1 over a 16 year period were three to 
five times more likely to die from a cardiac cause than those with the lowest decline, 
after adjusting for confounders.  Importantly, this cardiovascular mortality risk 
associated with FEV1 has been shown as part of a systematic review in a number of 




COPD morbidity in cardiovascular disease (CVD) 
With an ageing population it is perhaps unsurprising that a number of chronic 
diseases co-exist and are often not recognised and remain undiagnosed.  As well as 
the high prevalence of cardiovascular disease in COPD populations (discussed 
below) it comes as little surprise that the reverse is also true; namely within those 
patients with known CAD, COPD is often found.  Soriano et al found the prevalence 
of undiagnosed airflow limitation in community populations with CVD to be 19 % 
whereas in those hospitalised with CAD, the prevalence of COPD to be as high as 
33.6 %.
128
  Elsewhere the reported prevalence of COPD in patients hospitalised for 




Cardiovascular morbidity in COPD 
A number of cross-sectional studies have looked at cardiovascular disease 
prevalence in COPD.  In one such study looking at a large UK primary care records 
database of patients aged over 35 years by Feary et al, physician diagnosed COPD 
patients were five times more likely to have cardiovascular disease than those 
without the condition.
131
 Johnson et al reported that the adjusted HR for incident CVD 
increased from 1.1(CI 0.9, 1.3) in GOLD stage 1 to 1.5 (CI 1.1, 2.0) in patients with 
GOLD stage III/IV as compared to patients without COPD.
132
  A retrospective nested 
case-control study from Canada involving 11,493 individuals found that the 
prevalence of cardiovascular disease (MI, congestive heart failure (CHF) and 
arrhythmia) was higher in the COPD group than the controls even after adjustment 
for traditional cardiovascular risk factors. As well as pre-existing heart disease, this 
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study found an increased risk of hospitalisation due to cardiovascular disease in the 
COPD group.
133
  Similarly, in a retrospective matched case control study involving 
COPD patients with a mean follow-up of 2.75 years, hospitalisation was higher in the 
COPD cohort for all cardiovascular hospitalisation endpoints with a relative risk of 
2.09 (CI 1.99, 2.20) after adjusting for pre-existing cardiovascular disease and 
traditional risk factors.
134
 The prospective Lung health study found cardiovascular 
events to be the leading cause of COPD hospitalisations, accounting for 50% of 
hospital admissions.
135
  Even in moderate to severe COPD patients without pre-
existing heart disease, 50% are at high risk of developing cardiovascular events 
within 10 years.
136
   A recent systematic review of the literature supports the view that 
COPD is associated with increased risk of cardiovascular disease, with the risk of 




The outcome following hospitalisation for cardiovascular events appears to be worse 
for this population.   The web-based REAL registry included 2032 COPD patients 
who were followed up for 3 years following MI.  COPD was found to be an 
independent predictor of mortality and re-admissions for re-infarction, 
revascularisation and heart failure were significantly higher in those patients with 
COPD.
138
  A multicentre outcome study following MI revealed after extensive 
adjustment for baseline differences that COPD patients have a two-fold mortality 
rate, increased re-hospitalisation rates and worse health-status 1 year following MI 
compared to those patients without COPD.
129
  In a retrospective analysis by 
Wakabayashi et al COPD patients have higher rates of the composite endpoint of 
death or cardiogenic shock compared to patients without the condition following 
primary angioplasty or rescue PCI.
139
  Following percutaneous coronary intervention, 
COPD patient experience significantly higher incidence of angina, arrhythmias and 
most importantly composite major cardiovascular events (MACE). Importantly, a 
relationship with COPD severity and MACE was also found.
140
 A secondary 
prevention study for MI conducted between 1981 and 1988 demonstrated increased 
in-hospital (23.9%) and five-year (35.9%) mortality for those patients with COPD, 




RCT: randomised controlled trial; IHD: Ischaemic heart disease; CCF: congestive cardiac failure; MI: myocardial infarction; CVA: cerebrovascular accident; CHD: coronary 
heart disease
















No. of deaths 
All Cardiac causes   
n/N 
All Cardiac causes   
% of total 
 
Specific Cardiac causes, if reported 
% of total  
⌘Anthonisen135 
(RCT) 
1994 5887 5 48 149 37/149 25  
















6184 3 65 911 Not reported 27  
 
CCF 3; MI 3; CVA 4;  





5992 4 65 981 184/981  23 Cardiovascular 108 (11) 
Sudden cardiac 43 (4) 
Sudden death 33  (3) 
Vilkman144 
 
1997 2237 Not reported 67 1070  37  
Keistinen145 
 
1998 2727 8.5 50-54 973 Not reported Males 38 
Females 26 
CHD 27; CVA 4 
CHD 26; CVA 8 
Engstrom146 
 
2001 200 14 68 181 91/181 50 IHD 29 
Garcia-Aymerich92 
 





2004 625 2.3 64-67 162 Not reported 14  
Stavem147 
 
2005 405 26 50 196 89/196 45 IHD 20; CVA 5; Sudden death 14 
Other 5 
Curkendall133 2006 7575 4 Over 65  1975 Not reported 30  
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COPD and troponin 
Over the past decade it has become apparent that during an exacerbation of COPD, 
classically defined by the combination of worsening dyspnoea with increased sputum 
volume and/or purulence, there is subclinical myocardial damage typified by an 
increase in newer assays such as highly sensitive troponin as well as other 
biomarkers which predict mortality.148-151 The key question relates to the mechanisms 
behind this rise, since without an understanding of the mechanisms the ability to 
identify an appropriate intervention that will improve outcome is hindered. Søyseth 
and colleagues have sought to further our understanding of this relationship.152 
Specifically, they addressed the important issue as to whether the raised levels of 
troponin found at exacerbation are chronically raised or are a phenomenon related to 
the exacerbation itself, and found that the troponin levels were significantly higher in 
the exacerbator group compared to stable patients from a pulmonary rehabilitation 
clinic. It is however questionable whether these groups really represent similar 
populations in the stable and exacerbating state, with significantly different modes of 
referral, smoking histories and spirometry readings when measured during periods of 
stability.  In an ideal world these exacerbating COPD patients would be compared 
against their own baseline measures.  Such a study has recently been undertaken 
and Patel et al have shown small (+ 0.005 μg/L) but significant increases in troponin 
during COPD exacerbations that did not require hospitalisation, the increase 
persisting up to 5 weeks post exacerbation, a higher rise being found in those with 
pre-existing heart disease.153  Interestingly no relationship between exacerbation 
frequency and baseline troponin was found. 
 
Heart failure and COPD  
A number of studies have looked at the prevalence of heart failure in COPD. Early 
population studies have focused on systolic failure with very low estimates (0-16%) in 
selected patients without concurrent disease and 10-46% in unselected COPD 
patients.154  More recent prevalence estimates are similar, ranging from 7.1-31.3%.137 
The annual incidence rate of CHF in these populations has been reported as 3.7%.155 
In a long-term population study by Engstrom et al, a moderately reduced FEV1 was 
associated with an increased incidence of hospitalisation due to heart failure, in the 
absence of previous history or concurrent MI.156  The risk for hospitalisation is not just 
confined to those with moderately severe disease.  In the Health ABC study FEV per 
cent predicted had a linear association with heart failure risk (HR 1.21; 95% CI 1.11, 
1.32) as defined as treatment requiring hospitalisation which included those without 
overt lung disease.157  As well as systolic dysfunction diastolic dysfunction also 
 43 
contributes to the burden of heart failure, up to 50% of which may remain 
undiagnosed and contributes substantially to all-cause mortality whether mild or 
severe and is commonly found in patients with COPD.  Of those patients with heart 
failure, the presence of COPD further increases their risk of death and 
hospitalisation.158, 159 
 
The impact of shared exposures  
It may be that the relationship between COPD and cardiovascular disease (CVD) is 
solely due to shared common risk factors: 
 
Smoking 
It is well accepted that smoking causes both COPD and cardiovascular disease.  
Passive smoke inhalation, in a dose-response manner, also increases the likelihood 
of fatal and non-fatal MI with an estimated pooled odds ratio (OR) from a meta-
analysis of 1.22 (1.04-1.41) and 1.32 (1.04-1.67) respectively.  Similarly, increased 
risks have been observed for COPD mortality with ORs related to spousal smoking of 
1.67 in never-smoking males.160 
 
Smoke free legislation (SFL) 
Recently, there has been a significant focus on international public health strategies 
to combat the adverse effects of smoking, and second-hand smoke in particular. 
Although the impact of SFL on respiratory symptoms is well studied, in normal 
individuals data on lung function are less robust since the changes noted were 
arguably of little clinical relevance, suffered from poor participant compliance and 
were confounded by seasonal variation in temperature.161-167  The impact of SFL on 
COPD is unclear since the few studies that have assessed the rate of admissions for 
COPD exacerbations show conflicting results.168, 169  This is in contrast to the data for 
CVD.  A recent meta-analysis assessing the impact of SFL revealed a reduction of 
acute coronary syndrome risk in 30 of 35 estimates with a 10% (95%CI 6,14; 
p<0.001) pooled relative risk reduction, supporting the notion that smoke exposure 
has a significant independent role in cardiovascular morbidity, although whether 
those patients with concomitant COPD achieved equivalent improvements in 




The development of COPD as a result of damage caused by air pollution is well 
documented.171, 172 Day-to-day changes in pollutant levels and longer term exposure 
also affect CVD risk, and all commonly measured pollutants are positively associated 
with increased mortality and hospital admissions for cardiovascular disease. 
Hypotheses relate to direct pollutant-effects of oxidative stress, pulmonary and 
systemic inflammation or pro-coagulant reactions that, as will be discussed later, 
have significant overlap with the postulated effects of COPD.  Although observational 
studies have found associations between cardiac autonomic dysfunction and air 
pollution, this has not been borne out in controlled conditions and further mechanistic 
explanations are needed for this discrepancy.173-175 
 
The impact of differential prescribing practises 
COPD patients have been excluded from clinical trials involving β-blockers due to 
historical concerns over bronchoconstriction.176 Database studies persistently 
demonstrate a survival benefit for COPD patients receiving β-blockers in CAD and 
CCF.  Furthermore, a Cochrane review has confirmed the safety of cardio-selective 
β-blockers in COPD of all severities and a recent study has also demonstrated a 
survival benefit of cardioselective β-blockers during COPD exacerbations.177  The 
benefits of β-blocker use in heart failure extend to the use of non cardio-selective β-
blockers, an assertion supported by a recent meta-analysis, although the authors 
stress the absence of any randomised controlled trials on the subject.178-180  Despite 
the increasing awareness of the benefits of this class of drug in COPD, underuse 
persists due to lingering concerns over bronchoconstriction.181, 182  The suboptimal 
management of cardiovascular disease in COPD patients goes beyond inadequate 
β-blocker prescribing; in one retrospective study 13% of patients with confirmed 
coronary artery disease were on neither a statin or anti-platelet therapy and a further 
9% of the cohort had severe occult coronary artery disease.  This sub-optimal 
management is ill placed since based on the above evidence, COPD patients 
arguably have the most to gain. 
 
Although the under-prescribing of key medication contributes to cardiac risk, it is now 
appreciated that COPD is a multi-system disorder that exerts “systemic effects”.   
Despite the aforementioned shared risk, the intriguing finding that increased 
cardiovascular morbidity and mortality in COPD is independent of smoking and other 
conventional cardiovascular risk factors, age, and gender is driving research into 
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understanding the underlying mechanisms of this increased risk and to what extent it 
is modifiable.123, 126, 127, 147, 179, 183-185 
 
Models explaining the interaction between COPD and 
cardiovascular disease 
 
The hypotheses relating to why COPD patients are at increased risk of developing or 




Pulmonary hypertension model 
Lung hyperinflation model 
Shared genetics model 
 
Inflammation model 
Evidence is growing that COPD and cardiovascular disease may be linked through 
inflammatory processes contributing to atherosclerosis:  
Inflammation and coronary artery disease 
The involvement of inflammation in the development of atheromatous plaques is well 
established.186, 187  The majority of cells are monocytes which gain entry, along with 
T-cells and mast cells, via vessel adhesion molecules after exposure to irritative 
stimuli including cytokines, dyslipidaemia and hypertension. 188, 189  The monocytes 
develop into macrophages which themselves have an array of pro-inflammatory 
actions when studied in mice models.188  Thrombotic complications are not always at 
the most severely narrowed site but at recently disrupted fibrous plaques, which 
typically contain macrophages, whose caps have been thinned by inflammatory and 
immune processes.189, 190 Thus, the fate of an atherosclerotic lesion depends on the 
balance between pro-inflammatory and anti-inflammatory cytokines which in turn 
determines the magnitude of the inflammatory response.191 
 
C-reactive protein (CRP) is an acute phase reactant and a marker of systemic 
inflammation.  CRP and Interleukin (IL) 6, the pre-cursor to CRP, are increased 
during unstable angina and are markers of poor prognosis.194,192,195  In situations of 
coronary vasospasm rather than plaque rupture CRP is normal, suggesting vessel 
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inflammation not myocardial ischaemia causes the inflammatory response.193  CRP 
measured on a highly sensitive immunoassay (Hs-CRP) can predict MI and mortality 
in apparently healthy individuals.194, 195 Although association does not prove 
causality, many are convinced that further investigation is warranted.   
 
Hallmarks of atherosclerosis include endothelial dysfunction with reduced arterial 
compliance, increased central arterial pressure, left ventricular afterload and reduced 
diastolic coronary artery filling.  A measure of arterial stiffness, known as aortic pulse 
wave velocity (PWV), can be measured non-invasively using applanation tonometry 
of the radial artery.196 Repeatedly, aortic PWV has been shown to be an independent 
predictor of coronary artery disease in hypertensives, diabetics and the general 
population including the elderly.197-202  PWV is also associated with disease duration, 
the presence of CRP and interleukin (IL) 6 (independent of atherosclerosis), and in 
rheumatoid arthritis and other chronic inflammatory conditions.203, 204 
 
Statins have potent lipid lowering but also anti-inflammatory effects.  The JUPITER 
trial, a randomised double blind placebo-controlled trial, demonstrated a 1.2% 
absolute risk reduction (RR) and a 44% relative risk reduction in combined 
cardiovascular endpoints in healthy individuals when treated with Rosuvastatin 
versus placebo.  Significantly, participants had elevated HsCRP but lipid levels below 
treatment threshold, suggesting benefit due to anti-inflammatory rather than lipid 
lowering effects. Much controversy remains as to whether the population received 
care consistent with current standards and confounding lipid-lowering actions are 
hard to ignore.205   Future studies involving methotrexate and canakinumab, potential 
cardiovascular therapeutic agents without confounding effects, are planned to help 
establish the contribution of inflammation.  Respiratory therapeutics may also have a 
role to play.190, 206 
 
Inflammation and COPD  
COPD causes an airway inflammatory process, distinct from asthma, involving 
neutrophils, macrophages, T-lymphocytes and augmented concentrations of 
leukotriene B4, IL 1, 6 and 8b and tumour necrosis factor α (TNFα).207-212 There is 
evidence suggesting inflammation may spill-over from the lungs to the systemic 
circulation, most likely caused by alveolar macrophages which clear inhaled particles 
and initiate local and systemic inflammation.213, 214 Animal studies have shown 
movement of lung proteins to the systemic circulation is dependent on a number of 
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factors including lung inflammation, whereas human studies provide circumstantial 
evidence in the form of increased circulating levels of TNF-α, CRP and fibrinogen215-
218.  Furthermore, positron emission tomography studies have demonstrated 
excessive aortic inflammation in COPD, whose associated co-morbidities include 
skeletal muscle dysfunction, osteoporosis and diabetes which all have inflammatory 
aetiologies.212, 219-221  The complex nature of inflammation within COPD has recently 
been elucidated, at least to some extent, as a result of data from the ECLIPSE 
(Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) trial 
where it has been shown that in patients at risk of exacerbation, systemic 
inflammation defined according to a specific combination of several different 
inflammatory biomarkers persists during periods of stability.61  Subsequent 
populations studies have shown the same three biomarkers, CRP, WCC and 
fibrinogen in COPD patients can predict the risk of IHD with a hazard ratio compared 
to those with no evidence of a raised inflammatory profile of 2.19 (95% CI 1.48, 
3.23).222 
 
This pro-inflammatory state and resultant spill-over of pulmonary inflammation may 
lead to down-stream effects such as arterial stiffness which could provide a 
mechanistic link between COPD, CAD and diastolic dysfunction.223-225  Studies have 
indeed shown that arterial stiffness is raised in COPD and related to the extent of 
airflow obstruction and emphysema.226, 227  Furthermore, Patel et al have shown that 
during COPD exacerbations there are increases in PWV which are associated with 
myocardial injury, although due to the short observational period of 5 weeks no 
stepwise deterioration in PWV was identified.153  An alternative hypothesis has also 
been proposed which shifts the emphasis from left ventricular afterload excess to 
coronary microvascular inflammation.228 These concepts support the findings of 
reduced myocardial perfusion reserve in COPD patients in the absence of either 
ischaemia or infarction.229 
 
Pulmonary hypertension (PH) model 
Although PH is an established prognostic factor, its true prevalence in COPD is 
unknown due to selection bias in studies mainly assessing hospitalized patients.230  
The pathogenesis of pulmonary vascular disease is multifactorial, relating to 
alterations in vascular and pulmonary biology, gas exchange, structural changes in 
the pulmonary vasculature as well as mechanical factors.231 Pulmonary artery 
pressure (PAP) depends on pulmonary artery wedge pressure, cardiac output and 
pulmonary vascular resistance (PVR).  Many factors increase PVR in COPD (Box 2) 
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and alveolar hypoxia, which results in vascular remodelling and hypoxic 
vasoconstriction localised to the small pre-capillary arteries, is classically considered 
to be the most important.232   
 
The development of pulmonary hypertension in COPD is classically attributed to 
severe hypoxia in end-stage disease causing raised pulmonary pressures, right 
ventricular hypertrophy, dilatation and systolic failure, or “chronic cor pulmonale” 
resulting in reduced exercise tolerance and survival.  This simple hypothesis remains 
controversial;233 vascular remodelling is seen in patients with milder forms of the 
disease and pulmonary endothelial dysfunction develops in COPD before the onset 
of hypoxaemia which is thought to be due to the combination of the direct effects of 
cigarette smoke and that of local inflammation, and is considered one of the initiating 
events in the progression to pulmonary hypertension.231, 234 
 
It is argued that the severity of PH in most COPD patients cannot account for all the 
manifestations; although transient rises in PAP occur during nocturnal hypoxaemia 
and exacerbations, only 1-4% have a PAP >40 mmHg at rest, significantly lower than 
other forms of PH, and in sufficiently severe COPD to be considered for lung volume 
reduction surgery, the PAP may only be moderately elevated at baseline (26.3+/-5.2 
mmHg).235-239 
 
These observations have led to alternative explanations for the morbidity and a better 
appreciation of the contribution of diastolic dysfunction with the chronically pressure-
overloaded right ventricle (RV) causing leftward septal shift, ventricular 
interdependence and LV diastolic dysfunction, despite normal LV systolic function.240, 
241 The impact of diastolic dysfunction should not be discounted; in a single-centre 
echocardiographic out-patient study, including patients with COPD, moderate to 
severe diastolic dysfunction independently predicted mortality in patients with normal 
systolic function.242 Although PH associated diastolic dysfunction contributes to the 
cardiac morbidity of COPD, other mechanisms must also contribute since sub-clinical 








Box 2: Confirmed and suspected factors leading to increased PVR in COPD245 
 
 
Lung hyperinflation model 
Lung hyperinflation results from loss of elastic recoil combined with expiratory flow 
limitation, promoting increased expiratory lung volume (or “air trapping”) and intrinsic 
positive end-expiratory pressure (PEEPi) with significant clinical consequences in 
those with a more severe phenotype, including a two fold increase in all-cause 
mortality.62, 67  It exerts its effects via 2 mechanisms: 
 
The mechanical effects of hyperinflation 
Lung hyperinflation increases mediastinal pressures through stiffening of the parietal 
pleura and cardiac fossa, with potentially significant cardiovascular physiological 
consequences including left and right diastolic dysfunction.246  This assertion has 
been supported by a recent cross-sectional echocardiographic study which found 
sub-clinical diastolic dysfunction that was more severe in those with lung 
hyperinflation as assessed by static lung volumes.247  The diastolic dysfunction 
described has generally occurred despite preservation of systolic function, which in 
the case of those with RV hypertrophy has been attributed to the flattening or 
leftward displacement of the interventricular septum in emphysematous patients 248 
Although Lopez-Sanchez et al have recently found the prevalence of diastolic 
dysfunction in COPD to be as high 90% in consecutive hospital outpatients, they 
were unable to reproduce this association with lung hyperinflation and found no 
correlation with inflammation or right ventricular overload parameters.249 They were 
however able to find an association with exercise tolerance which has been 
replicated elsewhere.  Vassaux and colleagues have demonstrated that lung 
hyperinflation predicts a reduced oxygen pulse, a surrogate for cardiac performance 
during exercise.250 
 
Factors affecting PH in COPD Impact on pulmonary vessels 
Airflow limitation Pressure swings 
Emphysema Reduction of vascular bed 
Alveolar hypoxia Vasoconstriction/remodelling 
Hypercapnic acidosis Vasoconstriction 
Polycythaemia Hyperviscosity 
Lung/systemic inflammation Remodelling, including fibrosis 
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Observational echocardiographic studies have shown hyperinflation to independently 
predict cardiac chamber size.  Watz et al have demonstrated that static lung 
hyperinflation is associated with a reduction in size of all 4 cardiac chambers over a 
whole spectrum of disease severity and confirmed associations with LV diastolic 
dysfunction.  The increasing interest in COPD and cardiovascular disease has seen 
the introduction of a lung sub-study to the “Multi-ethnic study of atherosclerosis”, a 
large prospective cohort study designed to identify sub-clinical measures of CVD.  
Consistent with the study by Watz, in the 2816 participant lung sub-study significant 
associations were found between CT-quantified levels of emphysema and MRI 
measures of LV end-diastolic and end-systolic volumes.105  Subsequent population 
studies from MESA have shown reduced RV volumes although, perhaps surprisingly, 
to a lesser degree than the left ventricle.107  
 
The cause for reduced cardiac chamber volumes has also been investigated. The 
unaffected isovolumetric relaxation time suggests reduced pre-load conditions rather 
than a stiff myocardium as the cause for diastolic dysfunction, a concept supported 
by Jorgensen et al who found associations between decreased intrathoracic blood 
volume and LV performance in severe emphysema.251, 252  This is also supported by 
a further COPD CT study from the MESA cohort showing reduced pulmonary vein 
dimensions, which were inversely associated with the extent of emphysema on 
CT.253 
 
Further cardiac structural changes that occur in COPD that are as yet unexplained is 
the development of LVH in the absence of systolic dysfunction, hypertension or 
hypoxia with normal BNP levels, although lung hyperinflation may have a role, as 
recent associations have also been found with residual lung volume and RVol/TLC, 
although not with TLC or FRC.254  The relationship was independent of blood 
pressure and other traditional cardiac risk factors among older smokers with 
predominantly mild to moderate COPD, the contribution to LVM being similar to that 







Neuro-humoral effects of hyperinflation 
Activation of the sympathetic nervous system (SNS) in normal individuals causes 
cardiovascular remodelling, with altered PWV, arterial compliance and diastolic 
dysfunction, which may occur through direct effects on tone, modulation of baro-
receptor sensitivity or activation of the renin-angiotensin system.256-259   
Heart rate variability (HRV) expresses cyclic fluctuations of heart rate (HR) and 
reflects autonomic modulation by sympathetic and parasympathetic efferent nervous 
impulses of heart rhythm. A sympathetic predominance is a predictor of mortality 
post–MI and in COPD there is evidence of a depressed HRV response to 
sympathetic and vagal stimuli which has also been shown to be related to static 
hyperinflation.260, 261 As well as heart rate variability, SNS activation in COPD is 
demonstrated by the presence of increased noradrenaline turnover and increased 
plasma-renin activity.262 
Hyperinflation, as well as its mechanical restrictions, may also impact on the SNS via 
a lung inflation reflex, increased hypoxia and neural-respiratory drive, which drives 
skeletal muscle contractility with the subsequent ischaemic release of free radicals.263  
Shared genetics model 
Genome wide association studies 
There may be more to the relationship between COPD and cardiovascular disease 
than simply sharing smoking as a risk factor.  Parallel pathologic processes, as a 
result of shared genetics, may mediate the relationship between COPD and 
cardiovascular disease via gene-environment interactions causing connective tissue 
remodelling through modification of elastin content and proteolytic enzyme activity.   
There is extensive literature on the role of genomics and genome wide association 
studies in the understanding of the complex polygenic interactions of COPD and 
cardiovascular disease and the interested reader is referred to two well-written 
reviews on the subject.264, 265 Two examples are provided here to illustrate this large 
area of research.  Matrix metalloproteases (MMPs) are proteolytic enzymes that 
degrade collagen and elastin within the lung matrix and have other pro-inflammatory 
roles in smoking-induced emphysema models. MMPs also contribute to vascular 
remodelling in pulmonary hypertension (PH) and it is widely accepted that MMP 
polymorphisms are pivotal to non-pulmonary vascular remodelling in 
atherosclerosis.266-268  Polymorphisms of epoxide hydrolase and glutathione-s-
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transferase, involved in oxidative stress, are strongly associated with upper lobe 
emphysema and are risk factors for MI and atherosclerosis respectively.269, 270     
 
Telomere function and the aging process 
“The senescence hypothesis” is the shortening of telomere length, a marker of 
cellular aging, caused by the failure to protect DNA against oxidative injury and 
reactive oxygen species.271  Telomere shortening accelerates end-stage heart failure 
and several studies in diverse populations have shown an association, which exists 
before the development of clinical disease, between shorter telomeres in circulating 
leucocytes and both CAD and coronary artery calcification272-274. The oxidative 
damage and chronic inflammation in COPD, originating from environmental irritants 
such as cigarette smoking and air pollution, may reduce telomere length in circulating 
cells with important downstream effects on auto-immunity, potentially explaining the 
persistence of lung inflammation in COPD despite many years of smoking cessation, 
driving telomere attrition and increase cardiac risk over and above the risk associated 
with smoking.275-277 Inflammation and oxidative stress are involved in virtually all 
cardiovascular and associated diseases which may explain the wide number of 
conditions associated with telomere length and the emerging evidence points 
towards the potential use of telomere length as a marker of both cardiovascular and 
obstructive airways disease or as a therapeutic target.278, 279 
 
Evidence that COPD treatment reduces cardiovascular morbidity 
and mortality 
 
Effects of smoking cessation 
Smoking cessation results in an almost immediate improvement in blood pressure 
and heart rate, with the risk of stroke and CAD normalized to that of never smokers 
between 5 and 15 years after cessation.  During the 5 years follow-up of The Lung 
Health Study (LHS), involving 5887 smokers with mild to moderate COPD, smoking 
cessation was associated with a 32% reduction in all-cause mortality, the trend 
persisting for 14.5 years of follow-up, and a 45% reduction in cardiovascular mortality 
likely through a direct reduction of cardiovascular events, but probably also through 




Effects of oxygen therapy 
In the Nocturnal Oxygen Therapy Trial, 203 COPD patients with evidence of chronic 
hypoxaemia were randomised to receive oxygen supplementation. After a minimum 
follow-up of 12 months, the relative risk of death with nocturnal versus continuous 
oxygen was 1.94 (95% CI 1.17, 3.24).281  This protective effect was also seen in the 
Medical Research Council study where 5-year mortality for those receiving oxygen 
was half that of the control group.282  The benefit of oxygen in COPD patients with 
transient hypoxaemia related to sleep or exercise remains to be determined and is 
the subject of the “Long-term Oxygen Therapy Trial”.283 
 
Effects of pulmonary rehabilitation (PR)  
It is unclear to what extent the reductions in hospital admissions, exacerbations and 
mortality seen following PR in COPD are a result of reduced cardiac morbidity.  
Endurance training results in adaptive responses of the heart including resting 
bradycardia, increasing end-diastolic dimensions, non-pathological cardiac 
hypertrophy, improved ventricular function and resistance to ischaemic insult.284, 285 
Significant improvements (10.3 +/- 0.7 to 9.2 +/- 0.8 m/s) in carotid-radial PWV 
occurred in an isolated exercise intervention. A case-control study of a seven week 
multidisciplinary PR course demonstrated significant reductions in PWV from 9.8 (+/- 
3) to 9.3 (+/- 2.7) due to a reduction of 10mmHg in systolic blood pressure, the 
magnitude of which, if sustained, being sufficient to reduce cardiovascular morbidity 
and mortality by at least 13%.286, 287 Improvements in dynamic hyperinflation 
(progressive air trapping during exercise), neuromuscular coupling or tolerance to 
dyspnoegenic stimuli may have contributed to PWV improvement.288 
 
Effects of inhaled COPD therapies 
Two recent multi-centre, randomised, double-blind, parallel-group, placebo, 
controlled trials have raised the possibility that pharmacotherapy could affect 
survival. The 3-year TOwards a Revolution in COPD Health  (TORCH) study was 
conducted at 444 centres in 42 countries and randomised 6184 patients. Comparing 
salmeterol (SAL), fluticasone propionate (FP) and salmeterol/fluticasone propionate 
(SFC) combination inhaler with placebo, a reduction in all-cause mortality, the 
primary efficacy endpoint, despite a large differential drop-out from the placebo arm 
would have reached statistical significance (p=0.04) but for an interim analysis for 
safety resulting in a corrected p-value of 0.052.39   
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In the 4-year Understanding Potential Long-Term Impacts on Function with 
Tiotropium (UPLIFT) trial, 5993 patients were randomised to receive tiotropium or 
placebo.  Hospitalisations and mortality one month following the completion of the 
trial (and cessation of study drug) was the pre-specified secondary outcome 
measure.  Although a reduction in all-cause mortality versus placebo on an intention 
to treat basis was demonstrated, this did not reach statistical significance (HR 0.89, 
CI 0.79, 1.02). However, post-hoc, there was a significant reduction in all-cause 
mortality whilst on treatment after the protocol defined treatment period of 4 years 
(HR 0.84; CI 0.73, 0.97; p=0.016).40   
 
Data on adverse events in these trials further raises the possibility of cardio-
protective effects.  A post-hoc analysis in TORCH showed fewer cardiovascular 
events within the SFC group after adjusting for smoking status and gender (SFC 
11.3%, FP 13.8%, SAL 13.4%, placebo 14.6%).  In UPLIFT a relative risk reduction 
in cardiac mortality (RR 0.86; 95% CI 0.75, 0.99), CHF (RR 0.59; 95% CI 0.37, 0.96) 
and MI (RR 0.71; 95% CI 0.52, 0.99) were observed.289, 290 
 




Effects of inhaled COPD therapies 
Inhaled fluticasone with or without long acting β2-agonists reduce exacerbations and 
improve health status in COPD.39  Observational studies as well as double-blind 
placebo controlled biopsy studies have confirmed modulation of inflammation within 
the airway following administration of inhaled corticosteroids.291-293 Research data are 
conflicting with regards to whether inhaled therapies can reduce levels of systemic 
inflammation by reducing the spill-over of lung inflammation.  Pinto-Plata et al found 
a significantly raised CRP level in COPD patients, which was 20% lower in those 
taking inhaled corticosteroids. An open label prospective study demonstrated that 
salmeterol and fluticasone significantly reduced circulating CRP levels compared to a 
combination of an anti-cholinergic and albuterol.294 Furthermore, a proof of concept 
double-blind placebo controlled clinical trial by Sin et al found that withdrawing 
inhaled steroids increased CRP levels and re-introduction of inhaled fluticasone for 2 
weeks resulted in 50% and 26% reductions in CRP and IL-6 respectively.295 
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However, when repeated as an 11 centre randomised, placebo-controlled, double 
blind trial, no significant changes in CRP or IL-6 were identified, which may be due to 
a higher proportion of smokers in the latter study or the use of long-term inhaled 
corticosteroids modifying inflammatory processes within the lung.296 In any case, it is 
argued that lack of correlation between inflammatory biomarkers in the airway and 
the systemic circulation does not necessarily exclude the possibility of “spill over”, 
since many factors will influence concentrations in different body compartments; for 
example receptor binding influences the free concentrations of many cytokines, with 
potential downstream spill-over effects on the cardiovascular system without 
noticeable changes to the intermediary biomarkers.218   
 
The effect of inhaled therapies on PWV in COPD has been investigated.  249 
patients were randomised to receive fluticasone/salmeterol combination inhaler 
(Seretide) or placebo with a primary outcome measure of the change in PWV at 12 
weeks, which did not reach statistical significance on an intention to treat basis.  
However, in those patients that remained on the study drug throughout the trial, a 
significant, although modest, reduction (0.4 m/s) in PWV was achieved, which was 
found in a post-hoc analysis to be more marked in those with a PWV of greater than 
10.9 m/s at baseline.  Although an increase in aortic PWV of 1 m/s corresponds to an 
adjusted increased risk of 15% in CV mortality, the reverse is less clear.297  Clinically 
significant reductions are yet to be established and the effect of these reductions on 
cardiac structure and function are, until such studies are carried out, unknown. 
 
The	effect	of	phosphodiesterase-4	(PDE4)	inhibitors	
PDE4, a member of the PDE enzyme superfamily that inactivates cyclic adenosine 
monophosphate and cyclic guanosine monophosphate, is the main isoenzyme 
involved in inflammatory airway disease.298  The PDE4 inhibitors are a new anti-
inflammatory drug with efficacy and acceptable tolerability in pre-clinical studies in 
COPD with no effect on cardiac repolarization.299, 300  A Cochrane review involving 23 
RCTs, concluded that PDE4 inhibitors, including roflumilast and cilomilast, were 
associated with significant improvements in FEV over placebo regardless of severity 
or concomitant treatment, and reduced the likelihood of exacerbations.301   Given that 
it is administered orally, it seems likely that it will exert a systemic effect on 
inflammation and thereby potentially having a dual benefit on the cardiovascular 
system. In-vitro studies have pointed towards a third cardio-protective effect through 
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prevention of nitric oxide induced myocyte apoptosis, potentially protecting against 
myocardial ischaemia and ischaemic reperfusion injury.302 
 
Lung hyperinflation model: The effect of lung deflation 
Bronchodilators, whether beta-agonist or anticholinergic, improve air trapping in mild 
and more severe forms of COPD.  Lung deflation results in improved exertional 
dyspnoea and exercise tolerance due to a combination of reduced inspiratory muscle 
loading and dynamic hyperinflation.99, 102  Some of these improvements may also be 
due to an improvement in cardiovascular function. Jorgensen et al demonstrated 
increased left ventricular end-diastolic dimensions and filling with significant 
improvements in cardiac index following lung volume reduction surgery (LVRS).  In 
the National Emphysema Treatment Trial cardiovascular sub-study there were 
improvements in capillary wedge pressure post LVRS. At 6 months there was 
improvement in “O2 pulse”, the total oxygen consumed during maximal effort per 
heart beat and a surrogate for stroke volume, in a subsequent post-hoc analysis, 
which, interestingly, was also seen in a proportion of patients treated with medical 
therapy alone.303-305  Although this offers an insight into how lung deflation may 
improve cardiac function, the impact and exact onset is unclear since prospective 
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The aorta and aortic function   
 
The term aorta is derived from the Greek word “aorter” which refers to an 
umbilical/belt used to hang up the “aor”, the word Homer used for sword.  It was 
Aristotle who described the great vessel as an “aorte” something that hangs or 
carries (the heart).  Different models have subsequently been applied to the arterial 
system.  In the Windkessel model the arterial system is compared to a fire-house 
system where cushioning and conducting functions are separated: The large arteries 
cushioning the pulsations from the central pump, the wide bore hose acting as a 
conduit and the fire hose nozzle likened to the peripheral arterioles.306  Limitations to 
this model include the fact that cushioning and conduit functions are not in reality 
separated, with a progressive loss of cushioning function and progressive increase in 
conduit function from the aorta to the peripheral arteries, whose stiffness is further 
modulated by vasomotor tone through involvement of the sympathetic nervous 
system, renin-angiotensin system and local endothelial function.256, 257  A propagative 
model is therefore considered to more accurately reflect the nature of the circulatory 
system, the propagation (velocity) of the pressure wave being inversely related to the 
distensibility of the arterial tube.  It is the collagen and elastin contained within the 
aorta, which makes up to 60% of intima media, which provides the elastic buffering 
capacity, transforming the pulsatile effect caused by ventricular ejection into 
continuous blood flow.307-309  The elastin content and hence the elasticity reduces as 
one moves away form the heart.310  The buffering capacity of the aorta also typically 
reduces with age and in certain pathological states, described as stiffening of the 
aorta, with important clinical consequences.  The effects of arterial stiffness are wide-
ranging and result in microvascular damage in both the brain and kidneys.  The 
microvascular damage is caused by differential input impedance in these organs 
compared to other vascular beds.  The low resistance to flow in these organs expose 
the small vessels to high-pressure fluctuations. In renal disease the presence of 
arterial stiffness is independently associated with reduced creatinine clearance and is 
independent of plasma glucose, cholesterol, obesity and smoking. 311, 312 Reduced 
distensibility has been shown to result in left ventricular dysfunction and reduced 
exercise capacity. Early identification may provide a means to identify subtle  
changes in function prior to the occurrence of remodelling and provide a target for 
therapeutic interventions.307, 313, 314 
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The assessment of aortic function can occur specifically at different locations along 
its path, known as regional assessment or via a global assessment: 
 
Regional assessment of aortic function 
 
Aortic distensibility or compliance is defined as the relative change in area for a given 
pressure change and actually makes up 60-70% of the total systemic compliance.  It 
has been used on a regional level to assess aortic stiffness where a reduction in 
compliance has been shown to reduce coronary and endocardial perfusion in animal 
models with and without coronary artery stenosis;309, 315, 316 reduced compliance 
predicts reduced coronary flow velocity reserve in patients with suspected coronary 
artery disease,  and it modestly correlates with the extent of CAD and was a predictor 
of left ventricular end-systolic volume index post MI317-319. Even in the absence of 
overt cardiovascular disease, increases in proximal aortic stiffness associated with 
ageing results in unfolding of the aortic arch and is associated with increased left 
ventricular mass and mass to volume ratio.320 
 
Measurement of regional arterial stiffness 
CMR has compared favourably to ultrasound in the assessment of regional 
distensibility.  It has a number of advantages over other modalities including a wider 
field of view, the ability to precisely delineate aortic anatomy, sufficient spatial and 
temporal resolution to detect rapid and small changes in the aorta which can be 
isolated to specific segments, a lack of ionizing radiation as well as the simultaneous 
assessment of cardiac structure and function in an integrated study.310, 321 Typically 
cross-sectional images are acquired in the transverse plane at the location of 
interest, using a single breath-hold steady-state free procession (SSFP) technique 
that provides high temporal and spatial resolutions typically without respiratory 
motion artefacts.  Phase contrast sequences have also been used although SSFP 
images appear to result in better inter-observer reproducibility.322  Aortic contours are 
either manually drawn, segmented using semi-automated software or fully automated 
techniques, the latter techniques providing minimum and maximum cross-sectional 
area values for calculating the distensibility while avoiding the important inter-
observer variation often associated with manual tracing.314, 323-326 
 
Historically one of the difficulties in studying compliance has been the need for 
invasive monitoring, for example through cardiac catheterisation, to establish the 
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central pressure.  In recent years the development of non-invasive devices, which 
use validated transfer functions to estimate aortic pressure, have been employed 
with some success.  Peripheral waveform analysis with dedicated devices with an 
integrated invasively validated radial-to-aortic transfer function first enabled 
assessment of central systolic BP and are discussed further below.  Although wave-
form analysis occurred at the wrist, typically these tonometric devices such as the 
SphygmoCor were calibrated against brachial BP, the fundamental assumption being 
that very little wave amplification takes place between the brachial and radial 
artery.327 However, there is increasing evidence that this is not the case, which may 
significantly affect estimations of central pressure.328 The Vicorder device is a 
commercially available non-invasive relatively operator independent device which 
determines brachial artery pressure waveforms using a volume displacement 
technique and central blood pressure via a previously described brachial to aortic 
transfer function.329  Reliable estimates of central pressure have been demonstrated, 
where it was found to show better agreement and was highly correlated with invasive 
measures compared to the SphygmoCor.327  It has the further advantage that 
measurements can be made simultaneously during the CMR image acquisition.  
 
Global assessment of aortic function 
Global arterial stiffness is increasingly recognised as a surrogate for cardiovascular 
disease. Carotid-femoral pulse wave velocity (cfPWV) and Augmentation Index (AI) 
are commonly used methods for estimating global arterial stiffness. 
 
Pulse wave velocity (PWV)  
PWV is calculated from measurements of pulse transit time and the distance 
travelled by the pulse between 2 recording sites (PWV = Distance/transit time (TT).  
Pulse wave velocity (PWV) has the advantage that it is a direct measurement of 
parameters which are strongly linked to wall stiffness and has been shown to be 
highly clinically relevant.  It is associated with the presence of cardiovascular risk 
factors and atherosclerotic disease.330-332 Aortic PWV has been shown to be an 
independent predictor of all cause and cardiovascular mortality in hypertensive and 
diabetic patients.197, 198 Associations have also been found in well functioning older 
adults where in a cohort study 2488 participants that were followed up for 4.5 years 
there was a significant increase in relative risk of between 1.5-1.7 for total mortality 
and 2.1-3.0 for cardiovascular mortality in those patients in the upper quartiles of 
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PWV compared with the lower quartile.201  As well as a predictor for fatal events, in 
other population studies it has also been shown to be a predictor of non-fatal 
cardiovascular events in the general population independent sex, age, BMI, MAP, 
smoking and alcohol intake, where for a 1SD increment in PWV the risk increased by 
16-20%.202  These associations continue to remain significant in later life; a 
longitudinal study of elderly patients recruited following a hospital admission has 
shown that PWV is a strong independent predictor of cardiovascular death in 
subjects aged 70-100 years.199 Although numerous studies have given the general 
impression that PWV may have a predictive role in both cardiovascular and non-
cardiovascular mortality endpoints many were within very contrasting populations, 
the sizes of which were diverse providing very dissimilar risk estimates and 
publication bias cannot be ruled out. The predictive value of pulse wave velocity has 
however been the subject of a systematic review and metanalysis which has 
demonstrated a stepwise increase in the relative risk of clinical events from the first 
to third tertile of aortic PWV and has estimated that a 1m/s increase corresponds to a 
14-15% increase in total cardiovascular events and cardiovascular and all cause 
mortality.297 
 
Measurement of PWV  
There is no universal agreement as to which particular technique or device is optimal. 
It is however generally agreed that external factors impact on pulse wave velocity 
and as a consequence recommendations exist to standardise conditions (the control 
of room temperature, the timing of measurements, the avoidance of caffeine and 
alcohol for 3 and 10 hours respectively and the maintenance of consistent position 
(supine recommended) for all measurements.333  
 
Non-invasive bedside techniques 
A number of devices exist for the “bed-side” estimation of PWV and if the 
aforementioned external factors are controlled, variability in measurements remains 
between the devices and is dependent on: i) the site of measurement, ii) the 
algorithm used for timing of the pressure wave transit (TT) and iii) the method 
employed for calculating path length.  
Site of measurement 
Pulse wave velocity may be a surrogate marker of plaque burden or arterial 
calcification.334, 335 Studies have looked at its predictive value and it is clear that the 
site of measurement is important.  In end-stage renal disease whereas the upper and 
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lower limb PWV have no predictive value, the aorto-iliac pathway measured via 
carotid-femoral PWV is a predictor of cardiovascular and all cause mortality336, 337.  It 
is the carotid-femoral PWV (cfPWV) that is thought to be the most clinically relevant 
and robust measurement.  Studies have confirmed cfPWV to be an independent 
predictor of coronary artery disease in hypertensives and diabetics as well as the 
general population including the elderly and it is at present considered the gold 
standard.197-202, 297, 338  
 
Measurement of transit time 
The TT is the time delay of a waveform between two pulse points.  Originally it was 
not clear which part of the pressure wave should be used as the point of reference.  
Options included the point of minimum diastolic pressure, the first systolic peak (the 
point at which the first derivative of pressure is maximum), the late systolic peak (the 
point at which the second derivative of pressure is maximum) and the foot of the 
wave (the point yielded by the intersecting tangent to the initial systolic upstroke of 
the pressure tracing and a horizontal line through the minimum point).  The latter 
model, known as the “intersecting tangent model” is considered to be the most 
reproducible and there are theoretical reasons why this is likely to be the case; the 
foot of the wave is least likely to be influenced by distortion of the pressure waveform 
during its forward propagation through the arterial tree attributable, for example, to 










Figure 6 Measurement of carotid-femoral PWV with the foot to foot method. (reproduced with 
permission from the European Society of Cardiology © Eur Heart J. 2006; 27(21): 2588-605; Laurent S, 
Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al338.  
Currently available devices differ significantly with respect to measuring the TT.  The 
Complior® device uses pressure transducers for simultaneous recording of the 
carotid and femoral pulses that then use a correlation algorithm between each 
simultaneously recorded wave to derive the transit time. The SphygmoCor (AtCor 
devices. The Complior Systemw (Colson, Les Lilas, France)
employs dedicated mechanotransducers directly applied on
the skin.44 The transit time is determined by means of a cor-
relation algorithm between each simultaneous recorded
wave. The operator is able to visualize the shape of the
recorded arterial waves and to validate them. Three main
arterial sites can be evaluated, mainly the aortic trunk
(carotid-femoral) and the upper (carotid-brachial) and
lower (femoral-dorsalis pedis) limbs. This system was used
inmost of the epidemiological studies demonstrating the pre-
dictive value of PWV for CV events (Table 4).
Pressure waves can also be recorded sequentially from
different sites, and transit time calculated using registration
with a simultaneously recorded ECG. In the SphygmoCorw
system (ArtCor, Sydney, Australia), a single high-fidelity
applanation tonometer (Millarw) to obtain a proximal (i.e.
carotid artery) and distal pulse (i.e. radial or femoral)
recorded sequentially a short time apart and calculates
PWV from the transit time between the two arterial sites,
determined in relation to the R-wave of the ECG. The time
between the ECG and the proximal pulse is subtracted
from the time between ECG and distal pulse to obtain the
pulse transit time. The initial part of the pressure waveform
is used as a reference point. It is also possible to check
offline the variability of measurement over a range of
pulses, according to each algorithm. Since the measure-
ments are made a short time apart, the change in the isovo-
lumic period of the LV or heart rate variability has little or no
effect on measured pulse transit times.
Japanese researchers advocated the use of brachial-ankle
pulse-wave velocity (baPWV) and showed the aortic PWV
was the primary independent correlate of baPWV, followed
by leg PWV.47 Previous remarks concerning the calculation
of the path length apply here. In small cohorts of either
elderly community-dwelling people48 or coronary heart
disease patients,49 baPWV was an independent predictor
for CV deaths and events.
Methods using mechanotransducers or high-fidelity appla-
nation tonometers are well accepted for carotid-femoral
PWV measurement.
Methods based on Doppler probes and other methods
The distension waves obtained from the high-definition
echotracking devices (discussed subsequently) can be used


































































































































































































































































































































































































































































































































































































































































































Figure 1 Measurement of carotid-femoral PWV with the foot to foot
method.
2592 S. Laurent et al.









Medical, USA) device uses a tonometric transducer in a two-step process recording 
the pressure waves sequentially.  It then calculates the transit time between the 2 
arterial sites determined in relation to the R wave of the ECG. A limitation of this 
method is that since measurements are performed sequentially and compared 
through ECG-gating, error is introduced in the presence of a variable heart rate, and 
patients with arrhythmias such as atrial fibrillation are as a consequence very hard to 
assess.  A third device, Vicorder (Skidmore Medical, UK) simultaneously records the 
pulse waveform at the carotid and femoral site using inflatable cuffs and an 
oscillometric signal, which is digitally analysed to extract the pulse time delay in real 
time.  
 
These devices have been compared in head to head studies with some conflicting 
results. In comparisons between SphygmoCor and Complior®, Rajzer et al showed 
that differences in PWV between devices were as a result of path length rather than 
transit time measurements, whereas Millaseau et al demonstrated that the 
SphygmoCor device had significantly shorter transit times compared to the 
Complior® device, which ceased to be the case when the intersecting tangent model 
was applied to the Complior® data, suggesting that the algorithms were responsible 
for the disparity.  In these studies and others Complior® device has been shown to 
both overestimate and underestimate PWV compared to the SphygmoCor.340-342  
Improved reproducibility has been demonstrated in a more recent study containing 
increased numbers of patients for both these devices.342-345  
 
Hickson et al revealed significant differences in transit times between the 
SphygmoCor and Vicorder devices, although there was good overall linear 
agreement.  Further analysis confirmed that the differences in transit times were not 
due to the algorithms but path length differences.  There was a suggestion that at 
higher PWVs there is an inherent bias toward lower Vicorder PWV values compared 
to the SphygmoCor, which may be due to fixed stiffness to the extra segment of 
femoral artery included in the Vicorder measurement.  Alternatively, a low signal-
sampling rate could potentially cause larger errors in transit time.  The difference in 
sampling rates between The Vicorder (556Hz) and the SphygmoCor (acquired at 
128Hz and analysed at 1KHz) is unlikely to explain the inherent bias seen.346  Of the 
other studies that have compared these devices Kracht et al showed good 
reproducibility with comparable values for both devices but were studying younger 
people with PWVs whose values were lower than those where bias was identified by 
Hickson et al.347  A third study found the Vicorder to be less reproducible than the 
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SphygmoCor in a sample size of 30, with limits of agreement of  -4.24  to 4.72 m/s 
and -1.53 to 1.71m/s and co-efficient of variations of 22% and 7% respectively.348 At 
present no published data exist on the reproducibility of these measurements in 
COPD, where large intrathoracic pressure swings may have a considerable effect.349 
 
Measurement of path length 
The path length is estimated using a tape measure or callipers over the body surface 
between the carotid and femoral measuring sites. Different strategies of 
measurement have been employed by different investigators which can significantly 
affect the value of cfPWV derived, in some cases by up to 30%.340, 350, 351  Despite 
these discrepancies some studies fail to identify which method has been used.352  
The lack of standardisation extends to manufacturers who recommend the use of 
different derivations. The “direct measurement” (A), from carotid pulse site to femoral 
pulse site results in an overestimation of path length and therefore PWV.353  Other 
methods include suprasternal notch-to-femoral site (B), suprasternal notch-to-femoral 
site minus suprasternal notch-to-carotid site (C), carotid-to-femoral site minus 
suprasternal notch-to-carotid site. Invasive studies have suggested that the use of 
suprasternal notch-to-femoral site minus suprasternal notch-to-carotid site to 
calculate the distance during non-invasive measurements gives the best agreement 
with invasive data and predicts mortality in certain populations, although the invasive 
measurement in question only measured the PWV within the aorta and therefore 
does not necessarily equate to the real cfPWV which includes any additive effect that 
may arise in the iliac and carotid vessels.353, 354  
 
 
Figure 7 Different measurement techniques for path length; A: direct method; B: suprasternal notch 
to femoral site; C: B - suprasternal notch to carotid site (reproduced with permission from the European 
Society of Cardiology © Eur Heart J. 2006; 27(21): 2588-605; Laurent S, Cockcroft J, Van Bortel L, 
Boutouyrie P, Giannattasio C, Hayoz D, et al)338.  
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From a methodological point of view the precision of any particular measured 
distance is dependent on the accuracy of identifying the measurement site and the 
precision of the tape measure.  For those techniques that involve 2 measurements 
the error is made twice, is cumulative, and in certain circumstances may be larger 
than the discrepancy between different path length techniques.351  Furthermore, this 
study can only validate the specific device being tested (SphygmoCor) and further 
invasive studies are warranted involving different devices with the use of different 
path length measurements.  Until such a time that this occurs, with the exception of 
the SphygmoCor device, it seems reasonable to follow the manufacturers 
recommendations for path length measurement.  Despite this lack of standardisation, 
algorithms derived for the conversion of path length measurements has enabled the 
comparison and combination of values from different trials.251, 297, 351   
 
Augmentation index: The assessment of wave reflections 
 
The arterial pressure waveform is created by a combination of the forward pressure 
wave created by ventricular contraction and reflected waves which are reflected in 
the periphery at branch points or sites of impedance mismatch.  Whereas in elastic 
vessels with low PWV these reflected waves arrive in diastole, in stiff arteries the 
reflected wave may arrive in early systole, superimpose on the forward wave and 
boost systolic pressure (Figure 8). This phenomenon can be quantified through the 
augmentation index, defined as the difference between the first and second systolic 
peak, expressed as a percentage of the pulse pressure.  Values of augmentation 
index are derived from a process called pulse wave analysis.338  The nature of 
reflected waves in the periphery do not exactly mirror those centrally.  Whereas in the 
upper limb the reflective wave returns between 90-130 ms after the initial systolic 
upstroke, in the aorta the later return of more distal reflections tend to result in the 
augmentation occurring after 150ms.  It is however entirely impractical to use 
invasive techniques to assess central pressure waveforms in routine practice and the 
development of non-invasive devices which allow for measurement of arterial 
stiffness, including reliable and reproducible estimations of central pressures and 













Figure 8 Carotid pressure waveform as recorded by applanation tonometry. The height of the late 
systolic peak (P1) above the inflection (P2) defines the augmentation pressure, and the ratio of 
augmentation pressure to PP defines the AIx (in percent). (reproduced with permission from the 
European Society of Cardiology © Eur Heart J. 2006; 27(21): 2588-605; Laurent S, Cockcroft J, Van 
Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al338. 
 
PWA studies have sought to estimate central aortic pulse wave morphology through 
the analysis of the radial artery waveform by applanation tonometry.  Some have 
sought to estimate central pressures through the direct analysis of the radial artery 
morphology, through the temporal relationship to the aortic systolic peak and analysis 
of the late systolic shoulder.   Although they provide reasonable estimates of central 
and pulse pressure they do not provide any information on central aortic 
augmentation index.  Further limitations with these methods include the need for 
information on vessel diameter and significant inaccuracy in identifying the systolic 
shoulder when wave reflections are either very early, very late or when the pulse 
pressure is below 35 or above 85 mmHg.354   
 
Radial or brachial to aortic transfer functions 
The employment of radial to aortic transfer functions, the mathematical process by 
which the central pulsatile phenomenon can be estimated from peripheral waveforms 
have been calculated for the radial artery and incorporated into commercial devices, 
although this was initially met with scepticism.355, 356  Concerns included the accuracy 
of the transfer function and the fact that the original transfer function was based on 
invasive rather than non-invasive oscillometric estimations of blood pressure, while 
others argue that it is simply not possible to develop a single mathematical function 
that can accurately account for the many variables introduced by human variation 
and the impact of disease states.357-360 Subsequent validation studies demonstrated 
that transfer functions do improve the fit between estimated and measured values by 
up to 96%.361 Prospective validation studies showed that calculations of the aortic 
pressure wave (including augmentation) from the radial pressure wave agreed with 
measured aortic values to US Association for the Advancement of Medical 
Arterial pressure waveform should be analysed at the
central level, i.e. the ascending aorta, since it represents
the true load impo ed to th LV and central large artery
walls. Aortic pressure waveform can be estimated either
from the radial artery waveform, using a transfer func-
tion,77–79 or from the common carotid waveform. On b th
arteries, the pressure waveform can be recorded non-
invasively with a pencil-type probe incorporating a high-
fidelity Millar strain gauge transducer (SPT-301, Millar
Instruments). The most widely used approach is to perform
radial artery tonometry and then apply a transfer function
(Sphygmocor, AtCor, Sydney Australia) to calculate the
aortic pressure waveform from the radial waveform.77–82
Indeed, in contrast to the carotid artery, the radial artery
is well supported by bony tissue, making optimal applana-
tion easier to achieve.
Individual and generalized inverse transfer functions are
applied to reconstruct the aortic waveform from radial
tonometry.77–79 The e timation of central aortic pressures
is accepted as more accurate than the estimation of AIx (dis-
cussed subsequently).76,83–85 In addition, brachial artery
pressures re used as surr gates of radial artery pressures
for the calibration of central pressures, and this may intro-
duce some errors.64
De p te these lim ations, radial tonometry is popular,
since it is simple to perform and well tolerated. Carotid
tonometry requires a higher degree of technical expertise,
but a transfer function is not n cessary, since the arterial
sites are very close and waveforms are similar.77
There are two major issues in quantification of reflected
waves on central pressure waveforms. First, it is necessary
to assess the timing and the proportion of the reflected
wave, i.e. the time necessary for the pressure wave to
reach the reflection site (which is a theoretical site rather
than an actual site, as the reflected wave is a composite
of many reflected ‘wavelets’) and return. The inflection
point is the point in time which coincides with the peak of
the flow wave in the artery. The proportion of reflected
pressure wave is assessed through the AIx. As it is calculated
as the ratio between the augmentation pressure (pressure
above the inflection point) and pulse pressure, it is dimen-
sionless and usually expressed in percentage, but it does
not depend on the absolute pressure. Although the use of
a radial-to-aortic transfer function for the measurement of
central systolic blood pressure has been well estab-
lished,78,79 the accuracy of this approach for the determi-
nation of aortic AIx has been disputed.28,83–85 Indeed, the
measurement of AIx is dependent on higher frequency
signals than blood pressure measurement and the transfer
function appears to be less accurate and to show greater
between-subject variability at high frequencies.78,79,83
The second issue, more challenging,83,84 is the estimation
of absolute values of central pressures, including pulse
pressure, augmentation pressure, or systolic blood pressure.
Although the AIx is a relative measurement and can be
calculated without calibration, central pulse pressure,
augmentation pressure, and systolic blood pressure are
absolute values and require calibration. Direct measure-
ments obtained at the site of the common carotid artery
using applanation tonometry can be calibrated according
to the methods suggested by Kelly and Fitchett63 and Van
Bo tel et al.,7,31,64 with adaptation (Figure 4). Calibration
of the artery tonometer pressure wave is based on the
observation that mean BP is constant throughout the large
artery tree and that diastolic BP does not change substan-
tially.8 In practice, BP is measured at the reference artery,
in general, the brachial artery, with a validated BP device
and PP is calculated as SBP minus DBP. Applanation tonome-
try is performed at carotid artery. From these data, the
absolute value of PP at the target artery can be calculated.
An alternative is to compute mean BP on the carotid
pressure wave from the area of the wave in the correspond-
ing heart period. Carotid mean BP is then set equal to
brachial mean BP. Carotid PP is then computed from the
diastolic BP and the position of mean BP on the carotid
pressure wave. Carotid SBP is obtained by adding PP to
DBP (Figure 4).7,45,61,63,86
A transfer function may be useful when applanation tono-
metry cannot be applied at the site of the carotid artery, for
instance, in obese subjects or in patients with major athero-
sclerotic plaques or calcified arteries, in whom this method
may not be free from any risk. However, the use of a transfer
function should be limited to the upper limb, where elastic
properties remain relatively constant with age and disease,
as previously discussed. It would allow assessing carotid
artery and ascending aorta systolic BP and PP from radial
artery PP.31,80
Cent l AIx and central pulse pressure have shown inde-
pendent predictive values for all-cause mortality in ESRD
patients,87,88 and CV events in patients undergoing percuta-
neous coronary intervention (PCI)89 and in the hypertensive
patients of the CAFÉ study.90
Box 4: Position statement: Central pulse-wave analysis.
Pulse-wave analysis should be optimally obtained at the
central level, i.e. at the site of the carotid artery or
the ascending aorta, and either directly recorded or com-
puted from the radial artery waveform using a transfer
function. Pulse wave should be analyzed through three
major parameters: central pulse pressure, central systo-
lic pressure, and the AIx.
Pulse-wave analysis at peripheral sites
Other techniques were derived from peripheral waveform
shape analysis. The determination of the amplitude ratios
of the second derivative of the pulse pressure waveform,
obtained by finger photoplethysmography (Fukuda Electric
Figure 3 Carotid pressure waveform is recorded by applanation tonometry.
The height of the l te systolic peak (P1) above the inflec (P2) defines the
augmentation pressure, and the ratio of augmentation pressure to PP defines
the AIx (in percent).
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Instrumentation (AAMI) SP10 criteria.196  Furthermore data presented to and 
accepted by regulatory bodies were obtained from over 600 subjects.362  
 
As alluded to in the “measuring regional arterial stiffness” section (p61), it has 
recently been demonstrated that significant augmentation of the pulse wave occurs 
between the brachial and radial artery measuring points, which may result in 
inaccurate estimates of central pressure and augmentation index if radial artery 
readings are calibrated with brachial BP.  Furthermore, the estimates obtained for 
central pressures are very dependent on which peripheral values are used for the 
calibration, no matter which device is used.  Some devices such as the Vicorder 
partly overcome this by assessing the pulse wave at the level of the brachial artery. 
The classic calibration techniques employed by the commonly used SphygmoCor 
device have been shown to systematically underestimate central pressures 
compared to other commercially available devices which also employ transfer 
functions.  These findings have been replicated by Pucci et al, who have recently 
shown that although when calibrated against invasive diastolic pressure the central 
systolic pressure estimates obtained fulfilled the standards set by the AAMI for non-
invasive measures of blood pressure for both the Vicorder and SphygmoCor, this 
ceased to be the case when the devices were calibrated against non-invasive 
brachial measures of diastolic pressure.  Of the devices measured, the Vicorder, 
which employs an oscillometric technique at the level of the brachial artery, was the 
most accurate. Weber et al have also confirmed the ability to measure the pulse 
wave and peripheral blood pressure with a brachial cuff on an alternative device to 
accurately estimate central blood pressure with the use of a transfer function.327, 328, 
363, 364 
 
Although employed, the use of the transfer function for the estimation of 
augmentation index is more challenging due to the dependency on higher frequency 
signals, where it has been shown the transfer function appears to be less accurate 
and to show greater between subject variability.196, 365  Under-estimations of between 
6 (+/-20) % and 7(+/-9) % compared to invasively measured central values have 
been demonstrated.361, 366  Furthermore, many factors influence augmentation index, 
including the duration and pattern of ventricular ejection, exercise, time of day, age 
and medication.367-371  It is estimated that for every 1 bpm increase in heart rate there 
is a 0.6% absolute decrease on augmentation index.372   In population studies there 
appears to be a linear relationship between age and augmentation index up to 
approximately 60 years of age, where other factors such as changes to cardiac 
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output and LV ejection flow wave come into play.370, 373 It is therefore important to 
standardise conditions as much as possible and when this strategy is employed the 
values obtained for augmentation index are reproducible in a number of different 
populations, with significant correlations between different devices and acceptable 
variation.342, 345   
 
Predictive value of augmentation index 
Despite this variability the values obtained seem to have clinical relevance.  Some 
longitudinal studies have shown AI to be a predictor of all cause and cardiovascular 
mortality and events in patients with coronary heart disease, end stage renal disease, 
and following cardiac intervention.200, 374-377  Furthermore, a reduction in AI due to a 
reduction in the reflected wave, during therapeutic trials of hypertensive agents has 
resulted in favourable outcomes in both REASON (reduction in left ventricular mass) 
and CAFÉ (cardiovascular events).367, 378   However, other studies including those 
with end-stage renal disease and elderly populations could find no independent 
association between augmentation index and cardiovascular endpoints.379, 380 This 
topic has been subject to a recent systematic review and meta-analysis. There was 
significant heterogeneity amongst the studies for cardiovascular events but not total 
mortality.  Overall there was a relative risk for an absolute increase of central 
augmentation index by 10% of 1.318 and 1.384 for total cardiovascular events and 
total mortality respectively which corresponded to a risk increase of 31.8% and 
38.4%.  These findings were independent of blood pressure and heart rate.381   
Cardiac MRI 
 
Cardiovascular magnetic resonance (CMR) imaging has developed rapidly over the 
last two decades. CMR provides unparalleled image quality non-invasively, which is 
reflected in excellent accuracy and reproducibility. A major strength of CMR is the 
ability of multi-parametric imaging in one session. This versatility, the reproducibility 
and the non-invasiveness are key advantages of CMR over other advanced imaging 





Cardiac volumes and function 
 
Cardiovascular magnetic resonance (CMR) imaging is highly accurate and 
reproducible in measuring left ventricular (LV) volumes and mass and now 
established as the gold standard.382-384  To this end, CMR is highly superior to 2D 
echocardiography, partly due to the excellent image quality, but very importantly due 
to the avoidance of geometric assumptions that may lead to inaccuracies. 3D 
echocardiography is a promising new modality, as it avoids geometric assumptions 
as well, but without echo contrast administration underestimates the LV volumes  and 
sufficient image quality will not be achieved for both LV and RV.385 This insufficient 
image quality may not be random, and thus may prevent acquisition of cardiac data 
in important subgroups of subjects (e.g. with chronic obstructive airways disease or 
obesity). Most importantly, 3D echocardiography has not got the capability of the 
multi-parametric approach, which makes CMR so powerful. For CMR, compared to 
cast volume displacement of the left ventricle, a correlation of 0.99 was found.386 
Inter-study reproducibility has been reported in the range of 5% for LV mass and 
volume parameters in single centre studies.387-390  The accuracy and reproducibility of 
CMR in analysing cardiac volumes, function, and mass in heart failure compared to 
echocardiography allows for a substantial reduction in the number of patients needed 
in clinical trials.391  
 
Left ventricular end-systolic volume is an important diagnostic and prognostic factor 
in heart disease.392 Left ventricular hypertrophy and mass are powerful predictors of 
cardiovascular disease morbidity and mortality.393-396 Both systolic and diastolic 
parameters can be derived from standard CMR cine volume studies, such as peak 
contraction and filling rates and time to peak contraction and filling rates.  
 
LV ejection fraction is the most established endpoint in the medical community and 
has been extensively validated for diagnostic and prognostic purposes.397 In the 
available consensus statements, EF is the only specified marker for the diagnosis 
and classification of heart failure, whereas for the RV this measure gets little mention, 
partly due to lack of validation in large multicentre trials and partly due to the 
variability of the measurements.398  The shape of the RV is more complex than the 
LV and one cannot rely on one- or two-dimensional geometrical assumptions.  Right 
ventricular volume and mass can be determined without geometric assumptions from 
the same CMR dataset used for the left ventricle and is considered the most accurate 
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and reproducible for RV assessment.399 Many CMR publications found, as expected, 
similar left and right ventricular stroke volumes in healthy individuals but 
measurements remain more variable although still excellent given the complex shape 
of the RV.387, 400  Caudron et al have looked at variability of measurements in 
acquired heart disease and found a number of factors contribute to the variability, 
including the observers’ experience, choice of RV basal slice and processing time.401  
Tagging and other non-invasive measures of myocardial 
deformation 
 
Assessment of myocardial regional wall motion plays a key role in many diagnostic 
and therapeutic decisions in current clinical practice. Regional wall motion 
quantification may be a powerful tool to detect sub-clinical cardiovascular disease. 
Semi-quantitative grading of regional wall motion is the most frequently applied 
technique, but it is highly subjective and has limited reproducibility.  Tissue Doppler 
ultrasonography (US), strain imaging, and strain-rate imaging with echocardiography 
are highly dependent on transducer angulation and thus have inherent limitations in 
regard to complete three-dimensional myocardial coverage and reproducibility.402 
 
Left ventricular strain measurement abnormalities detected by CMR have been 
demonstrated to be earlier and more sensitive markers of contractile dysfunction than 
global LV EF in hypertrophic and hypertensive cardiomyopathy and chemotherapy 
induced cardiotoxicity.  Various techniques have been applied including displacement 
encoding with stimulated echoes and real-time myocardial strain encoding.403  CMR 
tagging is currently considered the “reference” method for regional wall motion.  It is 
used by a large number of centres and has been validated across different patient 
populations and showed good intra- and interobserver variability of both systolic and 
diastolic parameters in MESA.404-406  Radiofrequency and gradient pulses are used to 
saturate lines in the myocardium in which the signal is destroyed, and the lines 
therefore appear black, in a process by the name of spatial modulation of 
magnetisation (“SPAMM”).  The resultant tag-lines are used as non-invasive 
myocardial markers which are used to identify regional changes in deformation or 
strain during the cardiac cycle.  The movement of these lines throughout the cardiac 
cycle can be analysed in a semi-automated way in order to calculate local myocardial 
strain, which can be derived in circumferential, radial or longitudinal directions.   
Limitations persist with this technique, including the loss of tag definition in diastole 
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as magnetisation recovers towards equilibrium.  Efforts have been made to improve 
this with the use of complimentary SPAMM (CSPAMM).  Other practical limitations 
exist including the need for further images to be acquired. 
 
A novel–post processing technique called feature tracking has been developed which 
is a vector based analysis tool that uses a hierarchical algorithm to track in 2-
dimensions certain myocardial voxel features on standard SSFP images, thus 
deriving measures of strain and velocity in a similar manner to speckle-tracking and 
negating the need for specialised tagged images (Figure 9).407  A number of different 
parameters can be obtained directly or calculated from the raw data including 
endocardial velocity, which reflects the speed of the endocardium (cm*s-1 for radial 
and longitudinal velocities and deg*s-1 for circumferential velocities); strain, reflecting 
thickening/thinning in short-axis plane and shortening/lengthening in long-axis plane; 
endocardial strain rate, reflecting speed at which deformation occurs (measured in 
deformation*s-1) and torsion, calculated by dividing the difference in absolute values 
of circumferential velocities of the basal and apical slice by their distance  which 
reflecting the twist between the base and the apex of the LV. 
 
Initial studies looked at global strain on individual short axis slices.408, 409  It compared 
favourably with circumferential strain as measured by HARP in Duchene’s muscular 
dystrophy patients and has even allowed further clinical stratification that was 
otherwise may not have been possible.403  Subsequent studies have looked at the 
segmental level where these non-invasive post-processing tools have been used to 
identify LV dysynchrony through regional differences in radial strain, although other 
studies have found this parameter to be highly variable.  At present it appears that 
circumferential strain is the most reproducible parameter with apical values tending to 
be the most variable for all types of strain measurement, a situation also noted with 
tagging.407 An alternative algorithm has been developed for use on SSFP cine 
images which utilise a constrained deformable model.410  At present there is no data 















Figure 9 Feature tracking analysis for radial and longitudinal velocities of the left ventricle.  The 
48 blue lines represent tracking of the endocardial borders and the green vectors represent absolute 
values of the velocities. 
 
Imaging of pulmonary arteries 
 
The imaging of the pulmonary outflow tract with CMR has been incorporated into the 
routine assessment and management of congenital heart disease and is being 
increasingly employed within the field of pulmonary vascular disease. Traditional 
methods within these fields have involved the use of invasive assessment through 
right heart catheterisation or non-invasive assessment with echocardiogram with its 
inherent limitations of inadequate acoustic windows, short ultrasound penetrating 
depth or insufficient tricuspid regurgitation to estimate pulmonary pressure, a 
situation which is noted in 10-25% of pulmonary hypertension patients.411 412  The 
increasing number of conditions associated with pulmonary hypertension, including 
COPD, has led to an increased need for a less invasive assessment in the 
preliminary stages of the key endpoints that allow the close monitoring of those with 
less severe disease.413   
 
Pulmonary artery pulsatility 
The highly distensible pulmonary artery plays a key role in dampening the pulsatile 
flow from the RV prior to its arrival at the capillary level.414  This right ventricular–
pulmonary artery coupling is essential for the preservation of right ventricular 
haemodynamics, and alterations in pulmonary artery compliance may result in 
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elevated RV pulsatile workload and reduced contractile performance as seen in 
pulmonary hypertension.415  The changes in pulmonary artery compliance will 
precede any right ventricular remodelling that takes place and may represent a 
method by which early changes can be identified.   
 
Compliance is defined as the absolute change in lumen area for a given change in 
pressure and direct measurement necessitates knowledge of pulmonary artery 
pressure which is mainly acquired through invasive monitoring with right heart 
catheterization, a procedure not without risk and which does not readily lend itself to 
screening or use in research.414  Vessel wall stiffness (beta) can be calculated form 
the equation proposed by Hayashi et al and Kawasaki et al:416 417 β = [ln 
(PS/PD)]/(2Δ A/A), where PS/PD is the ratio to systolic and diastolic pressure and Δ 
A/A is the relative cross-sectional area change.  Previous research has shown that 
there is strong linear relation between systolic and diastolic pressure across a wide 
range of pulmonary artery pressures, thus implying that PS/PD is constant and Δ A/A 
the relative area change or RAC is inversely proportional to the stiffness constant 
and represents pulmonary artery elasticity.418  Given that the RAC (maxArea – 
minArea/min area) can be obtained non–invasively, CMR imaging therefore offers an 
attractive alternative by which non-invasive assessment may take place.  RAC has 
been shown to be reduced in pulmonary hypertension and furthermore is a predictor 
of exercise capacity, mortality and predicts response to treatment in certain 
groups.415, 418-421  Alterations in PA elasticity are observed in the course of the 
disease even before overt pressure alterations.414    RAC has good sensitivity for the 
detection of early elevations in pulmonary vascular resistance (PVR), prior to the 
development of any RV abnormalities.   Higher distending pressures therefore do not 
fully account for the increased stiffness suggesting a role of altered PA intrinsic 
elastic properties which may be particularly pertinent when considering pulmonary 
artery function in COPD.  It is feasible that the postulated mechanisms that contribute 
to aortic stiffness, lung hyperinflation, neurohumoral activation and systemic 
inflammation422, may also be involved in pulmonary artery stiffening.   One study has 
looked at pulmonary artery stiffness in COPD (SPAP 30 =/- 7.9) using 
echocardiography and has found stiffness to be increased compared to controls and 
related to NYHA functional class.423  Limitations of this study was an incomplete data 
set due to poor acoustic windows, the method by which the RPA was measured was 
not by a standardised method with the potential for underestimation of area change 


































All aspects of this thesis were conducted in accordance with the principles of the 
Declaration of Helsinki.  The COPD and cardiovascular disease database study 
received a favourable ethical opinion from the NRES Committee London – South 
East (11/LO/0562).  The Lung Deflation study (Eudract 2012-000927-42) received a 
favourable ethical opinion NRES Committee London – Chelsea (12/LO/0869).  The 
HAPPY London study received a favourable ethical opinion from NRES Committee 
London Central (13/LO/0094). 
 
Patient selection  
 
COPD patients were recruited from outpatient clinics at Bart’s Health NHS Trust, via 
advertisement, from the affiliated University Cardio-Respiratory Research Centre and 
from local General Practitioners.  The patients were identified by their primary care-
provider.   
 
Non-smoking and smoking controls for Chapter 5 were recruited from the HAPPY 
London cohort, an e-health cardiovascular primary prevention study for people with 




The diagnosis of COPD was made according to published criteria:424 A post 
bronchodilator FEV1/FVC ratio of <0.7 was required.  Patients were over 40 years of 
age with at least 15 pack-year smoking history. For the lung deflation study further 
requirements included post bronchodilator FEV1 of < 70%, evidence of lung 
hyperinflation (RVol ≥120 % predicted), demonstrating evidence of reversibility post 
bronchodilator of ≥ 7.5% predicted, and MRC score >1.   
 
Patients were eligible to act as smoking control subjects if they were smokers with no 
history of underlying respiratory disease and no evidence of airflow obstruction or 
limitation on spirometry.   
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General exclusion criteria included the presence of significant respiratory problems 
other than COPD e.g. clinically significant bronchiectasis or fibrosis (a history of 
previous asthma was acceptable provided the predominant diagnosis is COPD) and 
if they were unable to undergo study procedures; in particular, if they had contra-
indications to CMR in the case of the MRI studies. 
 
Lung function measurements 
 
All pulmonary function measurements were made after any cardiovascular 
assessments, after reliever therapies had been withheld for over 6 hours, refraining 
from exercising for 2 or more hours, smoking for 1 hour, exposure to cold air for 15 
minutes and after refraining from drinks with high levels of caffeine such as tea and 
coffee. 
 
The measurement of lung volumes: Plethysmography 
IC, SVC and TGV were measured before any other lung function measurements 
using whole body plethysmography (ZAN500, Germany) in a paired manoeuvre.    
Measurements were made as previously described in ATS/ERS guidelines.70 
Briefly, body plethysmography, first described by DuBois in 1956, applies the 
principle of Boyle’s Law which states at a constant temperature, the product of 
Pressure (P) and Volume (V) in a sealed vessel will be constant, (P1V1 = P2V2).  
The plethysmograph contains a pneumatograph which allows measurement of 
airflow and transducers which measure the mouth and box pressure respectively.  At 
the beginning of the test the subject has an unknown volume of gas in their chest. 
The subject is asked to breathe at their resting tidal volume.  A shutter interrupts their 
breath and measures the mouth pressure at end expiration when, since there is no 
airflow, the pressure of the gas in the alveolus is known to be atmospheric.  If his 
airway is then occluded so that no pulmonary gas can escape and he/she 
compresses the pulmonary gas through a voluntary respiratory manoeuver, the 
pulmonary gas will have a new pressure and volume.  The change in pulmonary gas 
pressure can be measured since mouth pressure equals alveolar pressure in a 
closed system.  From knowledge of the original pulmonary gas pressure and of the 
change in pulmonary gas pressure and volume, the original volume of gas in the 
chest, the thoracic gas volume or TGV, can be calculated.425  This is combined with 




Three valid spirometry efforts were attempted (with no more than eight) using the 
ATS/ERS guidelines on automated pulmonary function testing equipment (CPL PFT, 
United states or Microlab 3500, Micromedical, UK).426   Post bronchodilator-
salbutamol FEV1 and FVC were performed 15-20 minutes after the administration of 
400mcg of salbutamol.  Percentage predicted values were calculated according to 
NHANES III reference equations.427 
 
Diffusion capacity 
TLCO is used to assess the gas-exchange ability of the lungs, specifically 
oxygenation of mixed venous blood. The most commonly used method is the single-
breath method or breath-hold technique.  The technique was performed on 
automated pulmonary function testing equipment (CPL PFT, United States) 
according to manufacturers’ instructions and in accordance with ERS/ATS guidelines 
by a qualified respiratory physiologist with over 30 years experience.428 
 
Bedside measurements of PWV and augmentation index 
 
All measurements were performed by a single investigator with 18 months 
experience in arterial stiffness measurements (IS). IS was blinded to all previous 
bedside measurements of arterial stiffness except in the Vicorder reproducibility 
study (chapter 5). The brachial blood pressure was used to calibrate both the 
Vicorder and SphygmoCor devices.  In situations where both devices were employed 
(Vicorder Comparison Study; Chapter 5), the SphygmoCor measurements were 
performed first, followed by the Vicorder measurements. 
 
All arterial stiffness measurements were in a temperature controlled room with the 
patient rested for 15 minutes in a supine position and awake.  Patients were required 
to refrain from vasoactive medications for 2 hours, bronchodilator therapy for 6 hours, 
alcohol for 10 hours and smoking and caffeine for 3 hours prior to the measurements.   
Measurements were performed prior to CMR and lung function manoeuvres except 
during the estimation of central aortic pulse pressure while measuring aortic 
distensibility, which took place inside CMR scanner at the time of scanning. For those 
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measurements performed at the bedside, measurements were repeated 3 times and 




Measurements were obtained by placing a 10cm wide blood pressure cuff around the 
upper right thigh for measurement of the femoral pulse and a 3 cm wide partial cuff 
around the neck at the level of the carotid artery.  The path-length was calculated 
according to manufacturers instructions, from the suprasternal notch to a defined 
point on the upper part of the femoral Cuff.  The cuffs were inflated simultaneously to 
65 mmHg and 2 high quality waveforms were simultaneously recorded for 3 seconds 
using a volume displacement method.  The foot-to-foot transit time (TT) was 
measured as described previously and values for cfPWV were derived 
automatically.346   
Pulse	wave	analysis	
Two brachial blood pressure readings were obtained using a manual 
sphygmomanometer used for calibrating peripheral waveforms and immediately 
afterwards a brachial pressure wave trace was digitally computed by the Vicorder 
with the cuff statically inflated to 70 mmHg using a volume displacement technique.  
A previously described brachial-to-aortic transfer function was then applied by the 
Vicorder software to calculate the waveform and values for central BP.329 The first 
and second central systolic peaks were automatically identified by the software and 
used to calculate the augmentation index (difference in amplitude between first and 




The SphygmoCor device (software version CvMS V9, Atcor Medical) employs 
applanation tonometry (Miller Instruments Inc. Houston TX, USA) to sequentially 
record ECG gated carotid and femoral artery waveforms. The system software 
calculated TT by the intersecting tangent method, using the R wave of a 
simultaneously recorded ECG as a reference frame. The path length was calculated 
according to the guidelines of the ARTERY society and manufacturers 
recommendation (supra-sternal notch to femoral artery recording site – suprasternal 




Two brachial blood pressure readings were obtained using a manual 
sphygmomanometer, used for calibrating radial artery waveforms, which were 
recorded using the same high-fidelity applanation tonometer described above.   A 
previously validated radial-aortic transfer function was then automatically applied to 
the waveform to derive central BP.196  The first and second central systolic peaks 
were automatically identified by the software and used to calculate the Augmentation 
index  (difference in amplitude between first and second systolic peak/pulse pressure 
x 100). 
 
CMR data acquisition 
 
CMR hardware 
CMR imaging was performed on a 1.5T CMR system (Achieva, Philips, Netherlands) 
using a Software release 3.2 and Cardiac package installed.  The CMR machine has 
32 receiver channels and a dedicated 32-channel cardiac coil.  All subjects were 
asked to complete a separate safety consent form prior to the procedure on each 
occasion.  This is a safety precaution to ensure that the patients have not been fitted 
with any ferromagnetic device. 
 
CMR	protocols	
CMR at 1.5T was performed for measurement of left and right ventricular volumes, 
function, mass and tagging, left atrial volumes and function and aortic and pulmonary 
artery distensibility. Black blood imaging was performed in the transverse, coronal 
and oblique sagittal planes (in the plane of the aorta).  
 
Aortic sections, distensibility and total arterial compliance 
For the aorta sections planes were defined perpendicular to the thoracic aorta at the 
level of the pulmonary artery, and 10–14cm below this plane, immediately below the 
diaphragm at the level of the abdominal aorta.  SSFP cine images were acquired at 
these image positions during end-expiration.  
Peripheral blood pressure was measured using a MRI conditional oscillatory 
sphygmomanometer (Vicorder, Skidmore Medical, UK) and central blood pressure 
estimated using a validated transfer function used in calculating distensibility where  
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Distensibility (%/mmHg) = [(maximum Area– minimum Area)/PP x minimum Area] x 
100.414   
 
Minimum and maximum values were derived using an in-house validated automated 
endoluminal border-tracking programme written in MatLab (v.7.5).  The section of 
interest (ascending, descending or abdominal aortic section) was selected and the 
centre of the lumen manually identified. The programme then tracks the endoluminal 
border through all phases of the cardiac cycle and calculates cross-sectional area for 
each phase.  This is achieved by the radial detection of a signal change (thresholding 
technique) in comparison to a region of interest around the manually identified centre 
of the vessel.  The automated detection was considered acceptable if within one pixel 
of where the investigator would have placed the contour. 
 
Total arterial compliance (TAC) was calculated with the use of the central pulse 
pressure derived as described above and the stroke volume, described below: 
 
TAC (ml/m2/mmHg) = Stroke volume Index / Central pulse pressure313 
 
Pulmonary artery sections 
For the pulmonary artery sections, planes were defined perpendicularly to the main 
and also to right and left pulmonary arteries prior to any secondary branches and 
SSFP cine images were acquired at end expiration with a typical temporal resolution 
of 17 ms.  For the purposes of this thesis no invasive monitoring of pulmonary artery 
pressures were performed and as such pulmonary artery distensibility or compliance 
could not be measured.  However, pulsatility or relative area change (RAC) was 
measured and was calculated as follows: 
 
Pulsatility (%) = (Maximum Area  – Minimum Area) /Minimum Area  x 100 
 









Ventricular volume, mass and function 
Ventricular volumes and function data were acquired at 1.5 Tesla.  After pilot 
imaging, a stack of 12 short axis SSFP cine slices was acquired from the atrio-
ventricular groove to the cardiac apex, perpendicular to the ventricular long axes. 
Acquisitions were performed during held end-expiration, using retrospective 
electrocardiographic gating. Sequence settings were: echo time 1.44 ms, repetition 
time 2.9 ms, in-plane field of view 205x380 mm, acquired voxel size 1.9×2.04 mm 
(reconstructed to 1.46×1.48 mm), acquisition matrix 108×186 (frequency encoding × 
phase encoding), slice thickness 8 mm and a 2 mm gap between slices, 30 
reconstructed frames per cardiac cycle (typical temporal resolution of 46 ms for a 
heart rate of 60 beats per minute), flip angle 60°.    
 
7 mm slice thickness with 3mm slice gap has been validated for the LV volumes, 
ejection fraction and mass and has been shown to be comparable to 6mm 
thickness/4mm gap and 7mm thickness/no gap protocols and it reasonable to 
assume that 8mm with a 2mm gap is equally comparable.430-432 
 
Left and right ventricular endocardial contours were manually segmented based on 
the short axis stack of cine images, at each slice position, at end-diastole and end-
systole and summed for the whole ventricle using semi-automated software using 
CVI 42 (Circle Cardiovascular imaging Inc, Calgary, Canada).  Basal slices were 
included in the LV segmentation if more than 50% of the lumen was surrounded by 
myocardium and a visual control of the short axis slice position on the 4-chamber 
view, as described previously. The identification of the basal slice within the RV is 
more challenging. Although some have advocated acquisition axial or perpendicular 
to the long axis of the RV, short-axis acquisitions have been chosen since it allows 
for assessment of ventricular wall morphology and function as well as being more 
validated.433-436,387 Papillary muscles were included in the ventricular volume and 
excluded from the LV mass calculation.437, 438 This segmentation was used to quantify 
left and right ventricular end-diastolic and end-systolic volumes, and to calculate 
ejection fraction, stroke volume and stroke volume difference.  Epicardial contours 
were also manually segmented at end-diastole for the left ventricle. The final results 
represented the sum of the volumes for each individual slice based on Simpson’s 
rule, while mass was derived from the myocardial volumes multiplied by the density 
of the myocardium (1.05g/ml). LV and RV parameters were indexed to body surface 
area (BSA) as determined by the Mosteller formula.439 
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Atrial volumes and function 
After pilot imaging, a stack of 14 to 16 short axis SSFP cine slices was acquired from 
the atrio-ventricular groove, perpendicular to the atrial long axis. Acquisitions were 
performed during held end-expiration, using retrospective electrocardiographic 
gating. Sequence settings were: echo time 1.4 ms, repetition time 2.8 ms, in-plane 
field of view 205x380 mm, acquired voxel size 1.9×2.04 mm (reconstructed to 
1.46×1.48 mm), acquisition matrix 108×186 (frequency encoding × phase encoding), 
slice thickness 5 mm and a 0 mm gap between slices, 30 reconstructed frames per 
cardiac cycle (typical temporal resolution of 44 ms for a heart rate of 60 beats per 
minute), flip angle 60°. Left atrial endocardial contours were manually segmented 
based on the short axis stack of cine images, at each slice position, at end-diastole 
and end-systole using dedicated software, CVI 42 (Circle Cardiovascular imaging 
Inc., Calgary, Canada).  This multiple slice method was the preferred option to the 
area length method, which leads to an underestimation of atrial volumes and over-
estimation of function in comparison.440   Pulmonary veins were excluded at their 
ostia and the left atrial appendage was excluded at its base as described 
previously.441 LA volume was automatically calculated from all the included slices.  
Slices were excluded in the segmentation if more than 50% of the lumen was 
surrounded by myocardium. This segmentation was used to quantify left atrial end-
diastolic and end-systolic volumes, and to calculate the atrial ejection fraction 
(ejection fraction = 100*(EDV– ESV)/EDV, where EDV is the end-diastolic and ESV 
the end-systolic volume.).  Atrial parameters were indexed to body surface area 
(BSA) as determined by the Mosteller formula.439, 442 
 
Feature and tissue tracking 
 
Feature tracking and tissue tracking analysis was performed using dedicated 
software (Image-Arena, Version 4.6, TomTec Imaging Systems GmbH, 
Unterschleissheim, Germany and CVI 42, Circle Cardiovascular imaging Inc, 
Calgary, Canada, respectively).  Following uploading of the image the brightness is 
optimized to ensure optimal endocardial to blood pool discrimination.  Both epi- and 
endocardial LV contours were drawn.  All contours were tracked semi-automatically 
in all views.  For a particular slice level, the first phase was used to draw a contour 
that was then automatically propagated by the software to all phases of the cardiac 
cycle for that slice.  Manual image analysis correction was performed where the 
automated tracking visually seemed to be inaccurate.  Poor tracking was considered 
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to be present when the movements of the points along the border deviated from the 
movement of the apparent endocardial border by more than 50% of the myocardial 
width, as described previously.407  Tracking data were only saved when the contours 
seemed to be accurate. The 2- and 4-chamber views were used to determine all 
longitudinal parameters; radial parameters were derived from both short axis (SAX) 
and long axis views whereas circumferential values were derived from the SAX 
views.  In the SAX views, three slices were analysed: basal, mid-ventricular and 
apical).  The basal slice is identified as being the first slice without the presence of 
the outflow tract throughout the cardiac cycle. The mid-ventricular and apical slices 
were a further 2 cm and 4 cm respectively towards the apex.442  Post-analysis 
processing in the case of feature tracking included averaging of the 48 (feature-
tracking) software-created tracking points for each slice.  In the case of tissue 
tracking the number of contour points depends on the length of the contour and 
varies from between 20-50 points.  Unlike in feature tracking, these points are not 
directly used to calculate the strain values, rather inputted into the deformation model 
algorithm which calculates the values.  The phase representing end-systole was 
identified by the smallest mid-ventricular volume.  This allowed assessment of 




CSPAMM (complementary spatial modulation of magnetisation) imaging combines 
steady state free precession imaging with myocardial tagging as discussed above.  
2D CSPAMM grid images (horizontal and vertical tags) were acquired at three levels 
(basal, mid-ventricular and apical), selected manually at the time of acquisition.  The 
basal slice is identified as being the first slice without the presence of the out-flow 
tract throughout the cardiac cycle. The mid-ventricular and apical slices were a 
further 2 cm and 4cm respectively towards the apex.442 Images were acquired in one 
slice per breath hold with good contrast to noise ratio such that the tag lines persisted 
throughout the cardiac cycle.443 444 Typical parameters were as follows: Field of view 
214 x 214 mm; reconstructed voxel size 1.11 x1.11 mm, echo time 11 ms, repetition 
time 25 ms, no parallel imaging, flip-angle 25o, maximum number of cardiac phases 
33 (depending on heart rate) and a grid lines spacing of 7.5 mm in both horizontal 
and vertical directions. Each breath hold was typically 10-15 seconds. CIM Tag 2-D 
(v7.0, Auckland, NZ) post-processing tool was used to analyse the tagging 





Continuous parametric variables were expressed as means with standard deviations 
whereas non-parametric and categorical data as medians with interquartile ranges. 
The distribution of each variable was evaluated for symmetry using a histogram, and 
for normality using a normal plot.  
 
Parametric tests 
Where all distributional assumptions necessary for the conduct of parametric tests 
were met, hypothesis testing for statistical significance was performed using 
independent samples two-tailed t-tests. T-tests were used in cases where a single 
observation was made in two groups. Where more than two sets of observations 
were made, the one-way analysis of variance (ANOVA) method was used. Where 
assumptions regarding equal variance between groups were violated, but data were 
otherwise suitable for parametric analysis, the Welch test (modified t-test for use with 
unequal variance) was used.  
 
Non-parametric tests 
Where distributional assumptions necessary for the use of parametric tests were 
violated, non-parametric tests were used as follows: Mann-Whitney tests for 
independent samples; Wilcoxon matched pairs signed rank sum tests for paired 
samples; Kruskal-Wallis tests for more than 2 observations on the same individual. In 
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Introduction Significant cardiovascular morbidity and mortality exists in chronic 
obstructive pulmonary disease (COPD).  Arterial stiffness is raised in COPD and may 
be a mechanistic link. Non-invasive assessment of arterial stiffness has the potential 
to be a surrogate outcome measure, although no reproducibility data exists in COPD 
patients.  
Methods Two studies (23 and 33 COPD patients) were undertaken to 1) assess the 
Vicorder reproducibility of carotid-femoral pulse wave velocity and Augmentation 
index in COPD; 2) compare it to SphygmoCor; and 3) assess the contribution of lung 
hyperinflation to measurement variability. 
Results There were excellent correlations and good agreement between repeat 
Vicorder measurements for carotid-femoral pulse wave velocity (r=0.96 (p<0.001); 
mean difference ±SD = -0.03+/-0.36m/s (p=0.65); co-efficient of reproducibility = 
4.02%; limits of agreement = -0.68-0.75m/s). Augmentation index significantly 
correlated (r=0.736 (p<0.001); mean difference ±SD = 0.72+/-4.86% (p=0.48), 
however limits of agreement were only 10.42-9.02%, with co-efficient of 
reproducibility of 27.93%. Comparing devices, Vicorder values were lower but there 
was satisfactory agreement. There was no correlation between lung hyperinflation 
(as measured by residual volume percent predicted, total lung capacity percent 
predicted or the ratio of inspiratory capacity to residual volume) and variability of 
measurements in either study. 
Conclusion In COPD, measurement of carotid-femoral pulse wave velocity is highly 
reproducible, not affected by lung hyperinflation and suitable as a surrogate endpoint 
in research studies. Day-to-day variation in augmentation index highlights the 












Significant cardiovascular morbidity and mortality exists in chronic obstructive 
pulmonary disease (COPD) which is independent of shared risk factors such as 
smoking.185   Different mechanisms linking these two common conditions have been 
proposed, including arterial stiffness, a surrogate shown to be an independent 
predictor of cardiovascular disease in a number of other chronic inflammatory 
conditions.198, 203  A spill over of inflammation from the pulmonary to the systemic 
circulation whose down-stream effects result in raised arterial stiffness could provide 
the mechanistic link between COPD and cardiovascular morbidity and mortality. 
Similarly neuro-humoral activation of the sympathetic nervous system as a result of 
lung hyperinflation may be a contributory factor.422    
 
Carotid-femoral pulse wave velocity (cfPWV) and Augmentation Index (AI) are non-
invasive measures by which arterial stiffness can be measured. The arterial pressure 
wave is formed by a composite of ventricular contraction and a reflected wave that 
arrives back early in stiff arteries, adding to the forward wave, augmenting systolic 
pressure and forming the second systolic peak.  This phenomenon can be quantified 
as the AI, defined as the difference between the 2 systolic peaks expressed as a 
percentage of the pulse pressure.  It is derived from pulse wave analysis (PWA) 
where peripheral artery waveforms are acquired and validated transfer functions are 
used to derive values of the Aortic AI.  cfPWV is estimated by measuring the transit 
time of the pulse wave between two pulse points.338   
 
A number of commercial devices exist for arterial stiffness measurement although at 
present no consensus exists as to which is the most accurate or reproducible.  A 
novel relatively operator-independent device is now available which has potential 
advantages for screening programmes and use in intervention studies.  It has 
compared favourably with the more established SphygmoCor device, considered by 
some to be the gold standard, in normal individuals, and those undergoing routine 
angiography.327, 346 Although CfPWV has been found to be raised in COPD and 
related to disease severity and other studies report on pulse wave analysis (PWA), 
no data exist on the reproducibility of these devices in COPD patients, who due to 
their lung hyperinflation may have large intra-thoracic pressure swings with 
potentially significant breath-to-breath variation in the pulse wave.   Such information 
is integral to the design and powering of longitudinal intervention studies.226, 227, 445 
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The aim of this study was: 1) To assess the reproducibility of the Vicorder Device in 
measuring cfPWV and AI in COPD patients; 2) to compare the measurements with 
those of the SphygmoCor device in a second separate cohort of COPD patients and; 






Patients were prospectively enrolled between October 2011 and August 2012.  All 
patients were over 40 years of age, with a smoking history of at least 15 pack-years, 
and spirometric evidence of COPD according to ATS/ERS criteria.  They were 
clinically stable with no history or recent exacerbations or long-term oxygen therapy 
use.  Demographic data and a full medical and therapeutic history were collected on 
all participants.   Furthermore, lung function (spirometry and body plethysmograph) 
was performed in all participants. For the Vicorder reproducibility study 23 
consecutive patients had repeat measurements of cfPWV and PWA performed within 
2 weeks of each other.  For the comparison study with SphygmoCor a separate 
cohort of 33 consecutive COPD patients had cfPWV and PWA measurements 
performed on the same day with both devices.  No patients in the Vicorder 
reproducibility cohort were included in the comparison study cohort.  The study 
received a favourable review by the local research ethics committee and written 
informed consent was obtained from all patients. 
 
Measurement techniques 
All measurements were performed by a single investigator with 18 months 
experience in arterial stiffness measurements (IS). IS was blinded to the previous 
results in the Vicorder reproducibility study (VRS) but not the Vicorder Comparison 
Study (VCS) since measures were collected on the same day for the latter study.  
Vicorder and SphygmoCor measurements of PWV and PWA and pulmonary function 








Statistical analysis was performed using SPSS 21.0 for Mac (SPSS Inc., Chicago, 
Illinois, USA).   The distribution of the data was assessed visually.  Continuous 
variables were expressed as mean±SD for parametric variables and median 
(interquartile range) for non-parametric variables.  Agreement between repeated 
Vicorder values in the case of the VRS, and SphygmoCor and Vicorder values in the 
case of the VCS for both cfPWV and AI were analysed with a student’s paired t-test 
with further analysis performed using Bland-Altman Plots.446  Pearson’s correlation 
co-efficient was used to assess the strength of correlation between these values as 
well as the contribution of hyperinflation to the variability of PWV and AI.  All analyses 
were 2 sided and a probability of less than 0.05 was considered significant. 
 
Results  
Vicorder reproducibility study 
Demographic parameters for VRS are shown in Table 3.  Haemodynamic parameters 
for both VRS visits are shown in Table 4.  Good quality waveforms were available for 
all 23 patients.  There was a strong significant correlation between repeat Vicorder 
measurements with respect to cfPWV (r=0.96 p<0.001).  The mean difference ± SD 
between repeated cfPWV measurements was -0.03 +/-0.36 m/s (p= 0.65) with a co-
efficient of reproducibility (COR) of 4.02 % and limits of agreement (LOA) of -0.68-
0.75 m/s (Figure 10). Repeat path length and pulse transit time measurements were 
similar and strongly correlated with CORs of 3.6% and 4.77% respectively (Table 5).  
The repeat AI measurements were also strongly and significantly correlated (r=0.736 
p<0.001) with mean difference ±SD of 0.72+/-4.86% (p = 0.48), however LOA were 




Figure 10 a) Scatterplot of repeat Vicorder pulse wave velocity measurements. Solid line: line of 
equality; dotted line: linear regression line. b) Bland-Altman plot of the differences between repeat 
Vicorder pulse wave velocity measurements.  Solid line: mean value; dotted lines: Limits of 
Agreement (mean ± 2SD). PWV: pulse wave velocity 
 
Table 3: Demographic characteristics for Vicorder reproducibility study and Vicorder 






Number of participants 23 33 
Age (years) 65.9 ± 7.9 67.5 ± 8.2 
FEV1% 50.1 ± 18.9 52.9 ± 19.0 
FEV/FVC  45.9 ± 15.4 45.6 ± 13.2 
RVol% 163.9 ± 52.8 157.5 ± 47.7 
TLC% 113.7 ± 22.6 116.2 ± 39.2 
IC/TLC 33.4 ± 12.2 33.5 ± 9.4 
BMI (kg/m2) 25.9 ± 5.8 25.0 ± 8.7 
Pack year history 50(40-120) 56.9 ± 38.1 
Current smoker 4/23 5/33 
Males: females 12:11 19:14 
Statin  12/23 15/33 
Aspirin  8/23 8/33 
Anti-hypertensive  11/23 13/33 
ICS 1/23 3/33 
SABA 22/23 27/33 
LABA 1/23 2/33 
ICS/LABA 19/23 20/33 
LAMA 21/23 26/33 
Methylxanthines 3/23 6/33 
VRS: Vicorder reproducibility study; VCS: Vicorder comparison study; FEV1%: forced expiratory volume in one 
second per cent predicted of normal value; FEV/FVC: ratio of the forced expiratory volume/forced vital capacity; 
RVol%: residual volume per cent predicted of normal value; IC/TLC: ratio of inspiratory capacity to total lung capacity; 
TLC%: total lung capacity per cent predicted of normal value; BMI: body mass index: SBP: systolic blood pressure; 
DBP: diastolic blood pressure; ICS: inhaled corticosteroid; SABA: short-acting beta-agonist; LABA: long-acting beta-
agonist; LAMA: long-acting muscarinic antagonist 
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Figure 11 a) Scatterplot of repeat Vicorder augmentation index measurements. Solid line: line of 
equality; dotted line: linear regression line. b) Bland-Altman plot of the differences between repeat 
Vicorder augmentation index measurements.  Solid line: mean value; dotted lines: Limits of 
Agreement (mean ± 2SD). AI: Augmentation index. 
 
Vicorder comparison study 
Demographic parameters and haemodynamic parameters for VCS are shown in 
Table 3 and Table 4 respectively.  Good quality waveforms were achieved for AI, 
however, 3 patients were unable to record SphygmoCor cfPWV readings due to a 
variable heart rate. There were statistically significant differences in the mean 
differences of cfPWV and AI between devices.  Path length and pulse transit time 
differences were also significantly different between devices although strongly 
correlated (Table 5). The Vicorder device recorded lower values of both cfPWV and 
AI readings (mean difference ± SD -0.64 +/- 1.00m/s p=0.002 and mean difference ± 
SD -4.53 +/- 7.8 p=0.002, respectively). There was, however, a strong linear 
relationship between Vicorder and SphygmoCor for cfPWV (r=0.76 P<0.001) and AI 
(r=0.56, p=0.01) and Bland-Altman plots confirmed satisfactory agreement (Figure 12 
and Figure 13). 
 
The contribution of lung hyperinflation to reproducibility 
In order to assess the contribution of lung hyperinflation to the reproducibility of 
arterial stiffness correlations were performed between RVol%, TLC% and IC/TLC 
and the difference between repeated measurements of AI and PWV.  There was no 
significant correlation between the extent of lung hyperinflation and the variability of 




Table 4 Haemodynamic parameters for the Vicorder reproducibility study and comparison study 
 VRS VCS 
N 23 33 
 Visit 1 Visit 2 Vicorder SphygmoCor 
Heart Rate 
(beats/min) 
72.6 ± 11.5 73.1 ± 10.2 74.1 ± 11.6 75.3 ± 11.8 
Brachial SBP (mmHg) 138.5 ± 13.9 136.8 ± 15.8 129.1 ± 16.5 
Brachial DBP (mmHg) 75.6 ± 6.3 74.3 ± 8.1 69.6 ± 11.7 
MAP (mmHg) 102.0 ± 9.0 101.3 ± 10.2 90 ± 11.3 
Central SBP (mmHg) 130.9 ± 13.7 130.8 ± 14.5 119.2 ± 24.7 115.9 ± 15.2 
Central DBP (mmHg) 75.0 ± 6.9 74.1 ± 7.5 69.5 ± 10.9 70.6 ± 11.7 
PWV (m/s) 8.94 ± 1.23 8.97 ± 1.19 8.93 ± 1.3 9.5 ± 1.5 
AI (%) 17.8 ± 6.7 17.1 ± 6.7 21.9 ± 8.1 26.5 ± 8.6 
VRS: Vicorder reproducibility study; VCS: Vicorder comparison study; SBP; systolic blood pressure: 





Table 5 Mean transit time and path length data 
Vicorder reproducibility study 
     Visit 1 
Mean ± SD 
Visit 2 
Mean ± SD 
Mean Difference ±SD Correlation 
Path length (cm) 
66.4 ± 5.5 66.7 ± 5.0 




Transit time (ms)  
77.1 ± 11.9 76.2 ± 11.0 




Vicorder comparison study 
 Vicorder 
Mean ± SD 
SphygmoCor 
Mean ± SD 
Mean Difference ±SD Correlation 
Path length (cm) 
66.6 ± 5.3 47.9 ± 4.0 




Transit time (ms) 
75.7 ± 11.4 50.6 ± 8.5 








Figure 12 a) Scatterplot of Vicorder and SphygmoCor pulse wave velocity. Solid line: line of 
equality; dotted line: linear regression line. b) Bland-Altman plot of the differences between Vicorder 
and SphygmoCor pulse wave velocity.  Solid line: mean value; dotted lines: Limits of Agreement 






Figure 13 a) Scatterplot of Vicorder and SphygmoCor augmentation index. Solid line: line of 
equality; dotted line: linear regression line. b) Bland-Altman plot of the differences between Vicorder 
and SphygmoCor augmentation index.  Solid line: mean value; dotted lines: Limits of Agreement 







Table 6 Correlation between measures of lung hyperinflation and the variability of repeat AI and 





Difference between repeat haemodynamic measurements 
Vicorder reproducibility 
study 
Vicorder comparison  
study 







(p = 0.12) 
0.20 
(p = 0.36) 
0.10 
(p = 0.61) 
0.22 




(p = 0.35) 
0.16 
(p = 0.47) 
-0.092 
(p = 0.63) 
 
0.11 




(p = 0.48) 
- 0.32 
(p = 0.15) 
0.11 
(p = 0.58) 
-0.34 
(p = 0.08) 
 
 AI: augmentation index; PWV: pulse wave velocity; RVol%: residual volume per cent predicted of 
normal value; IC/TLC; ratio of inspiratory capacity to total lung capacity; TLC%; total lung capacity per 




The contribution of arterial stiffness to the cardiovascular morbidity in COPD is a 
topic of considerable interest422, 445. This is the first study to report reproducibility of 
Vicorder measures of arterial stiffness and, furthermore, how they compare to 
SphygmoCor measurements in patients with COPD.  The main finding of our study is 
that PWV measured by the Vicorder device is highly reproducible in COPD patients. 
The Vicorder reproducibility achieved in this study for PWV is better than some other 
published results including those in children and studies employing different 
commercially available devices.344, 347, 348, 447  The second finding is that the 
reproducibility of PWV or Augmentation index does not appear to be affected by lung 
hyperinflation and thirdly, although significant statistical differences exist between the 
Vicorder and SphygmoCor devices the Bland-Altman plot showed satisfactory 
agreement and the values showed good linear agreement in this COPD cohort.  
 
It is generally agreed that external factors impact on pulse wave velocity. A potential 
limitation of this study is that we are unable to gauge the impact of changes in 
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oxygenation, known to affect PWV and AI, since blood gas sampling was not 
performed.448 However, efforts had been made to minimise its occurrence through 
the recruitment of only clinically stable patients who did not require any form of 
oxygen therapy as well as the implementation of existing recommendations to 
standardise conditions.333  The value derived for PWV is also known to depend on 
the site of measurement, the algorithm used for timing of the pressure wave transit 
(TT) and the method employed for calculating path length.  
 
The predictive value of PWV is dependent on the site of measurement.  In end-stage 
renal disease whereas the upper and lower limb PWV have no predictive value, the 
aorto-iliac pathway measured via carotid-femoral PWV is a predictor of 
cardiovascular and all cause mortality.336, 337  It is the carotid-femoral PWV (cfPWV) 
that is thought to be the most clinically relevant and robust measurement and it has 
been  shown to be an independent predictor of coronary artery disease in the general 
population including the elderly and it is at present considered the gold standard.199, 
201, 297, 338  In line with the ARTERY society guidelines, both studies contained within 
this manuscript exclusively measured cfPWV.429   
 
The impact of the algorithm used to calculate the transit time has been investigated 
with different commercially available devices with conflicting results, some attributing 
differences to the algorithm whereas others identify path length measurements as the 
main driver for differences between devices.  This however is the first study to look at 
the contribution of lung hyperinflation to measurement variability.340, 341  Lung 
hyperinflation can be defined according to the residual volume with RVol% >120 
considered abnormal.  The patients enrolled in the two studies had had a substantial 
degree of lung hyperinflation, with mean RVol% values of 163.9 % and 157.5 % 
respectively, but no significant correlation between the extent of lung hyperinflation 
and variability of arterial stiffness measurements was identified in either of the 2 
studies regardless of which parameter for measuring lung hyperinflation was adopted 
(RVol, TLC or IC/TLC).  Hence our results are closely aligned with other studies that 
compare Vicorder and SphygmoCor, demonstrating that methodological differences 
in the measurement of path length are contributing to the differences seen in PWV 
values between these two devices, although significant differences were 
demonstrated there was good linear agreement between devices, and there was a 
bias towards lower values with the Vicorder.346, 449   
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Measurement of the path length can result in a disparity between values derived for 
PWV of up to 30%.350  We have shown that the path length is also the main driver for 
the variability of PWV measurements in both studies.  In the VRS the COR for path 
length accounts for most of the variability seen in pulse transit time.  In the VCS the 
situation is further complicated by different manufacturers recommending different 
methodologies to calculate the path length, as seen with the Vicorder and 
SphygmoCor devices.  From a methodological perspective the precision of any 
particular measured distance is dependent on the accuracy of identifying the 
measurement site and the precision of the tape measure.  For those techniques that 
involve 2 measurements, as in the case of the SphygmoCor, the error is made twice, 
is cumulative, and in certain circumstances may be larger than the discrepancy 
between different path length techniques.351  It is currently not clear which path length 
is the most appropriate or which device is the more accurate since validation of pulse 
wave velocity with invasive studies has proven difficult, a problem acknowledged by 
the published guidelines on validation of haemodynamic non-invasive measurement 
devices.429   The difficulty arises since the invasive measure chosen typically equates 
to the PWV within the aorta and does not take into account the additive effect that 
may arise from the iliac and carotid vessels.353, 450  This lack of a comparable invasive 
measure for PWV as well as AI is a resultant limitation of this study.  Screening tools 
to establish whether a subject has raised arterial stiffness require agreed normal 
ranges and a device which is both accurate and reproducible.  Although there have 
been developments in this field, until an agreed methodology for path length 
measurements and further validation studies are available it seems the most likely 
use of PWV will be in assessing the impact of particular interventions within clinical 
trials.251  In this setting accuracy is arguably less important than reproducibility; it not 
only impacts on the sample size but the mean bias, derived from such measures, is 
important for trial comparison in the context of systematic reviews and metanalyses. 
Reproducibility of a particular test is therefore paramount, and the Vicorder device 
has shown itself to be a highly plausible option in COPD studies looking to utilise 
cfPWV as a surrogate endpoint. 
 
Augmentation index is a measure of the augmentation of central blood pressure in 
systole by reflected pressure waves from the small peripheral arteries.338  It is 
dependent on ventricular ejection, the timing of reflected waves (and hence PWV) 
and the extent of reflection (determined by arterial tone).  In the VRS although the 
Bland-Altman plot showed reasonable agreement and the SD of differences were 
similar to previously published studies of different devices, the larger LOA and COV 
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associated with AI and resultant loss of statistical power would require far larger 
sample sizes to demonstrate any significant treatment effects.344  However a 
limitation of this study is that the repeat measurements were not performed on the 
same day for the VRS which, given the number of factors that contribute to 
augmentation, may have resulted in the differences observed.  The notion is 
supported by a study in chronic kidney disease that looked at day to day variations in 
AI which showed even greater variability in measures with a mean difference (SD) of 
2.6 (5.6).345  Furthermore, validation studies, which are more feasible for PWA due to 
the relative ease of acquiring invasive central blood pressures, have demonstrated 
that the Vicorder device is accurate.  Vicorder measures of central blood pressure, 
estimated using the same transfer function as AI, showed better agreement with 
invasive measures than the SphygmoCor and was highly correlated to the invasive 
measure.327  Despite this, in COPD the utility of AI in the elderly remains in question; 
although Janner et al showed a significant association between AI and COPD this 
was only for males less than 60 years of age once mild cases had been excluded.451   
 
In conclusion, this study highlights the highly reproducible nature of Vicorder PWV 
measurements in COPD patients, including those with lung hyperinflation, which 
offers a feasible alternative to traditional tonometry techniques that is ideally suited 
for use as a surrogate marker in intervention studies. The wide day-to-day variation 
in repeat AI measurements highlights the importance of such calculations prior to the 











Chapter Six  
Feature Tracking, Tissue Tracking And 
Tagging Assessment Of Myocardial 
Function In Stable Hyperinflated COPD: 






















Introduction Alterations to cardiovascular structure and function occur in COPD 
often with preservation of the ejection fraction. Global measures such as EF may not 
be sensitive enough to detect subtle changes in ventricular function.  Myocardial 
strain imaging, a non-invasive measure of cardiac deformation, can identify subtle 
changes in myocardial function although reproducibility in COPD has not previously 
been assessed.  The aims of this study were to establish inter-study reproducibility of 
myocardial tagging and newer CMR strain-imaging techniques in COPD patients 
and, secondly, to establish the extent of inherent bias between the newer techniques 
and the “gold standard” in the most reproducible parameters. 
Methods This study utilised the CMR scans of the 45 hyperinflated COPD patients 
randomised into the clinical trial detailed in Chapter 8.  The trial took place from 
November 2012 to August 2014. Tagging, feature tracking (FT) and tissue tracking 
(TT) analysis was undertaken on the baseline CMR and the scan following the 
placebo period.  
Results All 40 who completed the placebo arm of the study were included in the 
analysis. The inter-study reproducibility for global measures of tagging, FT and TT 
ranged from an ICC 0.002-0.659, 0.012-0.56 and 0.253-0.593, respectively. 
Circumferential strain was the most consistent and Bland-Altman plots confirmed 
acceptable agreement. FT-derived circumferential strain rate was consistent for 
diastolic parameters with moderate agreement (ICC 0.57). Diastolic parameters for 
longitudinal strain rate showed moderate agreement with best results in the 4-
chamber view (ICC 0.641). The best agreement with tagging was found with mid-
ventricular circumferential strain (FT mean difference +1.07±3.17 %; ICC 0.402; 95% 
CI 0.11,0.63: TT mean difference -2.17±2.23 %; ICC 0.424; 95 % CI 0.132, 0.649).  
Bland Altman plots confirmed acceptable agreement. Acceptable agreement was 
found between FT and tagging for the diastolic parameter of mid-ventricular peak 
circumferential strain rate (ICC 0.581 95% CI 0.33, 0.76) 
Conclusion The inter-study reproducibility of feature tracking and tissue tracking are 
comparable to tagging.  The assessment of intrinsic diastolic function in hyperinflated 
COPD shows promise.  The data we have provided here will allow for accurate 
powering of future COPD studies which may in turn allow a better understanding of 




Alterations to cardiovascular structure and function occur in COPD often with 
preservation of the ejection fraction (Chapter 7). It is however well recognised that 
global measures such as EF may not be sensitive enough to detect subtle changes 
in ventricular function.105, 405 
 
Strain is a sensitive measure of cardiac deformation.  It can be measured non-
invasively through the use of advanced imaging techniques and is therefore attractive 
for use in clinical trials to assess the effect of an intervention. Echocardiographic 
Doppler imaging has its own inherent limitations of operator dependency, noise 
interference, angle dependency and the use of geometric assumptions.452-454  
Speckle tracking has difficulties related to image quality, which is worsened by the 
poor echocardiographic windows secondary to lung hyperinflation in COPD.455, 456 
The development of cardiac magnetic resonance imaging based strain analysis is 
therefore a particularly attractive option in this cohort. 
 
Tagging, the present ‘gold standard’ for CMR systolic strain imaging, is not without its 
limitations and has never been validated in COPD. Low signal to noise ratio, tag 
fading and the need for prolonged breath holds are of particular concern when 
considering the assessment of diastole in a dyspnoeic population such as COPD. 
Furthermore, it requires further image acquisitions, thus increases scanning time and 
requires complex and laborious post-processing. A number of commercially available 
systems have a number of advantages over the ‘gold standard’. Before they can be 
applied to clinical trial settings, an understanding of the inter-study reproducibility in 
patients with COPD is necessary. 
 
The aims of this study were to establish the inter-study reproducibility of myocardial 
tagging and newer CMR strain-imaging techniques in COPD patients with evidence 
of lung hyperinflation to inform the powering of future studies and, secondly, to 
establish the extent of inherent bias between the newer techniques and the “gold 







This study utilised the CMR scans of the 45 hyperinflated COPD patients randomised 
into the clinical trial detailed in Chapter 8.  The trial took place from November 2012 
to August 2014.   
 
Image acquisition 
The details regarding SSFP and myocardial tagging image acquisition can be found 
in the Methods section (Chapter 4).  All images were acquired by ISS on the same 
scanner between 0800-1300 hrs.  Due to the nature of the crossover study design 
the time interval between baseline and placebo-period scans varied from 1 - 4 
weeks.    
 
Image analysis 
Details regarding the performing of the strain and strain rate analysis for tagging 
(CIM Tag 2-D v7.0, Auckland, NZ), tissue tracking (CVI 42, Circle Cardiovascular 
Imaging Inc., Calgary, Canada) and feature tracking (Image-Arena, Version 4.6, 
TomTec Imaging Systems GmbH, Unterschleissheim) can be found in the Methods 
section (Chapter 4).  Offline analysis of the tagged and SSFP scans were performed 
by one blinded observer in a random order (ISS - 2 years experience), on all scans.  
Scans were excluded from the analysis if post-processing software was unable to 
track the myocardium.  A schematic representation of how peak and reverse peak 
strain and strain rate values are derived can be found in Figure 14. 
 
For tissue tracking and tagging, global (transmural) strain and strain rate values were 
used.  For feature tracking, the means of the extracted endocardial and epicardial 
values were derived for circumferential and longitudinal strain and strain rates. The 
feature tracking output includes the transmural radial strain and strain rate values 
since radial strain is a representation of myocardial thickening and thinning and thus 
requires both endocardial and epicardial data for its calculation. 
 
Statistics 
Statistical analysis was performed using R 3.2.1 (R Foundation for statistical 
Computing, Vienna, Austria) and SPSS 21.0 for Mac (SPSS Inc., Chicago, Illinois, 
USA). 457  The distribution of the data was assessed visually.  Continuous variables 
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were expressed as mean (±SD) for parametric variables and median (interquartile 
range) for non-parametric variables.  Baseline and placebo period scans were 
compared to assess the inter-study reproducibility of tagging, tissue tracking and 
feature tracking.  Baseline imaging was used to assess the extent of inherent bias 
between the different modalities.  The differences in strain variables between 2 
exams were represented by mean difference and standard deviation of the mean 
difference.  Agreement was assessed through the intra-class correlation co-efficient 
(ICC) with a model of absolute agreement.  Agreement was classed as weak (ICC 
0.10 - 0.39), moderate (ICC 0.40-0.69) or strong (ICC 0.70-0.99).458  Bland-Altman 





Of the 45 patients randomised in the original study, the 40 who completed baseline 
and placebo assessments were included in the analysis.  Whilst 11 baseline and 7 
placebo images of the 200 acquired could not be analysed due to poor image quality 
for tagging, all images were of sufficient quality from feature tracking and tissue 
tracking. For their full demographic characteristics please refer to Table 7.   
 
Inter-study reproducibility 
For full breakdown of the results please refer to the supplementary appendix (pages 
157, 159, 161, 163).  
 
Tagging		
Overall the inter-study reproducibility for global measures of tagging ranged from an 
ICC of 0.002 to 0.659 with radial strain being the least reproducible and mid-
ventricular circumferential strain having the highest reproducibility.  The Bland-
Altman plots confirm acceptable agreement between measurements (Figure 15).  For 
longitudinal strain the 2-chamber was more reproducible than the 4-chamber with 
moderate agreement. 
 
All measures of systolic strain rate performed poorly apart from mid-ventricular 
circumferential strain rate (ICC 0.430; 95% CI 0.116, 0.667) and the 4-chamber 
longitudinal reverse peak strain-rate (ICC 0.377 95% CI 0.03, 0.645). 
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Figure 14 A schematic diagram explaining the derivation of parameters for strain and strain rate 
analysis.  SYS: systole; DIA: Diastole; P: peak; RP: reverse peak; TTRP: time to reverse peak; TTP: 
time to peak.  In this analysis we have only utilized peak and reverse peak. 
 
1. Parameters with peak before reverse peak 
 
 
Parameters with strain rate curves  
of this morphology have systolic peaks  





2. Parameters with reverse peak before peak 
 
Parameters with strain rate curves of  
this morphology have systolic  
reverse peaks and diastolic peaks  







3. Parameters with reverse peak only  
 
Parameters with strain curves of this  
morphology have reverse peaks only  





Table 7 Baseline demographics 
No of subjects 40 
Age, years 64.8±9.1 
Male, % 65% 
COPD assessment Test Score 17.5±8.6 
Smoking, Pack years 48.3±31.3 
Forced Expiratory Volume in 1 second, L 1.4±0.5 
FEV1 per cent predicted, % 49.7±15.5 
Residual Volume, L 3.7±0.9 
Residual Volume per cent predicted, % 164.9±33.8 
Pulse, beats/min 73±12 
Left Ventricular Mass Index, g/m2 95.3±25.3 
Left Ventricle End Diastolic Volume Index, ml/m2 66.1±12.9 
Left Ventricle End Stroke Volume Index, ml/m2 27.0±8.0 
Left Ventricle Ejection Fraction, %  59.7±6.6 
 
Circumferential strain rate also performed best within the diastolic parameters (mid-
ventricular peak circumferential strain rate ICC 0.673 (95% CI 0.44, 0.822).  Mid-
ventricular reverse peak radial strain rate was the only reproducible radial parameter 
from the tagging analysis (ICC 0.596, 95% CI 0.331,0.775).  The diastolic longitudinal 




Overall the inter-study reproducibility for global measures of feature tracking ranged 
from an ICC 0.012 to 0.56.  Circumferential strain was the most consistent (ICC 0.51-
0.56). The Bland-Altman plots confirm acceptable agreement between 
measurements (Figure 15).   Although more reproducible than tagging, the radial 
strain was variable with best results in mid-ventricular (ICC 0.451) and 4-chamber 
views (ICC 0.443). For global longitudinal strain, the 4-chamber gave better results 
than the 2-chamber (ICC 0.419 vs. 0.378). 
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Table 8 Inter-study reproducibility of global, systolic and diastolic end-points for tagging, feature tracking and tissue tracking. 
 Tagging Feature tracking Tissue tracking 

























































































































































































































CI: confidence interval; Diff: difference; ICC: intra-class correlation co-efficient; LoA: limits of agreement; SD: standard deviation. 
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Circumferential strain rate was consistent for systolic parameters, showing moderate 
agreement.  Peak radial strain rate remained variable, with best results in 4-chamber 
(ICC 0.437).  Systolic measures of longitudinal strain performed poorly. 
 
Circumferential strain rate was consistent for diastolic parameters with moderate 
agreement.  Unlike systolic strain rate the diastolic short axis radial strain performed 
better, with best results in mid-ventricle (ICC 0.604).  Diastolic parameters for 
longitudinal strain rate showed moderate agreement with best results in the 4-
chamber view (ICC 0.641). 
 
Tissue	tracking		
Overall tissue tracking inter-study reproducibility for global measures ranged from an 
ICC of 0.253 to 0.593.  Circumferential strain was the most consistent (ICC 0.523-
0.593).  The Bland-Altman plots confirm acceptable agreement between 
measurements (Figure 15).  Radial strain performed best in mid-ventricular slice (ICC 
0.541) and 2–chamber views (ICC 0.593). For global longitudinal strain the 2-
chamber gave better results than the 4-chamber, with moderate agreement. 
 
Systolic parameters generally performed poorly for circumferential and radial strain 
rate except the basal slice in short axis (0.597 and 0.492 respectively).  In the long 
axis the 2-chamber view was most reproducible for systolic radial strain rate (ICC 
0.542) and longitudinal strain rate parameters (ICC 0.368). 
 
Tissue tracking diastolic parameters also performed poorly apart from the short axis 
basal slice for radial (0.579) and circumferential strain rate (0.644).  The 2-chamber 













Figure 15 Bland-Altman plots showing inter-study reproducibility for global, systolic and 
diastolic strain and strain rate parameters derived from tagging, feature tracking and tissue 
tracking analysis. Units: Strain parameters %; Strain Rate %/s. Global parameters in top panel; 
systolic parameters in middle panel and diastolic parameters in bottom panel.  
 
 
Comparing techniques: Inherent bias 
The global value of mid ventricular circumferential strain showed the best agreement 
between techniques with a mean difference of +1.07±3.17 % for feature tracking and 
-2.17±2.23 % for tissue tracking.  Bland Altman plots confirmed acceptable 
agreement and a significant moderate interclass correlation was confirmed 
statistically (Table 9).   
 
There was also acceptable agreement for the diastolic parameter of mid-ventricular 
peak circumferential strain rate (Figure 16).  The mean difference was -4.06±26.3%/s 
for feature tracking and -22.69±32.86%/s for tissue tracking. The inter-class 
correlation was statistically significant for feature tracking (ICC 0.581; 95% CI 0.33, 
0.76) but only of borderline significance for tissue tracking (ICC 0.264; 95% CI -
0.049, 0.531).   
 
Overall no significant ICC was found between tagging values of radial strain and 
























Figure 16 Bland-Altman plots showing extent of agreement between feature tracking and tissue 
tracking versus tagging for mid-ventricular global strain (%) and diastolic and systolic strain rate 
(%/s) measurements.  
 
Discussion 
This is the first study to demonstrate the inter-study reproducibility of CMR-derived 
strain and strain-rate parameters in COPD patients with lung hyperinflation and the 
extent of inherent bias compared to the current CMR gold standard of myocardial 
tagging. 
 
We have demonstrated that both feature tracking and tissue tracking demonstrate 
similar degrees of inter-study reproducibility compared to tagging, with 
circumferential values being the most consistently reproducible.  We have also 
demonstrated that acceptable agreement exists with those values derived from 
myocardial tagging in the circumferential but not radial direction; and furthermore 
feature tracking appears to be a legitimate option for assessing diastolic function in 
hyperinflated COPD.  
 
As per previously published data, the inter-study reproducibility measured in this 
COPD cohort demonstrates moderate ICC.459  Factors that affect the reproducibility 
of CMR strain imaging include the strength of the magnetic field, image acquisition, 
image orientation, slice location and quality of tags.460  In an effort to avoid this 
variability, studies were obtained at the same site, on the same scanner with the use 
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Table 9: Agreement between different strain measurement techniques. SD; standard deviation: ICC; interclass correlation co-efficient: CI; confidence interval  
 
 Tagging Feature tracking Tissue tracking 
Variable, units Mean Value Mean 
difference 
SD Limits of 
Agreement 
ICC 95% CI Mean 
difference 
SD Limits of 
Agreement 




circumferential strain, %  
-16.41 1.07 3.17 -4.95, 7.09 0.402 0.11, 
0.63 





peak radial strain, % 









reverse peak longitudinal 
strain, % 











circumferential strain rate, 
%/s 









reverse peak longitudinal 
strain rate %/s 










peak circumferential strain 
rate, %/s 









reverse peak radial strain 
rate, %/s 









peak longitudinal strain 
rate, %/s 









of standardised prospectively gated protocols and imaging protocols for the selection 
of the short-axis slices performed by the same technician (IS).  In the case of feature 
tracking and tissue tracking analysis, these were performed on the same images, 
whereas the tagging images were acquired at the same sitting.  In an effort to mirror 
a real life scenario, in all cases the technician was blinded to the previously chosen 
slices.   
 
The differences in strain reproducibility can be explained by myocardial geometry.  
Strain accuracy is related to the number of tags or points of interest in a particular 
segment.  Since more points of interest are contained within a segment’s arc than its 
radius, circumferential strain, particularly at the level of the mid-ventricle is more 
reproducible than radial strain, a situation echoed in previous studies.460-462  The 
reduced circumferential strain reproducibility at the base in both feature tracking and 
tagging may be a result of the relative increase in through plane motion typically 
observed here.  Longitudinal strain data is also generally less reproducible than the 
short axis circumferential strain, possibly as a result of a tendency to track the mitral 
valve apparatus.   
 
Myocardial strain appears to have better inter-study reproducibility compared to 
myocardial strain rate.  This, and the better reproducibility in diastolic strain rate 
parameters compared to systolic strain rate may be explained by temporal resolution.  
In systole the change in strain will occur over a shorter period of time and therefore 
to accurately capture the change in strain (strain rate) a higher temporal resolution 
may be necessary.  The temporal resolution of CMR strain imaging is a known 
limitation and may account for these discrepancies.459 
 
For technical reasons the breath holds for tagging needed to be longer than those for 
the standard SSFP images, which may have had implications for the image quality at 
the end of diastole, particularly in this dyspnoeic COPD population.  Although our 
study demonstrated similar agreement with tagging for peak and reverse peak 
diastolic strain rates compared with other published studies, this may explain why the 
values for feature tracking and tissue tracking were more closely aligned with each 
other, demonstrating a consistent direction of inherent bias for diastolic parameters, 
compared to tagging.463  Validation of both feature tracking and tissue tracking is still 
lacking and until such data is available the ability to compare values across studies 
and vendors will be limited.  Despite this the ability of the newer imaging modalities, 
particularly feature tracking, to provide reproducible diastolic function data is 
 112 
particularly pertinent.  Recent studies have suggested that identification of diastolic 
dysfunction through non-invasive strain imaging predicts the development of atrial 
fibrillation and heart failure independent of established risk factors and markers of 
subclinical CVD.464  COPD patients often develop diastolic dysfunction with a 
preserved ejection fraction and have a high incidence of arrhythmias.158, 422 
Echocardiography is technically difficult in patients with lung hyperinflation and hence 
CMR-strain imaging may provide a modality whereby interventions that alter diastolic 
function prior to the onset of clinical manifestations can be identified, thus providing 
the tools to alter the natural history of cardiac disease in COPD.  These newer 
modalities have the added advantage of not needing further image acquisitions since 
they utilise the standard SSFP cines.  Furthermore, they can reduce the time needed 
to analyse strain imaging four fold, which may make the use of such techniques more 
viable in the clinical setting.465   
 
A number of limitations to this study deserve a mention.  Our study utilised two-
dimensional strain calculations to derive strain and strain rate parameters and the 
effect of through plane motion was not determined.  Furthermore, due to the nature 
of the RCT from which the data was used, the baseline and CMR scans were taken 
up to 4 weeks apart.  Despite every effort being made to ensure that the scans are 
comparable, minor variations in physiological state of those taking part cannot 
completely be excluded and may contribute to the inter-study reproducibility 
demonstrated. 
 
In conclusion, the inter-study reproducibility of feature tracking and tissue tracking 
are comparable to tagging. The assessment of intrinsic diastolic function with these 
parameters in hyperinflated COPD shows real promise.  The data we have provided 
here will allow for accurate powering of future COPD studies which may in turn allow 
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Introduction COPD is a complex multi-morbid disorder with significant cardiac 
mortality. Despite this, current cardiovascular scoring systems do not include COPD 
in their risk prediction models. The aims of this study were to assess whether 
differences in cardiovascular surrogate markers exist in COPD and to further our 
understanding of the relationship of COPD to cardiovascular structure and function. 
Methods This post-hoc cross-sectional analysis utilised baseline data from two 
randomised controlled trials (n=36 and 54, 90 patients in total). Patients underwent 
cardiac magnetic resonance imaging, arterial stiffness and lung function 
measurements. Of the 36 COPD patients, 26 were matched for global cardiovascular 
risk with 26 controls with normal lung function. Regression analysis was performed 
on all 90 to look at associations in those surrogates that showed differences. 
Results Pulse wave velocity (PWV) (mean difference +1.0 m/s, 95% CI 95% CI 0.1, 
1.9; p=0.033), and total arterial compliance (TAC) (mean difference -0.27 
mL/m2/mmHg, 95% CI 95% CI -0.4, -0.2; p<0.001) were adversely affected in COPD 
compared to the control group matched for cardiovascular risk. In the 90-patient 
cohort QRISK2 (β= 0.046, p=0.017) and FEV1 (β=-0.013, p=0.022) were associated 
with PWV in multivariate analysis. The relationship between QRISK2 and PWV 
appeared to be modified by COPD, where the interaction term reached borderline 
significance (p=0.060). FEV1 (β=0.005, p=0.004) was also associated with TAC in 
multivariate analysis. Cardiac chamber size and stroke volume was decreased in 
COPD compared to controls. The mean difference in left ventricle stroke volume 
index (LVSVI) and left and right end diastolic volume index was -10.3 ml/m2 (95% CI 
-15.4, -5.3, p<0.001), -14.1 ml/m2 (95% CI -22.1, -6.1, p<0.001) and -13.0 ml/m2 
(95% CI -23.9, -2.0, p<0.022) respectively, which were shown to be associated with 
airflow limitation in multivariate models.  In the COPD group (n=36) associations 
were found with lung hyperinflation (LVSVI: β=-0.075, p=0.032; Left atrial size: β=-
0.129, p=0.047) and fibrinogen (TAC: β= 0.716, p=0.030). 
Conclusions Surrogates for cardiovascular outcomes are adversely affected in 
COPD compared to a group matched for global cardiovascular risk, suggesting that 









Chronic obstructive pulmonary disease (COPD) is predicted to be the third leading 
cause of death worldwide by 2020.466  It is a complex multi-morbid disorder in which 
up to 37% succumb to cardiovascular causes rather than respiratory failure123. The 
precise mechanisms contributing to cardiovascular risk in COPD are not yet fully 
elucidated but lung hyperinflation and systemic inflammation are postulated as 
possible mechanisms.422   
 
Predicting prognosis in COPD has proven to be difficult.467  Airflow limitation as 
measured by the FEV1 is the hallmark of COPD and was traditionally used for 
predicting all cause mortality. However, when used in isolation it only shows a weak 
association with all cause mortality in COPD and has therefore been combined in 
multi-dimensional risk assessments to improve its predictive value.30, 468  Regarding 
cardiovascular mortality it has been suggested that a reduction in forced expiratory 
volume in one second (FEV1), combined with a smoking history is a better predictor 
than cholesterol.122  Despite this, current accepted global cardiovascular risk scores 
do not factor in COPD severity which raises the possibility that risk estimation in this 
cohort may be suboptimal.469, 470 
 
A number of algorithms for estimating cardiovascular risk have been developed and 
are advocated by national cardiovascular prevention guidelines to communicate risk 
and facilitate treatment decisions. QRISK, a multifactor cardiovascular disease risk 
prediction algorithm, was developed and validated for use in the United Kingdom.   
QRISK predicts the likelihood of a myocardial infarction or cerebrovascular accident 
in the next 10 years based on routinely collected data from National Health Service 
general practitioner databases in the United Kingdom. QRISK includes traditional 
cardiovascular disease risk factors (age, sex, systolic blood pressure, smoking 
status, and serum cholesterol:high density lipoprotein ratio) that are incorporated in 
the long established Framingham risk equations. Its most recent incarnation, QRisk 2 
2011, also includes self-assigned ethnicity (white or not recorded, Indian, Pakistani, 
Bangladeshi, other Asian, black African, black Caribbean, Chinese, other including 
mixed race), body mass index (kg/m2), family history of coronary heart disease in 
first degree relative, Townsend deprivation score, treated hypertension, and 
diagnosis of rheumatoid arthritis, atrial fibrillation, type 2 diabetes, and chronic renal 
disease. 469, 471, 472 
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Aortic distensibility, total arterial compliance and left ventricular mass (LVM) have 
been identified as cardiac magnetic resonance (CMR) surrogates of cardiovascular 
risk, a modality which provides unparalleled image quality non-invasively with 
excellent accuracy and reproducibility.197, 473-475 Carotid-femoral pulse wave velocity 
(PWV), a non-invasive bedside measure of global arterial stiffness, is also an 
independent predictor of coronary artery disease.197, 200, 202   
 
The aim of this study was to assess whether there are differences in cardiovascular 
surrogate markers in COPD compared to controls with normal lung function matched 
for global cardiovascular risk and to further our understanding of the relationship of 
COPD to cardiovascular structure and function. 
 
We hypothesised that: 1) Established non-invasive surrogates of cardiovascular risk 
would be adversely affected in hyperinflated COPD compared to a control group with 
equivalent global cardiovascular risk scores and 2) These differences will relate to 





This post-hoc cross-sectional analysis utilised baseline data from two randomised 
controlled trials that have been undertaken at our centre.   
 
COPD group 
The COPD group consisted of the 45 consecutive stable hyperinflated patients as 
described in the main methods section. All patients with a prior history of 
cardiovascular disease (7) or atrial fibrillation (2) were excluded, leaving 36 evaluable 
hyperinflated COPD patients. 
 
Control group with known cardiovascular risk 
The control group was drawn from 96 participants with a global 10-year 
cardiovascular risk score > 10% who were recruited to the Heart Attack Prevention 
Programme for You (HAPPY) London (clinicaltrials.gov, NCT01911910), a primary 
prevention randomised controlled study (RCT) aiming to reduce cardiovascular risk 
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in a cohort free of pre-existing cardiovascular disease. Only those patients that 
underwent CMR imaging with normal spirometry and an absence of respiratory 
disease or atrial fibrillation were included, leaving 54 evaluable subjects.  Thus 
overall there were 90 evaluable subjects, 36 from the COPD cohort and 54 from the 
control group prior to matching. 
 
Cardiac parameters 
Please refer to Methods section (Chapter 4) detailing the acquisition of cardiac 




The matching of the groups was performed using SAS (SAS Institute Inc., Cary, NC, 
US, Version 9.3). Patients were matched by QRISK2 score ± 2% to test the initial 
hypothesis. Statistical analysis was performed using SPSS 21.0 for Mac (SPSS Inc., 
Chicago, Illinois, USA). The distribution of the data was assessed visually. 
Continuous variables were expressed as mean ± SD for parametric variables and 
median (interquartile range) for non-parametric variables. Differences between the 
matched COPD and controls were assessed using paired t-tests. 
Univariate followed by multivariate linear regression analysis was performed on all 90 
evaluable subjects to evaluate associations between lung function parameters and 
the surrogate endpoints that showed differences between the groups. Where an 
association was found further regression analyses were performed on the interaction 
terms to establish whether the presence or absence of COPD as a binary variable 
had any impact on the relationship between QRISK2 and the cardiovascular 
surrogates. Univariate followed by multivariate linear regression analysis was 
performed on all 36 evaluable COPD subjects to evaluate associations between lung 
hyperinflation and systemic inflammation and surrogate endpoints that showed 
differences between the groups. 
The extent of intra-observer agreement was assessed via the Bland-Altman method 
on 20 randomly selected patients (10 from each cohort) for the CMR measures and 
on 16 of the HAPPY London cohort with respect to the Vicorder measures of PWV 





Of the 36 eligible COPD patients 26 were successfully matched for 10-year global 
cardiovascular risk ± 2% based on the QRISK2 scoring system with 26 out of the 54 
HAPPY London participants having normal lung function.  Baseline demographics 
and pulmonary function of the 52 matched individuals are shown in Table 10. As 
expected, there were no differences in QRISK2 score (p=0.693), age (p=0.447), 
gender (p=0.161), blood pressure (p=0.447), renal function (p=0.055) or cholesterol 
treatment (p=0.449) between the groups. However, the control group had a higher 
prevalence of diabetes than the COPD group, whilst the COPD group had more 
impaired pulmonary function and significant smoking history. The baseline 
demographics and pulmonary function for the COPD and Control groups making up 
the 90 patient cohort are shown in Table 11. 
 
Inter-observer agreement 
The Bland Altman plots (Figure 17) confirmed acceptable agreement between ISS 
and MYK measurements of PWV (bias 0.43 m/s, limits of agreement (LOA) -0.91-
1.76, Intra-class correlation coefficient (ICC) 90.5 %), aortic pulse pressure (bias -
1.14 mmHg, LOA -22.9-23.2, ICC 86.4 %), aortic relative area change (Thoracic 
ascending aorta (TAA) bias 0.0093, LOA -0.0634-0.820, ICC 80.2 %; thoracic 
descending aorta (TDA) bias 0.0014, LOA 0.0185-0.0213, ICC 97.9 %; abdominal 
aorta (ABA) bias -0.0029 LOA -0.0190-0.02774, 99.2 %) left ventricle end-diastolic 
volume index (LVEDVI) (bias -3.6 ml/m2 LOA-12.5-5.8, ICC 96.6 %), left ventricular 
mass index (LVMI) (bias -2.9 g/m2, LOA -13.65-7.83, ICC 87.5 %)  and LVSVI (bias 
2.0 ml/m2 LOA -2.5-8.5, ICC 92.5 %). 
 
Global arterial stiffness: Total arterial compliance and PWV  
PWV and total arterial compliance were adversely affected in COPD compared to the 
control group matched for cardiovascular risk. PWV was increased in the COPD 
group compared to the matched controls with a mean difference of +1.0 m/s (95% CI 
0.1, 1.9; p=0.033), whereas TAC was reduced by -0.27 mL/m2/mmHg (95% CI -0.4, -





Table 10: Demographic and pulmonary function characteristics of COPD and control groups 





















DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FEV1: forced expiratory 
volume in 1 second; FVC: forced vital capacity; HT: hypertension; SBP: systolic blood pressure, SD: 
standard deviation.  Plus–minus values are means ± SD. * Denotes p-value of <0.05 † The QRisk2 
score is a validated global cardiovascular risk score which predicts the likelihood of a myocardial 
infarction or cerebrovascular accident in the next 10 years based on routinely collected data from 














10-year global cardiovascular risk 
(QRisk2) score†, % 
19.3±6.9 18.6±7.0 0.693 
Age, yrs 63.7±5.1 64.9±7 0.447 
Male n (%) 21 (81) 17 (65) 0.161 
Pulse, beats/min 63±11 76±14 0.001* 
eGFR, mL/min/1.73m2 89±18 78±20 0.055 
Brachial SBP, mmHg 134±12 138±23 0.447 
Brachial DBP, mmHg 82±10 79±11 0.221 
HT treatment, n (%) 16 (61) 9 (35) 0.050 
Cholesterol treatment, n (%) 15 (58) 12 (46) 0.449 
 
Diabetes, n (%) 7 (27) 0 (0) 0.006* 
Smoking, pack years 5±10 44±36 <0.001* 
FEV1, mL 3204±743 1419±597 <0.001* 
FEV1 % predicted 103±14 49±15 <0.001* 
FEV/FVC, % 75±5 47±14 <0.001* 
Residual Volume, mL - 3852±956 - 




Figure 17 Bland-Altman plots showing agreement between measurements a) Left ventricular end 
diastolic volume index (LVEDVI), b) Central pulse pressure, c) Left ventricular stroke volume 
index (LVSVI), d) Thoracic ascending aorta pulsatility, e) Left ventricular mass index, f) Pulse 




Local arterial stiffness: Aortic distensibility 
Although numerically reduced in the COPD group compared to controls in all 3 
regions analysed, no statistical differences were identified in aortic distensibility 
(mean difference TAA: -0.41 %/mmHg x10-3 95% CI -0.9, 0.1, p=0.088; TDA -0.29 
%/mmHg x10-3 95% CI -0.8, 0.2 p=0.216; ABA -0.27%/mmHg x10-3 95% CI -1.2, 0.6, 
p=0.536).  
 
Left ventricular mass 
No differences in LVMI were identified between the matched groups (mean 
difference 2.8 g/m2; 95% CI -2.5, 8.1, p=0.291) (Table 12). 
 
Ventricular size and function 
Chamber size was decreased in the COPD group compared to the control group with 
mean differences in LVEDVI and RVEDVI of -14.1 ml/m2 (95% -22.1,-6.1 p<0.001) 
and -13.0 (95% CI -23.9, -2.0 p<0.022 respectively. There was a corresponding 
reduction in LVSVI (mean difference -10.3 ml/m2 95% CI -15.4, -5.3, p<0.001) but no 
differences in LV ejection fraction, which was preserved in both groups. Despite a 
reduction in stroke volume, cardiac index was maintained as a consequence of an 
increased heart rate in the COPD group (76±14 vs. 63±11 beats/min, p=0.001).   
 
Univariate and multivariate analysis for the 90 patient cohort 
The baseline demographics and pulmonary function for the COPD and Control 
groups making up the 90 patient cohort are shown in Table 11. 
Pulse	wave	velocity	
The results of the univariate and multivariate analyses for the whole 90 patient cohort 
are shown in Table 13.  QRISK2 and FEV1 were associated with PWV in the 
multivariate analysis.  A 10 % worsening of FEV1 percent predicted was associated 
with a 0.1 m/s increase in PWV when adjusting for other co-variates in the model. 
Whereas a 10% increase in QRISK2 was associated with 0.4 m/s increase in PWV 
when adjusting for other co-variates in the model.  However, the relationship 
between QRISK2 and PWV appears to differ when stratified according to the 
presence or absence of COPD (COPD group r2=0.26; control group r2=0.0031) which 
approached significance on formal stepwise regression analysis of the interaction 
term (p=0.060) (Figure 18).  
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Total	arterial	compliance	
Male gender and FEV1 were positively associated with TAC, whereas age, pulse, 
systolic BP were negatively correlated in multivariate analyses. For every 20% 
decrease in FEV1 there is 0.1 mL/m2/mmHg decrease in TAC across both cohorts 
when adjusting for other co-variates in the model. The relationships between 
QRISK2 and TAC for the COPD and matched controls are shown in Figure 18. For 
both the COPD and the control group there was only a very weak relationship 
between QRISK2 and TAC (COPD, r2=0.35; Control group r2 = 0.25).  Stratifying 
according to the presence or absence of COPD revealed no significant interaction. 
Cardiac	volumes	
The results of the univariate and multivariate analyses for LVEDVI, LVSVI and 
RVEDVI for all 90 participants are shown in Table 14.  Both pulse and FEV1 were 
independent predictors of LVEDVI and SVI.  
 
The contribution of lung hyperinflation and systemic inflammation to 
cardiovascular structure and function in COPD 
Pulse	wave	velocity	and	total	arterial	compliance		
The univariate and multivariate analysis of TAC and PWV for the 36 COPD group is 
shown in the lower panel of Table 12. There did not appear to be a relationship with 
lung hyperinflation or total white cell count. For TAC both fibrinogen and FEV1 were 
only associated in the univariate analysis; whereas Q-risk, fibrinogen and dyspnoea 
scores were related to PWV in the multivariate analysis.  
Cardiac	Volumes	
Information on hyperinflation, levels of systemic inflammation and atrial size were 
available for the COPD cohort (n=36). Increasing plasma fibrinogen levels and 
worsening airflow limitation and lung hyperinflation were associated with smaller 
LVEDVI and RVEDVI in the univariate analyses (Table 14). Worsening airflow 
limitation and hyperinflation were also associated with reduced LVSVI, whilst 
worsening airflow limitation, airflow obstruction and lung hyperinflation were 
associated with decreased maximal left atrial size (size of the left atrium just prior to 
mitral valve opening at the end of ventricular systole). Two different multivariate 
models were analysed. In Model 1 all parameters with a p-value of <0.1 in the 
univariate analysis were included. The relationship between worsening airflow 
limitation and reduced LVSVI was stronger in the COPD group compared to the 
aforementioned analysis of all 90 participants (β 0.202 vs. 0.129).   
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Table 11 Demographic and pulmonary function characteristics of all eligible patients from the 
COPD cohort and HAPPY London cohort used in univariate and multivariate analyses 
variable COPD group Control group 
n 36 54 
10-year global cardiovascular risk 
(QRisk2) score†, % 
17.0±10.2 19.2±7.0 
Age, yrs 63±9 64±6 
Male n (%) 21(58) 41 (76) 
Pulse, beats/min 72±16 62±11 
eGFR, mL/min/1.73m2 80±20 85±19 
Brachial SBP, mmHg 133±22 132±12 
Brachial DBP, mmHg 77±11 79±9 
HT treatment, n (%) (25) 29(54) 
Cholesterol treatment, n (%) 13±36 33(61) 
Diabetes, n (%) 0(0) 13(24) 
Smoking, pack years 47±33 7±10 
FEV1, mL 1393±616 3158±808 
FEV1 % predicted 49±16 101±13 
FEV/FVC, % 45±13 74±4 
Residual Volume, mL 3763±900 - 
Residual Volume, % predicted 172±37 - 
 
 
DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FEV1: forced expiratory 
volume in 1 second; FVC: forced vital capacity; HT: hypertension; SBP: systolic blood pressure, SD: 
standard deviation.  Plus–minus values are means ± SD. † The QRisk2 score is a validated global 
cardiovascular risk score which predicts the likelihood of a myocardial infarction or cerebrovascular 
accident in the next 10 years based on routinely collected data from National Health Service general 
practitioner databases in the United Kingdom.  
 
Similar relationships were also seen for RVEDVI but not for LVEDVI.  There were no 
multivariate relationships between any of the parameters with left atrial size in Model 
1.  Following the exclusion of FEV1 from the analysis (Model 2) a 10% increase in 
residual volume percent predicted resulted in a 1.3 ml and 0.75 ml volume reduction 

























Figure 18 Differences in pulse wave velocity, total arterial compliance and their relationship to 




The principle novel findings of our study are 1) PWV and TAC, two known 
independent predictors of cardiovascular disease, are adversely affected in stable 
hyperinflated COPD over and above a cohort considered to have equivalent global 
cardiovascular risk but normal lung function. 2) There appears to be an interaction 
between COPD and QRISK2 with regard to its relationship to PWV 3) Fibrinogen 
levels are related to PWV in COPD. 
 
Concerns have recently been raised about the accuracy of a number of different 
scoring systems and over-estimation of risk in the general population.476  However, 
the 1.0 m/s increase in PWV presented in the COPD cohort, a disease with an 
estimated UK prevalence 13.5% in those over 35 years of age, equates to an age, 
sex and risk-factor adjusted increase in relative risk of cardiovascular events and 
mortality of 14 and 15 %, respectively.297, 477  This raises the possibility that the 
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presence of smoking status alone in current cardiovascular scoring systems may be 
insufficient to predict cardiovascular risk in this common disease. 
 
The novel finding in this preliminary data that an interaction appears to exist between 
COPD and the QRISK2 in relation to PWV has potential clinical implications.  Whilst 
it has been shown that the addition of Framingham risk score to FEV1 improves risk 
stratification for cardiovascular events compared to FEV1 alone, our findings 
importantly allude to the opposite scenario; that the inclusion of COPD may improve 
the predictive ability of cardiovascular risk scores themselves and should be further 
confirmed in larger population studies.136  Secondly, this interaction implies that 
COPD could potentially act as a modifiable risk factor.  This is a concept supported 
by previous post-hoc analyses of large randomised controlled trialsand two more 
recent randomised controlled trials where the treatment of COPD with conventional 
therapies have led to a reduction in pulse wave velocity.289, 290, 478, 479  
 
Consistent with other studies we have found a relationship between FEV1 and 
PWV.226 Mechanisms proposed for the association between PWV and COPD include 
systemic inflammation and the effects of hyperinflation on neurohumoral activation.422  
CT defined emphysema has been associated with PWV whilst reports linking 
systemic inflammation to PWV in COPD have been inconsistent.227  Sabit et al found 
relationships with Interleukin (IL)-6, whereas a more recent study found no 
relationship with leukocytes, C-reactive protein, IL-6, IL-8 or soluble tumour necrosis 
factor receptor pathway 2.  Whilst we also found no relationship with leucocytes, we 
have found a relationship between PWV and fibrinogen, a marker of systemic 
inflammation in both COPD and cardiovascular disease.226, 480, 481  An accurate 
understanding of the role of fibrinogen in the relationship between COPD and 
cardiovascular disease is lacking and is the subject of the ERICA project (Evaluation 
of the Role of Inflammation In Non-pulmonary Disease Manifestations in Chronic 





Table 12 Comparison of cardiovascular endpoints between COPD and control group matched for global cardiovascular risk 
 
 
CI: confidence interval; COPD: chronic obstructive pulmonary disease; LVEDVI: left ventricle end diastolic volume index; LVEF: left ventricle 
ejection fraction: LVESVI: left ventricle end systolic volume index; LVMI, left ventricle mass index; LVSVI: left ventricle stroke volume index; PWV: 
carotid-femoral pulse wave velocity; RVEDVI: right ventricle end diastolic volume index;  SE: standard error.  
Data expressed as mean±SD.  








Control group matched 






of COPD vs 
Control group 
(SE) 
95% CI P 
Cardiac Volumes, Mass and Function      
LVEDVI, mL/m2 77.7±12.2 63.6±15.7 -14.1(3.9) -22.1, -6.1 0.001* 
LVESVI, mL/m2 28.7±7.7 24.9±7.5 -3.8(1.9) -7.9, 0.2 0.062 
LVSVI, mL/m2 49.0±6.9 38.7±10.1 -10.3(2.5) -15.4, -5.3 <0.001* 
Cardiac Index mL/min/m2 3079±607 2868±610 -211(170) -560.5, 138.4 0.225 
LVEF, % 63.4±5.4 61.0±6.5 -2.5(1.5) -5.6, 0.6 0.115 
LVMI, g/m2 50.0±7.9 52.7±8.5 2.8(2.6) -2.5, 8.1 0.291 
RVEDVI mL/m2 90.5±17.6 77.5±19.5 -13.0(5.3) -23.9, -2.0 0.022* 
Vascular Function 
Global Measures 
     
PWV, m/s 8.0±1.9 9.0±1.4 1.0(0.4) 0.1, 1.9 0.033* 
Total Arterial Compliance, mmHg/ml/m2 0.950±0.19 0.680±0.24 -0.27(0.1) -0.4, -0.2 <0.001* 
Local Measures      
Aortic Distensibility, %/mmHg x10-3      
Thoracic Ascending  2.01±0.9 1.59±1.0 -0.41(0.2) -0.9, 0.1 0.088 
Thoracic Descending 2.24±1.0 1.95±0.8 -0.29(0.2) -0.8, 0.2 0.216 
Abdominal 3.27±1.2 3.00±1.8 -0.27(0.4) -1.2, 0.6 0.536 
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Table 13: Univariate and multivariate predictors of pulse wave velocity 
 
Variable Pulse Wave velocity m/s Total Arterial Compliance mmHg/ml/m2 
 Univariate** Multivariate† Univariate** Multivariate¶ 
Whole Cohort n=90 
 β P-value β P-value β P-value β P-value 
Age, yrs 0.095 <0.001*   -0.010 0.022* -0.007 0.045* 
Gender (male)     -0.195 0.589   0.263 <0.001* 0.136 0.012* 
QRisk2, % 0.042 0.033* 0.046 0.017* -0.003 0.490   
Pulse, bts/min 0.012 0.299   -0.010 <0.001* -0.005 0.013* 
Systolic blood pressure, mmHg 0.045 <0.001*   -0.005 0.008* -0.002 0.253 
eGFR,  mL/min/1.73m2 0.007 0.443   0.002 0.148   
FEV1, % predicted -0.011 0.044* -0.013 0.022* 0.006 <0.001* 0.005 0.004* 
FEV/FVC , % -0.016 0.11   0.008 <0.001* <0.001 0.904 
 
COPD Cohort n=36 
        
Age, yrs 0.117 <0.001*   -0.011 0.010* -0.006 0.145 
Gender (male) -0.215 0.689   0.152 0.047* 0.142 0.051 
QRisk2, % 0.077 0.002* 0.062 0.021* -0.004 0.277   
Pulse, bts/min 0.005 0.776   -0.005 0.067 -0.003 0.235 
Systolic blood pressure, mmHg 0.050 <0.001*   -0.004 0.020* -0.001 0.713 
eGFR,  mL/min/1.73m2 -0.010 0.453   0.001 0.703   
FEV1, % predicted -0.005 0.783   0.005 0.041* 0.003 0.156 
FEV/FVC , % 0.001 0.979   0.002 0.569   
Residual Volume, % predicted‡ -0.003 0.717   -0.001 0.220   
IC/TLC, %‡ -0.568 0.844   0.972 0.125   
Fibrinogen, g/l ‡ 0.823 0.026* 0.716 0.030* -0.137 0.010* -0.060 0.286 
Wcc, x109/l‡ 0.012 0.912   0.006 0.711   
Oxygen saturations %‡ -0.045 0.478   <0.001 0.998   
CAT score‡ -0.059 0.052* -0.044 0.140 0.001 0.888   
MRC score‡ 0.236 0.022* 0.188 0.027* -0.011 0.494   
Smoking history, pack years  0.005 0.539   -0.001 0.273   
β: unstandardised beta co-efficient; eGFR: estimated glomerular filtration rate; FEV1: forced expiratory volume in 1 second; FVC: forced vital 
capacity *Denotes p-value of <0.05**; Univariable predictors with p < 0.1 were entered into multivariate model; †Age and systolic BP excluded from 
multivariate analysis since adjusted for in the composite global QRisk2 score; ‡ Measurements only available in COPD group 
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Table 14: Univariate and multivariate predictors of cardiac chamber size and stroke volume 
 
Total cohort n=90 LVEDVI ml/m2 LVSVI ml/m2 RVEDVI  ml/m2 
 Univariate** Multivariate Univariate** Multivariate Univariate** Multivariate 
 β P-value β P-value β P-value β  β P-value β P-value 
Age, yrs -0.302 0.2   0.027 0.867   -0.358 0.219   
Gender (male) 10.46 0.005* 5.430 0.069 7.169 0.005* 3.121 0.118 21.3 <0.001* 15.137 <0.001 
Pulse, bts/min -0.713 <0.001* -0.528 <0.001* -0.46 <0.001* -3.12 <0.001* -0.768 <0.001* -0.512 <0.001 
Systolic blood pressure, 
mmHg 
-0.165 0.113   -0.023 0.749   -0.025 0.050* -0.043 0.663 
Pulse wave velocity m/s -2.7 0.046* -0.576 0.575 -1.582 0.087* 0.065 0.924 -0.070 0.132   
FEV1, % predicted 0.293 <0.001* 0.219 0.033* 0.241 <0.001* 0.129 0.042* 0.341 <0.001* 0.192 0.096 
FEV1/FVC, % 0.382 <0.001* -0.080 0.640 0.361 <0.001* 0.886 0.412 0.436 0.001* -0.019 0.923 
             
COPD cohort n=36 LVEDVI ml/m2 LVSVI ml/m2 
 Univariate** Multivariate Univariate** Multivariate 
 Model 1 Model 2 Model 1 Model 2 
 β P-value β P-value β P-value β P-value β P-value β P-value 
Age, yrs -0.223 0.413     0.088 0.598     
Gender (male) 2.323 0.636     1.073 0.720     
Pulse, bts/min -0.533 <0.001* -0.438 0.001* -0.458 0.001* -0.286 0.001* -0.235 0.004* -0.253 0.003 
Systolic blood pressure, 
mmHg 
-0.164 0.130     0.021 0.749     
Pulse wave velocity m/s -1.509 0.337     0.501 0.603     
FEV1, % predicted 0.431 0.003* 0.276 0.073 - 0.282 0.001* 0.202 0.036* - 
FEV1/FVC, % 0.189 0.308     0.163 0.145     
Residual volume % 
predicted 
-0.137 0.035* -0.011 0.866 -0.079 0.149 -0.095 0.016* -0.023 0.560 -0.075 0.032* 
White cell count  -0.154 0.880     0.315 0.611     
Fibrinogen  -8.000 0.017* -4.559 0.094 -5.22 0.064 -2.436 0.246     
Smoking history, pack -0.024 0.751     -0.012 0.797     
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years 
Oxygen saturations, % -0.251 0.657     -0.061 0.859     
LV ejection fraction -0.514 0.155     0.336 0.126     
COPD cohort n=36 RVEDVI ml/m2 LAESVI ml/m2 
 Univariate** Multivariate Univariate** Multivariate 
 Model 1 Model 2  Model 1 Model 2 
 β P-value β P-value β P-value β P-value β P-value β P-value 
Age, yrs -0.225 0.521    0.631 0.003* 0.486 0.101 0.395 0.146 
Gender (male) 12.818 0.036* 10.8 0.035* 11.66 0.034* -4.454 0.271     
Pulse, bts/min -0.452 0.021* -0.354 0.035* -3.89 0.030* -0.19 0.142     
Systolic blood pressure, 
mmHg 
-0.200 0.151     0.081 0.377     
Pulse wave velocity m/s -1.274 0.529      2.184 0.090 -0.221 0.881 -0.002 0.999 
FEV1, % predicted 0.585 0.002* 0.451 0.027* - 0.247 0.050* 0.134 0.411 - 
FEV1/FVC, % 0.258 0.276     0.297 0.048* -0.043 0.818 0.026 0.877 
Residual volume % 
predicted 
-0.154 0.067 0.023 0.786 -0.089 0.072 -0.17 0.001* -0.105 0.137 -0.129 0.047* 
White cell count  0.551 0.671     0.151 0.858     
Fibrinogen  -10.868 0.010* -0.249 0.083 -7.22 0.060 -2.303 0.429     
Smoking history, pack 
years 
0.036 0.716      0.017 0.787     
Oxygen saturations, % 0.569 0.426     0.167 0.721     
LV ejection fraction -0.555 0.233     0.312 0.300     
RV ejection fraction -0.076 0.866     0.618 0.029* 0.339 0.101 0.369 0.143 
 
β: unstandardised beta co-efficient; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; LAESVI: left atrium end systolic volume 
index; LV: Left Ventricle; LVEDVI: left ventricle end diastolic volume index; LVSVI: left ventricle stroke volume index; RV: right ventricle RVEDVI: right 
ventricle end diastolic volume index. 
*Denotes p-value of <0.05  
** Univariable predictors with p < 0.1 were entered into multivariate Model 1.  FEV1 excluded from Model 2. 
Total arterial compliance as measured by PP/SVI is accurate over a wide range of 
aortic pressures, heart rates and extents of wave reflections.483  TAC has been 
shown to be a predictor of cardiovascular events, in normal individuals free from 
cardiovascular disease, hypertensives and the elderly.484-486  However, unlike PWV 
we found no relationship with QRISK2 in univariate or multivariate analysis.  Arterial 
stiffness measures are surrogate measures of end-organ disease representing an 
index of the summed effects of aging and exposure.  However, these surrogate 
measures have varying abilities to predict particular types of cardiovascular events.  
Whilst the QRISK2 score is designed to predict both the risk of myocardial infarction 
and stroke, TAC when measured using MRI has recently been shown to be 
independently associated with non-fatal cardiac events only, including hospitalisation 
for congestive heart failure and arrhythmia.474 This may in part explain the lack of 
relationship. 
Although numerically reduced compared to controls, there were no statistical 
differences in distensibility between groups.  Whilst not supportive of the hypothesis, 
the successful matching of large conduit arterial function in this cohort suggests that 
the differences in PWV and TAC shown may relate to differences in more distal, 
smaller arteries. Lower arterial compliance is associated with cardiac events in the 
general population after adjustment for demographic, anthropometric and traditional 
cardiac risk factors.487  Endothelial dysfunction has been implicated in COPD, where 
microalbuminuria, an indirect measure of it, is associated with all cause mortality.  
Many causes have been implicated in COPD and include sympathetic smooth 
muscle activity, hypoxia, systemic inflammation, oxidative stress, and physical 
activity.257, 488, 489 
 
We have confirmed the findings of previous studies, which were limited by lacking 
suitable control groups and/or the inclusion of more severe patient populations, that 
COPD patients have smaller cardiac chambers and stroke volumes, and maintain 
cardiac output through a compensatory increase in heart rate 105, 107, 251, 490. The 
cause of the reduced cardiac chamber size is thought to be a pre-load effect. 105, 251-
253  As presented in chapter 8, lung deflation in the short-term results in at least 
partial reversal of these effects, with decompression of the cardiac chambers, 
improvements in stroke volume, cardiac output and atrial ejection fraction.  The long 
term implications of these findings on heart failure and arrhythmia, both known to be 
increased in COPD, are as yet unknown, but may identify another therapeutic target 
in the prevention of cardiac co-morbidity.137  At present COPD remains a risk factor 
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for heart failure mortality and has been incorporated into risk scores accordingly.491 
The findings presented here add weight to the belief that the same should be done 
for cardiovascular risk.  COPD prevalence is higher than rheumatoid arthritis, a 
condition which is already included in QRISK score.  An estimated 1 million COPD 
patients in the UK are undiagnosed.477  The inclusion of COPD terms would not only 
potentially improve risk estimation but would also promote the early diagnosis of 
COPD through increased usage of pulmonary function testing and the availability of 
pulmonary function data on primary and secondary care databases. 
 
The results have to be interpreted in the context of the study design.  This is a post-
hoc cross sectional analysis so we are only able to establish association but not 
causation. The groups were matched for overall cardiovascular risk but there were 
disparities between the groups, particularly in relation to prevalence of diabetes and 
extent of smoking.   Given the relatively small sample size these findings should be 
interpreted with caution and replicated on a larger scale; the absence of a 
relationship does not necessarily mean that it does not exist.  The COPD cohort in 
our study were all hyperinflated, thus further research is required to see if the results 
can be generalised to patients with milder COPD or those with differing clinical 
phenotypes. Our primary purpose was to investigate the applicability of 
cardiovascular risk scores to patients with COPD by way of assessing surrogates of 
cardiac risk and as such our investigation regarding the proposed mechanisms 
surrounding increased risk have not been exhaustive.    
 
In summary, PWV and TAC are adversely affected in hyperinflated COPD compared 
to a group matched for global cardiovascular risk. The relationship between 
cardiovascular risk scores and PWV appears to be modified by COPD, suggesting 
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Abstract 
Introduction COPD patients develop increased cardiovascular morbidity with 
alterations in cardiac structure.  Postulated mechanisms include the deleterious 
effect of lung hyperinflation.  The effect of reducing lung hyperinflation by 
pharmacological treatment on cardiac function has not previously been studied. 
Methods This single-centre, randomised, double-blind placebo-controlled study  
investigated the effects of reducing lung hyperinflation with seven days of the inhaled 
corticosteroid/long-acting β2-agonist (ICS/LABA) fluticasone furoate/vilanterol (FF/VI) 
100/25mcg on cardiac structure, function and arterial stiffness assessed by cardiac 
magnetic resonance in 45 hyperinflated COPD patients.  Patients were randomly 
assigned 1:1 to the two-period complete-block crossover design, with a seven-day 
minimum washout.  The primary outcome was change from baseline in right 
ventricular (RV) end diastolic volume indexed to body surface area (EDVI) versus 
placebo. (ClinicalTrials.gov:NCT01691885). 
Results FF/VI treatment resulted in a 5.8ml/m2 (CI 2.74, 8.91; p<0.001) increase 
from baseline in RVEDVI versus placebo, and a 429ml (p<0.001) reduction in 
residual lung volume.  Left ventricular (LV) end-diastolic and left atrial end-systolic 
volumes increased by 3.63ml/m2 (p=0.002) and 2.33ml/m2 (p=0.002).  A post-hoc 
analysis showed an increase of 4.87ml/m2 in RV stroke volume (p=0.003) and an 
unchanged RV ejection fraction (EF).  The LV showed similar adaptation, whereas 
the left atrial EF improved by +3.17% (p<0.001).  There were no changes to intrinsic 
myocardial function or systemic vasculature, but pulmonary artery pulsatility 
increased in two of three locations studied (Main +2.9% p=0.001; Left +2.67% 
p=0.030).  FF/VI safety profile was similar to placebo. 
Conclusion Pharmacological treatment of chronic obstructive pulmonary disease 
has consistent beneficial and physiologically plausible effects on cardiac function and 
the pulmonary vasculature that may contribute to the favourable effects of ICS/LABA 
treatment in COPD.  Whether intrinsic myocardial function can be modulated through 









Chronic obstructive pulmonary disease (COPD) is a complex multi-morbid condition 
in which patients often succumb to cardiovascular causes rather than respiratory 
failure, the incidence of which has been reported as high as 50%.  It is now apparent 
that this relationship is independent of smoking and other common shared risk 
factors.  Explanations proposed include the contribution of lung hyperinflation, 
caused by the loss of elastic recoil combined with expiratory flow limitation, which is 
associated with a two-fold increase in all-cause mortality.62, 63, 422 
 
In cross-sectional studies, increased levels of static lung hyperinflation and 
emphysema are associated with reduced cardiac chamber size and function.105, 107, 
251, 252  The extent to which these structural alterations could potentially be modified 
through pharmacological treatment of lung hyperinflation has never been studied in a 
prospective manner.   
 
Studies investigating cardiac function in COPD have traditionally used 
echocardiography, thermodilution or cardio-pulmonary exercise testing, which have 
their own inherent limitations of poor acoustic windowing in hyperinflated lungs, being 
highly invasive and representing surrogates of cardiac function respectively.  Cardiac 
magnetic resonance (CMR) provides unparalleled image quality non-invasively, with 
excellent accuracy and reproducibility of cardiac structure and function433.  
Furthermore, novel imaging techniques allow tracking of myocardial deformation 
providing information on intrinsic function. 
 
The primary objective of the study was to test the hypothesis that the cardiac 
structural and functional alterations seen in stable hyperinflated COPD are modifiable 
through pharmacological lung deflation 
 
Methods 
Study design and participants 
 
This study was a single-centre, Phase IIIb, randomised, double-blind, placebo-
controlled, crossover study (ClinicalTrials.gov:NCT01691885; HZC116601).  From 
November 2012 to August 2014, 96 non-hypoxic COPD patients with at least a 15 
 135 
                   
 
Figure 19 Study design enrolment and outcome Panel A shows the design of the study.  Each 
patient, in two separate treatment periods, received 7-14 days of treatment and matching placebo 
separated by a 1-week washout period.  Panel B shows the screening, randomisation, treatment 
and follow-up of patients. AE: adverse event; CMR: cardiac magnetic resonance; COPD: chronic 
obstructive pulmonary disease; FF: fluticasone furoate; LRTI: lower respiratory tract infection; MRI: 














1a 1b 2 3 4 5 6 
–7(±3) 22(+7) 15(±2) 8(+7) 1 29(±2) 
Placebo FF/VI  
100/25 μg QD 
FF/VI  












96 subjects recruited 
45 underwent randomisation 
Excluded 51 
39 did not meet entry criteria 
22 lung hyperinflation criteria 
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8 use of prohibited medication 
2 COPD exacerbation/LRTI 
1 systemic inflammatory disorder 
4 withdrew consent 
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6 did not tolerate MRI 
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pack-year history of smoking were recruited from the outpatients departments of an 
inner-city teaching hospital and the affiliated clinical research centre (Figure 19). 
 
Eligible patients were >40 years of age, demonstrating post-bronchodilator forced 
expiratory volume in 1 second (FEV1) percent-predicted and FEV1/forced vital 
capacity (FVC) ratio < 70%, and a Medical Research Council score of >1. 
Furthermore evidence of lung hyperinflation as defined by a residual volume (RVol) 
>120 percent-predicted, was required, which improved by ≥7.5% following 400mcg of 
inhaled salbutamol.  For a full list of the exclusion criteria, please refer to the 
Appendix Section 2.  All patients gave written informed consent.  The study was 
approved by a local ethics review committee and conducted in accordance with the 
Declaration of Helsinki. 
 
All long-acting bronchodilators, inhaled corticosteroids (ICS) and oral COPD 
medications were stopped prior to screening after which participants entered a 7(±3) 
day run-in period where they received short-acting bronchodilators only.  Subsequent 
visits occurred at the beginning and end of each treatment period and one week 
following trial completion, where trial procedures were carried out and any 
unscheduled visits to a healthcare provider or the occurrence of any adverse events 
(AEs) were noted (Figure 19). 
 
Randomisation and masking 
 
Randomisation occurred at visit 2 following baseline CMR.  The central 
randomisation schedule was generated by the GlaxoSmithKline statistics group, 
using a validated computerised system (RandAll; GlaxoSmithKline, London, UK), and 
treatment assignment was masked until database freeze.  An interactive telephone 
system (RAMOS; GlaxoSmithKline, London, UK) was used for randomisation and 
drug-supply management.  Eligible patients were randomly assigned 1:1 to the two-
period complete-block crossover, receiving FF/VI 100/25mcg followed by placebo or 
placebo followed by FF/VI 100/25mcg once daily over two 7-day (maximum 14) 
treatment periods separated by a 7(±2) day washout period.  The masking of the 
study drug was such that the treatments were indistinguishable.  
 
Study Procedures 
1.5T CMR imaging (Achieva, Philips, Netherlands) was performed at baseline and 
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following each treatment period to acquire 2-chamber, 4-chamber and short axis 
cardiac views as well as cross-sections of the aorta and pulmonary arteries.  
Measures of regional and global arterial stiffness and measures of cardiac volumes, 
mass, function and feature-tracking derived measures of deformation were acquired 
as described in the methods section (Chapter 4). 
Following screening, patients performed spirometry body plethymosgraphy 
manoeuvres at baseline and following each treatment period as described in the 
methods section (Chapter 4). 
 
Outcomes 
The primary outcome was change in right ventricular end diastolic volume index 
(RVEDVI) from baseline versus placebo after seven (maximum fourteen) days of 
treatment.  Other pre-specified outcomes included structural, volumetric and 
functional changes compared to placebo of the RV, LV and LA as well measures of 
intrinsic myocardial function of the right and left ventricle, local and regional 




Analysis was performed using the per-protocol population, defined as those who 
received at least one dose of study-drug without any deviations that were considered 
to impact on the primary efficacy analysis. 
 
Due to a lack of data relating to the cardiovascular effects of pharmacological lung 
deflation, the effect size chosen was extrapolated from studies of lung-volume 
reduction surgery.492  An effect size of 5ml/m2 was selected since it was hypothesized 
that the changes following pharmacological lung deflation would be of a smaller 
magnitude to those seen following lung volume reduction surgery. 
 
Sample size calculations are based on the primary outcome and use Hudsmith and 
colleagues’ estimate of between subject standard deviation (SD) of 16 and assumed 
a 0.75 correlation between same-subject measurements.433  Using the 
resulting within subject SD of 8.13 and two-period crossover design, a total of 44 
subjects with evaluable data from both periods provides 80% power to detect 
5ml/m2 change in RVEDVI at a two-sided significance level of 0.05. 
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Change from baseline in RVEDVI was analysed using mixed model analysis, with 
period, treatment group, and baseline RVEDVI fitted as fixed effects and subject as a 
random effect.  All other pre-specified outcomes and post hoc analyses of SV and 
RV EF were similarly assessed. The relationship between change in RVol and 
RVEDVI, and the treatment effect once patients with a history of cardiovascular 
disease were excluded, was explored post hoc.  All programming was performed with 
SAS (version 9.3).  
 
Results  
Of the 96 patients who were screened, 45 underwent randomisation.  The  
per-protocol population consisted of 43 (96%) who completed FF/VI treatment and 42 
(93%) patients who completed treatment with placebo.  Demographic and clinical 
characteristics are provided in Table 14 and Table 15.  The order in which patients 
received treatment and placebo had no impact on the primary efficacy outcome.  
Following treatment with FF/VI for 7 (maximum 14) days, there was a mean increase 
from baseline in the primary efficacy outcome RVEDVI of 5.8ml/m2 (95% CI 2.74, 
8.91, p<0.001) compared with placebo (Figure 20; Table 16), an increase of 7·4% 
relative to the placebo adjusted-mean. There were corresponding improvements in 
all measures of lung hyperinflation and airflow limitation from baseline, with a 429 ml 
RVol reduction and increases of 261 ml, 4.6%, 220 ml and 350 ml in inspiratory 
capacity (IC), IC/total lung capacity (TLC), FEV1 and FVC, respectively (Table 17)  
 
Following increases in RVEDVI, there was an adaptive RV stroke volume increase 
(+4·87ml/m2 95% CI 1·81, 7·93; p=0·003), resulting in a maintained RVESVI (+0·95 
ml/m2 95% CI -0·66, 2·57; p=0·240) and RVEF (+1·28% 95% CI -0·72, 3·28; 
p=0·203).  Consistent with the primary outcome LV and atrial volumes were 
increased from baseline versus placebo (LVEDVI +3·63 ml/m2 95% CI 1·39, 5·88; 
p=0·002; LAESVI +2·33 ml/m2 95% CI 0·88, 3·77; p=0·002). The increased SV 
without alterations in pulse resulted in an improvement in cardiac index by +0·203 
l/min/m2 (95% CI 0·069, 0·337, p=0.004).  The LA also demonstrated small but 
significant improvements in EF (+3·17% 95% CI 1·65, 4·68; p<0·001). The 
unchanged LV mass over the treatment duration described was expected and 
confirms the high reproducibility of CMR (Table 16; Figure 21) 
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Figure 20 Box-plot of change from baseline in right ventricular end diastolic volume index for 
fluticasone furoate/vilanterol 100/25 μg once daily versus placebo following 7–14 days of 
treatment. Baseline is the assessment taken at pre-dose on Day 1.  FF: fluticasone furoate; VI : 
vilanterol; RVEDVI: Right ventricle end diastolic volume index  
There were no differences in any of the 6 strain or strain-rate parameters involved in 
assessing the intrinsic myocardial function of the RV compared with placebo (Table 
16). In the LV there was an improvement compared to baseline in the reverse-peak 
value of mid-ventricular circumferential strain by -1·5% (95% CI -2.92, -0.02; 
p=0·047) compared with placebo. All of the other 8 parameters assessing the LV 
global, systolic or diastolic intrinsic myocardial function were unchanged 
 
There were no alterations to systemic arterial stiffness on a local or regional level, 
with no changes in PWV, AI or distensibility at three aortic locations versus placebo. 
However, the change from baseline pulsatility was numerically increased in the 
pulmonary circulation compared to placebo in all 3 regions analysed, reaching 
statistical significance in the MPA and LPA (MPA +2.9% 95% CI 1·20, 4·59; p=0·001 
LPA +2·67% 95% CI 0·28, 5·06; p=0·030) (Table 16; Figure 21) 
 
There were no significant treatment interactions affecting change from baseline 
RVEDVI by any of the pre-specified categorical or continuous subgroups.  Post hoc, 
no relationship was found between change from baseline in RVol and RVEDVI.  
Excluding patients with a history of cardiovascular disease, totalling 7 from placebo 
and 8 from the FF/VI periods, did not effect the primary outcome measure (+ 5.62 



















































Age at enrolment, yr  64.4±9.0 
Male sex – no. (%) 28 (62) 
Body-mass index, kg/m2 † 25.1±4.4 
Body surface area, m2 †† 1.8±0.2 
Race – no. (%)  
Caucasian 39 (87) 
African American/African heritage 6   (13) 
Current smoker - no. (%) 21 (47) 
Smoking history, Pack yr  48.5±30.9 
Pre-study COPD therapy  no. (%)  
Inhaled corticosteroid 3 (6) 
Long acting beta-agonist  1 (2) 
Inhaled corticosteroids/ long acting beta-agonist 
combination 
23 (51) 
Long acting muscarinic antagonist 25 (56) 
Exacerbation in last 3 years – no. (%)  
Requiring antibiotics or oral corticosteroids at home  
0 8   (18) 
1 7   (16) 
2 9   (20) 
>2 21 (47) 
Requiring hospitalisation  
0 34 (76) 
1 8   (18) 
2 2   (4) 
>2 1   (2) 
Lung function parameters§  
Pre bronchodilator FEV1, litres 1.26±0.55 
Post bronchodilator FEV1, litres 1.47±0.55 
Post bronchodilator FEV1 % of predicted 52.5±12.2 
Post bronchodilator FEV1/FVC, % 45.3±10.3 
Pre bronchodilator IC, litres 2.10±0.70 
Pre bronchodilator IC/TLC, % 30.0±6.75 
Pre bronchodilator RVol, litres 3.80±0.99 
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Pre bronchodilator RVol % of predicted 168.8±37.0 
Reversibility RVol, litres¶ -0.53 ± 0.30 
Reversibility % of predicted RVol ¶ -23.8 ±11.2 
DLCO, mmol/min/kPa  4.9±2.0 
DLCO% of predicted 56.48±18.74 
KCO, mmol/min/kPa/litre  1.0±0.3 
KCO % of predicted 67.66±20.78 
Symptom scores  
MRC dyspnoea scale — no. (%)  
1 0 
2 26 (58) 
3 14 (31) 
4 5 (11) 
5 0 
Total score at baseline on COPD assessment test*, units  18±8 
Cardiovascular background  
Ischaemic heart disease/angina– no. (%) 8 (18) 
Atrial fibrillation– no. (%) 2 (4) 
Cerebrovascular disease – no. (%) 1 (2) 
Hypertension – no. (%) 16 (36) 
Statin therapy no. (%) 14 (33) 
Diabetes – no. (%) 1 (2) 




Plus–minus values are means ±SD.  
† The body-mass index is the weight in kilograms divided by the square of the height in meters. 
†† The body surface area is calculated according to the Mostellar method: Height (cm) x Weight (kg) / 
3600 )½ 
‡ Exacerbations during the 3 years before screening were self-reported. 
§ Clinical data are from the screening visit except DLCO and KCO which are from baseline visit. FEV1: 
forced expiratory volume in 1 second; FVC: forced vital capacity; IC: inspiratory capacity; TLC: total 
lung capacity; Rvol: residual volume; DLCO: carbon monoxide diffusion capacity; KCO: carbon 
monoxide transfer coefficient 
¶ Reversibility denotes the change in the Rvol after the administration of 400 μg of salbutemol 
*Scores on the COPD assessment test are based on a scale of 0 to 40, with lower scores indicating 





Table 16 Baseline data of cardiovascular efficacy endpoint 
 
Variable N  Placebo N FF/VI 
Cardiac structure CMR     
Right ventricle 
EDVI, ml/m2 43 79.4±17.4 44 78.6±18.0 
ESVI, ml/m2 43 29.3±8.7 44 29.2±8.6 
SVI, ml/m2 43 50.0±12.3 44 49.4±12.8 
EF, % 43 63.1±6.8 44 62.8±6.8 
Left ventricle 
EDVI, ml/m2 43 65.6±13.3 44 65.3±13.5 
ESVI, ml/m2 43 26.9±7.8 44 26.8±7.8 
SVI, ml/m2 43 38.6±7.8 44 38.5±8.0 
EF, % 43 59.4±6.4 44 59.4±6.4 
LVMI, g/m2 43 53.5±11.7 44 53.4±11.7 
Left atrium 
EDVI, ml/m2 43 24.0±18.2 44 24.2±18.0 
ESVI, ml/m2 43 40.3±17.9 44 39.9±18.0 
SVI, ml/m2 43 16.3±5.4 44 15.7±6.4 
EF, % 43 43.4±11.2 44 40.9±17.5 
Regional arterial stiffness  
Vicorder  
    
PWV, m/s 43 8.8±1.6 44 8.8±1.6 
Augmentation index, % 43 22.1±10.4 44 21.5±10.6 
Local aortic stiffness$ 
CMR distensibility, %/mmHg  
    
Thoracic ascending aorta 42 0.167±0.11 43 0.165±0.11 
Thoracic descending aorta 42 0.205±0.11 43 0.206±0.11 
Abdominal aorta 42 0.333±0.19 43 0.331±0.19 
Pulmonary artery stiffness$ 
CMR pulsatility, % 
    
Main pulmonary artery 42 24.9±8.4 43 24.7±8.5 
Right pulmonary artery 42 34.2±8.4 43 33.8±8.1 
Left pulmonary artery 41 29.6±9.5 42 28.9±9.1 
Intrinsic myocardial function$  
Right ventricle feature tracking analysis 
Global parameters, %     
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Data expressed as mean±SD.  
Indexed values are calculated as raw values divided by body surface area 
EDVI: End diastolic volume index; ESVI: End-systolic volume index; SVI: Stroke Volume Index; EF: 
Ejection Fraction; PWV: carotid-femoral pulse wave velocity; RP: reverse peak; P: Peak; SP: systolic 
peak; SRP: systolic reverse peak; DRP: diastolic reverse peak; DP: diastolic peak. 
LAEDVI is the volume of the left atrium at the end-of ventricular diastole; LAESVI is the volume of the 
left atrium at the end of ventricular systole just prior to mitral valve opening 
$ Reduced patient numbers for particular endpoint since data excluded on basis of poor image quality 
 
The incidence of on-treatment adverse events in placebo and FF/VI 100/25.  There 
was one reported drug-related event in each treatment group.  All withdrawals were 
due to COPD exacerbations (FF/VI 100/25, 2 (5%); placebo, 1 (2%).  No serious AEs 




To our knowledge, this is the first randomised, placebo-controlled study to 
demonstrate that changes in cardiac structure and function can be achieved following 
the pharmacological treatment of lung hyperinflation. In stable hyperinflated COPD, 
lung deflation with FF/VI results in structural alterations to both sides of the heart, 
improved biventricular stroke volume, left atrial function and pulsatility within the 
pulmonary circulation.   
 
Lung deflation in this short-term study had no effect on systemic vascular function, 
intrinsic systolic or diastolic myocardial function, or ejection fraction of either 
ventricle.  We have shown in hyperinflated COPD that reduced cardiac chamber size 
exists due to a reduced pre-load effect, and that lung deflation in the short-term 
results in decompression of the heart and associated pulmonary vasculature.  This  
 
Longitudinal strain RP 42 -19.0±8.2 43 -18.9±8.2 
Radial strain P 42 31.0±12.2 43 31.0±12.1 
Systolic parameters, 1/s     
Radial strain rate SP 42 1.5±0.5 43 1.5±0.5 
Longitudinal strain rate SRP 42 -1.3±0.6 43 -1.3±0.6 
Diastolic parameters, 1/s     
Radial strain rate DRP 42 -1.0±0.5 43 -1.0±0.5 
Longitudinal strain rate DP 42 1.1±0.6 43 1.1±0.6 
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Figure 21 Forest plot of other cardiovascular efficacy outcomes. ABA: abdominal aorta; CI: 
confidence interval; EDVI: end diastolic volume index; EF: ejection fraction; ESVI: end systolic volume 
index; FF: fluticasone furoate; LPA: left pulmonary artery; MI: mass index; MPA; main pulmonary artery; 
RPA: right pulmonary artery; RVEDVI: right ventricular end diastolic volume; SVI: stroke volume index; 
TAA: thoracic ascending aorta; TDA: thoracic descending aorta; VI = vilanterol 
 
leads to relative normalisation of end diastolic volumes and subsequent improvement 
in stroke volume.  
 
Reduced RV size in hyperinflated COPD has been a consistent finding in recent 
CMR studies.  RVEDV indexed to BSA, the primary end point in this study, has been 
shown to be reduced in volume by 18ml/m2 compared to age, gender and body-size 
matched controls in those patients with severe emphysema.252  In a prospective, 
multicentre cohort study of over 6000 participants involving two subgroups from the 
Multi-Ethnic Study of Atherosclerosis (MESA), a 10% increase in CT-defined 
emphysema was associated with a reduction in RVEDV by 2.43 ml (95% CI 0.7, 
4.16) and 3.25 (95% CI 2.29, 4.20) for current and ex-smokers respectively.107   
Given that CT-emphysema values of 40% can be seen, based on the BSA of our 
study, up to a 7.22ml/m2 reduction in RVEDVI may be attributed to emphysema. 
RVEDVI was selected as the primary endpoint for this study since the thin-walled RV 
was considered most sensitive to changes in pre-load conditions.  We have 
demonstrated a 5.8ml/m2 change from baseline compared to placebo suggesting 
partial reversal of the changes attributed to lung hyperinflation. 
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Table 17 Results of cardiovascular efficacy outcomes of FF/VI 100/25 versus placebo 
 Placebo  FFVI    
 N Least squares mean 
change from baseline 
(SE) 
N Least squares mean 
change from baseline 
(SE) 
Difference of  
FFVI 100/25 from 
placebo  









    
Right ventricle 
Primary efficacy outcome 
EDVI, ml/m
2
 41 -0.47 (1.39) 43 5.35 (1.37) 5.83 2.74, 8.91 <0.001* 
Other efficacy outcomes 
ESVI, ml/m
2
 41 0.28 (0.77) 43 1.23 (0.76) 0.95 -0.66, 2.57 0.240 
SVI, ml/m
2
 41 -0.76 (1.24) 43 4.11 (1.21) 4.87 1.81, 7.93 0.003* 




 41 0.03 (1.01) 43 3.66 (0.99) 3.63 1.39, 5.88 0.002* 
ESVI, ml/m
2
 41 0.60 (0.63) 43 1.29 (0.62) 0.70 -0.88, 2.27 0.375 
SVI, ml/m
2
 41 -0.62 (0.85) 43 2.37 (0.84) 2.99 1.11, 4.87 0.003* 
EF, % 41 -1.36 (0.82) 43 0.20 (0.80) 1.55 -0.35, 3.46 0.107 
LVMI, g/ m
2




 41 0.51 (0.49) 43 0.68(0.48) 0.17 -0.68, 1.02 0.690 
ESVI, ml/m
2
 41 0.8 (0.87) 43 3.12 (0.86) 2.33 0.88, 3.77 0.002* 
SVI, ml/m
2
 41 0.27 (0.54) 43 2.45 (0.53) 2.18 1.20, 3.16 <0.001* 
EF, % 41 -0.65 (0.86) 43 2.51 (0.85) 3.17 1.65, 4.68 <0.001* 
Regional arterial stiffness 
Vicorder 
       
PWV, m/s 42 -0.03 (0.14) 43 -0.14 (0.13) -0.11 -0.39, 0.16 0.405 
AI, % 42 1.66 (1.17) 43 3.18 (1.163) 1.53 -1.06, 4.11 0.241 
Local aortic stiffness $ 
CMR distensibility, %  
       
Thoracic ascending aorta 39 -0.014 (0.009) 41 -0.005 (0.009) 0.009 -0.009, 0.027 0.326 
Thoracic descending aorta 39 -0.012 (0.011) 41 0.010 (0.012) 0.023 -0.001, 0.046 0.056 
Abdominal aorta 39 -0.015 (0.020) 41 0.013 (0.019) 0.028 -0.015, 0.071 0.189 
Pulmonary artery stiffness$  
CMR pulsatility, % 
       
Main pulmonary artery 39 -0.33 (0.98) 40 2.56 (0.97) 2.90 1.20, 4.59 0.001* 
Left pulmonary artery 38 -0.30 (0.92) 40 2.37 (0.89) 2.67 0.28, 5.06 0.030* 
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Analysis performed using an ANCOVA model with covariates of treatment, baseline, period and subject as a random effect. EDVI ; End diastolic volume index; ESVI: End-
systolic volume index; SVI: Stroke Volume Index; EF: Ejection Fraction; PWV: carotid femoral pulse wave velocity. RP: reverse peak; P : Peak; SP : systolic peak; SRP: 
systolic reverse peak; DRP : diastolic reverse peak; DP: diastolic peak.  
Indexed values are calculated as raw values divided by body surface area;  
¶Left Atrium EDVI is the volume of the left atrium at the end-of ventricular diastole ; 
¶Left Atrium ESVI is the volume of the left atrium at the end of ventricular systole just prior to mitral valve opening 
* Denotes p-value of < 0.05;  
$  
Reduced patient numbers compared to primary efficacy endpoint since some data excluded on basis of poor image quality 
Right pulmonary artery 39 0.93 (1.13) 41 2.22 (1.10) 1.29 -1.26, 3.84 0.313 
Intrinsic myocardial function$  
Right ventricle feature tracking analysis 
     
Global parameters, %        
Longitudinal strain RP 40 -0.47 42 -0.36 0.12 -2.70, 2.93 0.934 
Radial strain P 40 4.25 42 5.64 1.40 -8.12, 10.91 0.768 
Systolic parameters, 1/s        
Radial strain rate SP 40 0.09 (0.12) 42 0.14 (0.12) 0.05 -0.25, 0.35 0.742 
           Longitudinal strain rate SRP       40 0.00 (0.07) 42 0.13 (0.07) 0.13 -0.04, 0.30 0.120 
Diastolic Parameters, 1/s        
Radial strain rate DRP 40 0.21 (0.09) 42 0.12 (0.09) -0.09 -0.34, 0.158 0.466 
Longitudinal strain rate DP 40 -0.08 (0.07) 42 -0.10 (0.07) -0.01 -0.16, 0.14 0.876 
 147 
Table 18 Results of pulmonary efficacy outcomes of FF/VI 100/25 versus placebo 
 





N Least squares 
mean change 
from baseline  
(SE) 
N Least squares mean 
change from baseline  
(SE) 
Diff of  
FFVI 100/25 from placebo  




Spirometry   
FEV1, l 43 0.00 (0.052) 44 0.22 (0.052) 0.220 0.12, 0.31 <0.001* 
FVC, l 43 0.11 (0.071) 44 0.46 (0.071) 0.350 0.21, 0.49 <0.001* 
FEV1/FVC, % 43 -0.9 (1.10) 44 1.1 (1.09) 2.02 -0.3, 4.3 0.092 
Body Plethysmograph  
Rvol, l 42 0.028 (0.074) 43 -0.401 (0.074) -0.429 -0.59, -0.27 <0.001* 
IC, l 42 -0.012 (0.044) 43 0.249 (0.044) 0.261 0.17, 0.35 <0.001* 
IC/TLC, % 42 -0.5 (0.54) 43 4.1 (0.54) 4.6 3.1, 6.0 <0.001* 
 
Analysis performed using an ANCOVA model with covariates of treatment, baseline, period and subject as a random effect. CI: Confidence Interval; FEV1: forced 
expiratory volume in 1 second; FVC: forced vital capacity; Rvol: residual volume; IC: inspiratory capacity; TLC: total lung capacity.  
* Denotes p-value of < 0.05 
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Table 19 Summary of on-treatment adverse events 
 
 Placebo FF/VI 100/25 
N 43 44 
Serious adverse events 0  0  
Any on-treatment event  5 (12) 6 (14) 
Headache 2 (5) 2 (5) 
Fatigue 1 (2) 1 (2) 
Pain in extremity 1 (2) 1 (2) 
Chest pain 1 (2) 0 
COPD exacerbations 1 (2) 0 
Contusion 1 (2) 0 
Dizziness 1 (2) 0 
Influenza 0 1 (2) 
Joint swelling 1 (2) 0 
Local swelling 1 (2) 0 
Muscle spasms 1 (2) 0 
Nausea 0 1 (2) 
Neck pain 1 (2) 0 
Pruritus 0 1 (2) 
Rhinitis 0 1 (2) 
Toothache 0 1 (2) 
Urinary tract infection 1 (2) 0 
Data presented as numbers of patients (percent) 
 
 
Reduced cardiac chamber size in COPD has been attributed to the stiffening of the 
mediastinum or, alternatively decreased ventricular pre-load through vascular 
remodelling in emphysema or increased intrathoracic pressure due to gas trapping 
and airflow obstruction.
62, 105, 251, 422
  Given the irreversible nature of emphysema, 
alterations to airways resistance and increased functional strength are likely to be 





The long-term clinical consequences of the changes in cardiac size and function 
presented here are not fully determined.  Subclinical changes in RV morphology 
have recently been shown to affect patient centred outcomes and may be an early 
marker of cardiopulmonary dysfunction.  On a population level, one SD decrement 
(11ml/m
2
) in RVEDVI has been associated with a 12% increase in the risk of 
dyspnoea after adjustment for spirometric measurements and CT-defined 
emphysema.
493
  Furthermore, increases in cardiac output are associated with 
improvements in walking intensity across all severities of COPD, and reduced atrial 
ejection fraction, independent of atrial size, predicts the development of atrial 
fibrillation in dyspnoeic patients.
494-496
  Thus, the ability to modify cardiac morphology 
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and function does therefore appear to independently impact on relevant clinical and 
patient-centred outcomes, and highlights the importance of identifying and optimally 
treating this “lung-deflator” clinical phenotype.
497
   
 
The ability to alter ventricular size and SV through lung deflation has also been seen 
following lung volume reduction surgery (LVRS).  Mineo and colleagues using 
thermodilution demonstrated an increase of 9 and 3ml/m
2
 in RVEDVI and RVSVI, 
respectively.  Post-hoc data from the National Emphysema Treatment Trial (NETT) 
demonstrated improvements in O2-pulse, an exercise-testing surrogate for SV, 
following LVRS in surgical “lung-deflators”.  The modalities used to measure cardiac 
volumes are not directly comparable.  Despite this, the direction of RVEDVI changes 
shown here are in line with those following LVRS, but given the volume reductions 




The proposed mechanisms causing alterations to the heart following short-term 
changes in lung volume are corroborated by changes in the opposite direction 
observed in patients receiving ventilator support in critical care.  Incremental 
increases in positive end-expiratory pressure and RVol decreased the RVEDVI by 4–
5ml/m
2
 in those patients with a non-dilated RV without affecting transmural pressure; 
while a second study demonstrated that reduced cardiac output was due to a 




As well as its effects on the chambers of the heart, the intriguing finding that lung 
deflation results in improved PA pulsatility warrants further consideration.  There is a 
scarcity of published data on PA stiffness in COPD.  The MESA-COPD study has 
shown that in COPD patients free from cardiovascular disease, pulsatility was 
reduced compared to smoking controls in adjusted models.
502
  A second 
echocardiographic study utilised Doppler flows and maximal systolic frequency shift 
to estimate PA stiffness and found it to be reduced in COPD compared age and sex-
matched non-smoking controls.  Although these changes may have been a result of 
raised PA pressures (30+/-7.9mmHg), Hilde and colleagues have demonstrated a 
disparity between PA pressures and RV remodelling in COPD.
423, 503
  They identified 
a cohort of patients with reduced PA compliance, rather than raised pulmonary 
pressures, with echocardiographic appearances typically associated with pulmonary 
hypertension.  This suggests a role for altered PA intrinsic elastic properties in RV 
adaptation.  An altered inflammatory profile from cigarette smoke leading to 
endothelial dysfunction has been implicated.
504, 505
  It is unlikely that the PA 
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inflammatory profile during this short-term study will have been altered sufficiently by 
the ICS component of FF/VI to modify the intrinsic elastic properties.  Increased 
pulsatility may be caused by increased SV and subsequent PA distension.  
Alternatively lung deflation may have altered the elastic properties through 
decompression of the PA.  Such alterations have been known to occur earlier than 
changes in RV performance and early work by Milnor and colleagues demonstrated 
that 30% of RV power is spent generating the oscillatory component of flow.
506, 507
 
Therefore improvements in stiffness could have potentially clinically important long-
term benefits in reducing afterload, increasing ventricular efficiency and potentially 
attenuating the RV adaptation seen in COPD.   
 
There are several limitations of this study.  Firstly, it is a single-centre study within a 
predominantly Caucasian cohort of COPD patients, and as such may not apply to 
other populations.  Secondly, we have included all patients with evidence of lung 
hyperinflation based on RVol, which is still considered to be the best way to evaluate 
therapies aimed at reducing air-trapping
79
.  As a consequence, participants have not 
been clinico-radiographically separated, according to emphysematous versus chronic 
bronchitic phenotypes, and we are unable to establish a differential treatment effect.  
Thirdly, we have used novel cardiac imaging techniques to help understand the 
impact of lung deflation on cardiac deformation and vascular function, but for 
practical and ethical reasons have not employed invasive pressure monitoring.  
Finally, due to the brevity of this study there were no significant safety findings. 
 
In summary, our study confirms that through pharmacological treatment of COPD, 
consistent and physiologically plausible beneficial effects on cardiac structure, 
function and the pulmonary vasculature can be achieved in the short term.  Whether 
intrinsic myocardial function can be modulated through prolonged periods of lung 













Chapter Nine:  




























The focus of this thesis was to establish the utility of non-invasive cardiovascular 
physiological measurements and imaging modalities in COPD, and to better 
understand the relationship between COPD, lung hyperinflation and its treatment on 
cardiovascular structure and function. 
 
I have demonstrated for the first time that a novel, relatively operator-independent, 
device for the assessment of arterial stiffness is reproducible and not affected by 
lung hyperinflation.  It is therefore an acceptable alternative to the more validated but 
more time-consuming SphygmoCor for use in longitudinal clinical studies involving 
hyperinflated COPD patients.  With an increasing number of devices being 
developed, difficulties will persist until there is consensus regarding the specific site 
of measurement and path length estimation.  Either invasive validation studies, or 
non-invasive studies utilising CMR are needed to identify the most accurate devices 
and allow their employment in clinical practice. 
 
I have established for the first time the interstudy reproducibility of 3 separate cardiac 
deformation analysis techniques in COPD.  I have highlighted the often unpublished 
variation in reproducibility that exists depending on which particular strain parameter 
is being considered.  Progress in their development would be greatly accelerated if 
we are able to establish which of the newer modalities and algorithms produce the 
most accurate information.  This could be achieved through the modelling of cardiac 
deformation and applying the algorithms to such a model.  Despite their current 
limitations, some parameters have sufficient reproducibility to be employed in clinical 
studies and these parameters are particularly attractive for use in COPD due to 
difficulties with echocardiography in lung hyperinflation.  A full understanding of the 
relative importance of these strain parameters to cardiac function and dysfunction is 
lacking.  Future work needs to focus on the identification of particular groups of 
deformation parameters which define, as well as help predict, different aspects of 
systolic and diastolic myocardial performance in COPD.  Understanding cardiac 
strain data in this way would thereby elucidate distinct prognostic indicators of 
cardiac dysfunction.  This can potentially be achieved through the use of statistical 
dimensionality reduction techniques, such as principle component analysis or 
Bayesian principle component analysis.  These are quantitative methods for data 
reduction and classification to develop simplified patterns from correlated multi-item 
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data, thereby identifying a smaller number of independent underlying components 
which best explains the variation in the dataset.   
 
I have confirmed that cardiac chamber size is reduced and that these reductions 
relate to airflow limitation.  Furthermore, I have found that cardiovascular prognostic 
markers are adversely affected in COPD compared to a group with normal lung 
function, considered to have equivalent cardiac risk according to validated scoring 
systems, and the relationship between the QRisk2 prediction model and pulse wave 
velocity appears to be modified by the presence or absence of COPD.  It may 
therefore be that we are underestimating cardiac risk in COPD, and the presence or 
absence of COPD as a binary variable, or FEV1 per cent predicted, should be 
incorporated into these risk prediction models to increase their predictive value.  The 
beneficial knock-on effect of this implementation may be the early pick up of COPD 
in primary care, allowing potentially life-prolonging early interventions.  The high 
levels of cardiovascular co-morbidity in COPD is well accepted within the respiratory 
world, but less so outside of it so large cohort or population studies with “harder” 
cardiovascular endpoints emphasising the suboptimal risk prediction in COPD may 
be needed to drive this change. 
 
Furthermore, I have demonstrated relationships between cardiovascular surrogates, 
cardiac structure, airflow limitation and systemic inflammation in COPD patients. This 
highlights the possibility that adapting the COPD phenotype or systemic inflammation 
in some way may enable cardiac structure and prognosis to be modified.  Chapter 
Eight sheds some light on this as will the results of the recently completed, but as yet 




I have demonstrated for the first time in a RCT that the pharmacological reduction of 
lung hyperinflation results in structural alterations to both sides of the heart, improved 
biventricular stroke volume, left atrial function and pulsatility within the pulmonary 
circulation.  This study has opened up a number of avenues for further research:  
The effects of prolonged lung deflation are still unknown.  Further studies would need 
to confirm that the changes demonstrated persist over the longer term.  Other key 
areas for further research would be to establish, with a sufficiently powered study 
based on the reproducibility data from Chapter Six, whether COPD treatment can 
indeed alter intrinsic myocardial function.   
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Alternative directions include investigating what impact the ICS component has on 
vascular function within the systemic circulation and whether the ICS would further 
enhance the effects seen in the pulmonary circulation.  On a public health level the 
priority remains to investigate the effect of the early identification of smokers to 
encourage cessation and thereby prevent the development of COPD.  The hope 
would be that if we are able case-find at an early enough stage we may be able to 
alter its natural history and prevent the ensuing heart failure and cardiac arrhythmias. 
The development of closer relationships between primary and secondary care 
through an integrated care system, such as that being developed in the UK for the 
management of COPD, will hopefully provide the infrastructure to undertake such 
research.    
 
In summary, I have demonstrated that cardiac imaging modalities exist that can be 
utilised in COPD to help us better understand the vital role the disease and its 
treatment plays in the development of cardiac structural and functional alterations, 
morbidity and mortality, and I have given credence to the suggestion that this 
relationship may be modifiable. A great deal of exciting work is still needed to better 












Unrelated published manuscripts arising during my 
PHD period  
 
Moving from the Oslerian paradigm to the post-genomic era: are asthma and 
COPD outdated terms? Thorax 2013 Louis E Vanfleteren, Jan-Willem Kocks, Ian S 




Reporting standards in cardiac MRI, CT and SPECT diagnostic accuracy 
studies: Analysis of the impact of STARD criteria European Heart Journal of 
Cardiovascular Imaging 2014 Edd N Maclean, Ian S Stone, Felix Ceelen, Xabier 





























The following tables contain all the inter-study and agreement analysis performed for 
Chapter 6: 
 
Table 20 Tagging inter-study reproducibility. SD; standard deviation: ICC; inter-class correlation 
coefficient: CI; Confidence interval  n=34: Green= global value; red = systolic value, blue = diastolic value 





Limits of Agreement ICC 95% CI 
Apical  
Peak Radial Strain, % 
49.91 157.27 920.26 -1591.24, 1905.77 0.003 -0.348, 0.345 
Apical  
Peak Radial Strain 
Rate, %/s 





Reverse Peak Radial 
Strain Rate, %/s 





17.77 0.07 3.14 -5.90, 6.03 0.547 0.249, 0.752 
Apical  
Peak Circumferential 
Strain Rate, %/s 





-106.18 3.00 29.38 -52.83, 58.82 0.143 -0.214, 0.467 
Mid-ventricular  
Peak Radial Strain, % 
35.71 6.12 15.58 -35.72, 23.49 0.321 -0.011, 0.59 
Mid-ventricular 
Peak Radial Strain 
Rate, %/s 
221.61 -33.39 98.59 -220.72, 53.93 0.186 -0.154, 0.488 
Mid-ventricular 
Reverse Peak Radial 
Strain Rate, %/s 





-16.41 -0.13 2.56 -5.00, 4.73 0.659 0.42, 0.813 
Mid-ventricular  
Peak Circumferential 
Strain Rate, %/s 





-83.79 -2.91 16.16 -33.61, 27.79 0.430 0.116, 0.667 
Basal 
Peak Radial Strain, % 





Peak Radial Strain 
Rate, %/s 
328.73 -114.02 465.97 -999.36, 771.32 0.054 -0.282, 0.380 
Basal  -339.49 138.94 614.47 -1028.55, 1306.42 0.010 -0.322, 0.341 
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Reverse Peak Radial 








-0.23 3.74 -7.33, 6.86 0.241 -0.097, 0.531 
Basal  
Peak Circumferential 
Strain Rate, %/s 





-74.00 -4.29 14.68 -32.19, 23.60 0.453 0.144, 0.683 
2-chamber  
Peak Radial Strain, % 
24.25 -0.73 14.24 -27.78, 26.32 0.304 -0.053, 0.594 
2-chamber  
Peak Radial Strain 
Rate, %/s 
161.89 -9.63 102.48 -204.33, 185.07 0.039 -0.316, 0.387 
2-chamber 
Reverse Peak Radial 
Strain Rate, %/s 
-148.09 16.79 87.032 -148.56, 182.15 0.217 -0.145, 0.530 
2-chamber  
Reverse Peak 
Longitudinal Strain, % 
-12.39 -0.81 3.00 -6.51, 4.90 0.396 0.052, 0.657 
2-chamber  
Peak Longitudinal 
Strain Rate, %/s 





-70.45 -6.25 17.83 -40.14, 27.63 0.284 -0.074, 0.570 
4-chamber  




-25.03, 22.03 0.306 -0.051, 0.595 
4-chamber  
Peak Radial Strain 
Rate, %/s 
147.20 -23.42 103.09 -219.30, 172.45 0.132 -0.23, 0.463 
4-chamber  
Reverse Peak Radial 
Strain Rate, %/s 
-123.55 -8.99 73.42 -148.50, 130.52 0.283 -0.076, 0.57 
4-chamber   
Reverse Peak 
Longitudinal Strain, % 
-13.65 0.64 3.21 -5.45, 6.73 0.337 -0.016, 0.617 
4-chamber  
Peak Longitudinal 
Strain Rate, %/s 
62.61 3.45 20.24 -35.00, 41.90 0.486 0.162,  0.716 
4-chamber Reverse 
Peak Longitudinal 
Strain Rate, %/s 











Table 21 Feature tracking inter-study reproducibility: SD; standard deviation: ICC; inter-class 
correlation coefficient: CI; Confidence interval: Green= global value; red = systolic value, blue = diastolic 
value 







ICC 95% CI 
Apical  
Peak Radial Strain, % 
24.90 1.60 19.21 -34.90, 38.11 0.359 0.06, 0.60 
Apical  
Peak Radial Strain Rate, 
%/s 
142.76 -1.01 64.33 -123.25, 121.23 0.402 0.11, 0.631 
Apical  
Reverse Peak Radial 
Strain Rate, %/s 
157.67 13.44 69.23 
-118.10, 
144.984 





-24.20 2.00 6.33 -10.02, 14.01 0.56 0.307, 0.74 
Apical  
Peak Circumferential 









-177.56 18.45 65.43 -105.87, 142.77 0.488 0.215, 0.692 
Mid-ventricular  
Peak Radial Strain, % 
37.57 -4.32 14.91 -32.66, 24.02 0.451 0.168, 0.665 
Mid-ventricular 
Peak Radial Strain Rate, 
%/s 
178.30 -17.10 57.67 -126.67, 92.46 0.344  0.043, 0.589 
Mid-ventricular Reverse 
Peak Radial Strain Rate, 
%/s 




-17.23 0.75 4.03 - 6.90, 8.39 0.531 0.269, 0.721 
Mid-ventricular  
Peak Circumferential 
Strain Rate, %/s 
87.71 -0.17 27.53 -52.48, 52.13 0.57 0.321, 0.747 
Mid-ventricular Reverse 
Peak Circumferential 
Strain Rate, %/s 
-110.53 7.97 27.85 -44.95, 60.89 0.467 0.189, 0.677 
Basal 
Peak Radial Strain, % 
35.86 -2.51 18.41 -37.50, 32.48 0.059 -0.252, 0.359 
Basal  
Peak Radial Strain Rate, 
%/s 
165.15 -8.23 63.62 -129.11, 112.65 0.277 -0.032, 0.538 
Basal  
Reverse Peak Radial 
Strain Rate, %/s 





-17.74 0.65 4.44 -7.78, 9.08 0.51 0.242, 0.706 
Basal  
Peak Circumferential 
Strain Rate, %/s 
103.12 -8.53 32.54 -70.35, 53.30 0.549 0.293, 0.733 
Basal  
Reverse Peak 







Peak Radial Strain, % 
37.79 -3.07 21.64 -44.18, 38.03 0.0127 -0.294, 0.318 
2-chamber  
Peak Radial Strain Rate, 
%/s 
169.06 7.68 97.35 -177.29, 192.65 0.0827 -0.379, 0.23 
2-chamber 
Reverse Peak Radial 
Strain Rate, %/s 
-149.76 4.76 68.58 -125.55, 135.07 0.24 -0.071, 0.51 
2-chamber  
Reverse Peak 
Longitudinal Strain, % 
-14.41 0.43 4.69 -8.48, 9.34 0.378 0.082, 0.614 
2-chamber  
Peak Longitudinal Strain 
Rate, %/s 
83.42 -7.76 31.00 -66.65, 51.14 0.405 0.114, 0.633 
2-chamber  
Reverse Peak 
Longitudinal Strain Rate, 
%/s 
-94.15 4.05 32.51 -57.71, 65.82 0.315 0.01, 0.567 
4-chamber  
Peak Radial Strain, % 
30.65 -0.67 13.01 25.39, 24.06 0.443 0.158, 0.66 
4-chamber  
Peak Radial Strain Rate, 
%/s 
148.76 -1.70 57.55 -111.06, 107.66 0.437 0.152, 0.656 
4-chamber  
Reverse Peak Radial 
Strain Rate, %/s 
-130.82 -0.31 49.74 -94.81, 94.19 0.378 0.082, 0.614 
4-chamber   
Reverse Peak 
Longitudinal Strain, % 
-12.39 0.28 5.32 -10.38, 9.83 0.419 0.13, 0.643 
4-chamber  
Peak Longitudinal Strain 
Rate, %/s 
84.30 -4.04 31.24 -63.40, 55.31 0.641 0.416, 0.792 
4-chamber Reverse 





41.91 -83.41, 75.86 0.195 -0.118, 0.473 
Right Ventricle Peak 
Radial Strain, % 
30.96 4.09 20.88 -35.58, 43.76 0.169 -0.144, 0.453 
Right Ventricle  
Peak Radial Strain Rate, 
%/s 
147.97 10.20 57.88 -99.77, 120.17 0.362 0.064, 0.602 
Right Ventricle 
Reverse Peak Radial 
Strain Rate, %/s 
-127.19 -4.92 59.33 -117.65, 107.81 0.369 0.071, 0.607 
Right Ventricle  
Reverse Peak 
Longitudinal Strain, % 
-15.61 - 0.17 6.00 -11.58, 11.23 0.606 0.369, 0.77 
Right Ventricle  
Peak Longitudinal Strain 
Rate, %/s 
99.65 -6.34 45.48 92.76, 80.09 0.412 0.121, 0.638 
Right Ventricle  
Reverse Peak 
Longitudinal Strain Rate, 
%/s 
-105.74 1.30 44.18 -82.63, 85.23 0.572 0.323, 0.748 
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Table 22 Tissue tracking inter-study reproducibility: SD; standard deviation: ICC; inter-class 
correlation coefficient: diff; difference: CI; confidence Interval: Green= global value; red = systolic value, 
blue = diastolic value 











23.42 -1.33 8.08 -16.67, 14.01 0.314 0, 0.572 
Apical  
Peak Radial 
Strain Rate, %/s  














Strain Rate, %/s 




Strain rate, %/s 




22.55 -2.03 5.11 -11.73, 7.68 0.541 0.274, 0.731 
Mid-ventricular 
Peak Radial 
Strain Rate, %/s 














Strain Rate, %/s 




Strain Rate, %/s 









Strain Rate, %/s 





-264.78 40.18 130.54 -207.85, 288.20 0.579 0.324, 0.756 












Strain Rate, %/s 




Strain Rate, %/s 




25.83 -1.27 5.10 -10.96, 8.42 0.593 0.343, 0.765 
2-chamber  
Peak Radial 
Strain Rate, %/s 










-14.14 0.11 2.45 -4.54, 4.77 0.51 0.235,  0.711 
2-chamber  
Peak Longitudinal 
Strain Rate, %/s 




Strain Rate, %/s 




28.67 -2.67 8.05 -17.96, 12.62 0.343 0.033, 0.594 
4-chamber  
Peak Radial 
Strain Rate, %/s 













-14.56 0.75 2.83 -4.63, 6.13 0.253 -0.066, 0.525 
4-chamber  
Peak Longitudinal 
Strain Rate, %/s 




Strain Rate, %/s 
-125.36 19.98 61.23 -96.37, 136.32 0.291 -0.025, 0.555 
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Table 23  Agreement between different strain measurement techniques. SD; standard deviation: ICC; interclass correlation co-efficient: CI; confidence interval: LoA; Limits 
of agreement 





SD LoA ICC 95% CI Mean 
difference 
SD LoA ICC 95% CI 
Apical  
Peak Radial Strain, % 49.91 24.72 79.84 
-126.98, 
176.41 -0.022 -0.33, 0.30 26.53 78.32 
-122.29, 
175.35 -0.020 -0.335, 0.301 
Apical  
Peak Radial Strain Rate, 
%/s 
322.90 182.98 513.72 -793.09, 1159.05 -0.064 -0.37, 0.26 152.60 548.73 
-889.99, 
1195.19 -0.074 -0.382, 0.251 
Apical  
Reverse Peak Radial 
Strain Rate, %/s 
-303.90 -156.98 442.40 -997.54,  683.58 0.047 -0.36, 0.28 -122.46 478.77 
-1032.13, 
787.21 -0.039 -0.352, 0.283 
Apical  
Reverse Peak 
Circumferential Strain, % 
17.77 6.12 6.51 -6.24, 18.48 0.026 -0.29, 0.34 -3.68 4.22 
-11.70, 
4.34 0.101 -0.224, 0.407 
Apical  
Peak Circumferential 
Strain Rate, %/s 
94.58 -50.38 71.42 -186.08 85.32 0.286 -0.04, 0.55 -40.46 253.86 
-522.78, 





-106.18 66.52 89.85 -104.19, 237.23 -0.182 -0.47, 0.14 22.83 253.95 
-459.68, 
505.33 -0.008 -0.324, 0.312 
Mid-ventricular  
Peak Radial Strain, % 35.71 -2.34 23.52 
-47.016, 
42.34 -0.022 -0.33, 0.29 12.93 17.27 
-19.89, 
45.74 -0.215 -0.492, 0.102 
Mid-ventricular 
Peak Radial Strain Rate, 
%/s 
221.61 41.62 112.96 -173.01, 256.26 -0.051 -0.36, 0.26 68.55 112.18 
-144.59, 
281.69 -0.184 -0.467, 0.135 
Mid-ventricular Reverse 
Peak Radial Strain Rate, 
%/s 
-195.20 -44.18 97.44 -229.33, 140.97 -0.066 -0.37, 0.25 -57.05 89.95 
-227.95, 
113.88 -0.102 -0.399, 0.216 
Mid-ventricular Reverse 
Peak Circumferential -16.41 1.07 3.17 -4.95, 7.09 0.402 0.11, 0.63 -2.17 2.23 
-6.41, 





Strain Rate, %/s 
75.67 -14.06 26.33 -64.10, 35.96 0.581 0.33, 0.76 -22.69 32.86 
-85.12, 
39.74 0.264 -0.049, 0.531 
Mid-ventricular Reverse 
Peak Circumferential 
Strain Rate, %/s 
-83.79 25.60 23.20 -18.49, 69.70 0.142 -0.18, 0.43 14.85 23.36 
-29.53, 
59.23 0.234 -0.082, 0.508 
Basal 
Peak Radial Strain, % 50.40 15.01 75.36 
-28.16, 
158.19 -0.047 -0.35, 0.27 11.11 75.14 
-131.67, 
153.88 -0.027 -0.333, 0.287 
Basal  
Peak Radial Strain Rate, 
%/s 
328.73 165.37 459.66 -707.97, 1038.72 -0.074 -0.38, 0.24 36.92 476.12 
-867.71, 
941.55 -0.023 -0.33, 0.29 
Basal  
Reverse Peak Radial 
Strain Rate, %/s 
-339.49 -201.56 584.22 -1311.59, 908.46 -0.070 -0.37, 0.25 -68.36 595.14 
-1199.12, 
1062.40 -0.000 -0.31, 0.31 
Basal  
Reverse Peak 
Circumferential Strain, % 
-14.1 
 3.78 4.28 
4.35, 
11.91 - 0.3 -0.31, 0.31 6.04 3.83 
-1.23, 
13.31 0.340 0.032, 0.587   
Basal  
Peak Circumferential 
Strain Rate, %/s 
68.71 -34.51 41.25 -112.89, 43.86 0.036 -0.34, 0.28 -71.06 56.92 
-179.21, 





-74.00 36.30 29.38 -19.51, 92.12 
-0.190 
 -0.47, 0.13 95.35 59.03 
-16.81, 
207.52 -0.487 -0.692, 0.208 
2-chamber  
Peak Radial Strain, % 24.25 -11.77 18.49 
-46.91, 
23.36 -0.230 -0.51, 0.10 -1.38 11.63 
-23.48, 
20.72 0.324 0.002, 0.586 
2-chamber  
Peak Radial Strain Rate, 
%/s 
161.89 -2.74 97.48 -187.96, 182.48 -0.027 -0.35, 0.30 3.00 70.04 
130.07, 
136.07 0.346 0.028, 0.602 
2-chamber 
Reverse Peak Radial 
Strain Rate, %/s 
-148.09 -0.16 66.52 -126.55 126.24 0.370 0.06,  0.62 17.62 60.67 
-97.66, 
132.90 0.589 0.33, 0.766 





Longitudinal Strain, % 
9.12 6.81 
2-chamber  
Peak Longitudinal Strain 
Rate, %/s 
56.45 -25.94 30.26 -83.43, 31.55 0.146 
-0.185, 
0.448 -40.67 30.93 
-99.44, 
18.10 0.020 -3.04, 0.34 
2-chamber  
Reverse Peak 
Longitudinal Strain Rate, 
%/s 
-70.45 19.82 26.81 -31.11, 70.76 -0.031 -0.35, 0.30 20.64 24.64 
-26.17, 
67.46 0.210 -0.12, 0.499 
4-chamber  







Peak Radial Strain Rate, 
%/s 
147.20 10.83 108.79 -195.87, 217.52 -0.205 -0.50, 0.14 -59.15 139.27 
-323.77, 
205.46 0.148 -0.456, 0.194 
4-chamber  
Reverse Peak Radial 
Strain Rate, %/s 
-123.55 -0.94  60.28 
-115.47, 
113.58 0.052 0.28, 0.38 45.05 92.72 
-131.13, 
221.22 -0.215 -0.509, 0.127 
4-chamber   
Reverse Peak 
Longitudinal Strain, % 




 0.112, 0.665 
4-chamber  
Peak Longitudinal Strain 
Rate, %/s 
62.61 -18.81 28.80 -73.54, 35.90 0.309 -0.02, 0.58 -52.26 127.33 
-294.19, 
189.67 -0.051 0.375, 0.286 
4-chamber Reverse 
Peak Longitudinal Strain 
Rate, %/s 
-77.43 -2.19 25.57 -50.78, 46.40 0.192 -0.15, 0.49 46.67 109.70 
-161.76, 
255.11 0.044 -0.291, 0.371 
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Section two 
Exclusion criteria for the randomised controlled trial detailed in Chapter 8 
Subjects meeting any of the following criteria were not be enrolled in the study: 
1. Pregnancy: Women who are pregnant or lactating.  
2. Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior 
history of asthma are eligible if they also have a current diagnosis of COPD).  
3. α1-antitrypsin deficiency: Subjects with known α-1 antitrypsin deficiency as 
the underlying cause of COPD  
4. Other respiratory disorders: Subjects with active tuberculosis or lung cancer 
as well as clinically significant bronchiectasis, sarcoidosis, pulmonary fibrosis, 
interstitial lung diseases or other active pulmonary diseases. Pulmonary 
hypertension from causes other than COPD.  
5. Lung resection or transplantation: Subjects with lung volume reduction 
surgery within the 12 months prior to Screening or having had a lung 
transplant or pneumonectomy.  
6. A moderate/severe COPD exacerbation that has not resolved at least 14 
days prior to screening and at least 30 days following the last dose of oral 
corticosteroids (if applicable).  
7. Lower respiratory tract infection: Subjects with lower respiratory tract infection 
that required the use of antibiotics within 30 days prior to screening.  
8. Pulmonary Rehabilitation: Patients to be excluded if they have been in the 
acute phase of pulmonary rehabilitation in the 4 weeks prior to screening  
9. Current severe heart failure (New York Heart Association class IV). Subjects 
will also be excluded if they have a known ejection fraction of <30%.  
10. Abnormal and clinically significant 12-lead ECG  
11. Other systemic inflammatory conditions associated with chronic inflammation 
in the opinion of the investigator (e.g. rheumatoid arthritis, connective tissue 
disorders and Inflammatory Bowel Disease)  
12. Other significant diseases / abnormalities: Any life-threatening condition with 
life expectancy <1 year, other than vascular disease or COPD, that might 
prevent the subject from completing the study.  
13. Coronary Artery Bypass Grafting (CABG) in the 6months prior to screening.  
14. Myocardial infarction, cerebrovascular event or coronary artery intervention 
other than CABG in the 1 month prior to screening.  
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15. History of malignancy within the past 5years, other than non-melanoma skin 
cancer.  
16. End stage chronic renal disease: Subjects will be excluded if on renal 
replacement therapy (haemodialysis or peritoneal).  
17. Drug/food allergy: Subjects with a history of hypersensitivity to any of the 
study medications (e.g. beta-agonists, corticosteroid) or components of the 
inhalation powder (e.g. lactose, magnesium stearate). In addition, patients 
with a history of severe milk protein allergy that, in the opinion of the study 
physician, contraindicates the subject’s participation will also be excluded.  
18. Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or 
drug abuse within the last 2 years.  
19. Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy 
(LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. 
Oxygen should not be initiated during the trial.  
20. Questionable validity of consent:  Subjects with a history of psychiatric 
disease, intellectual deficiency, poor motivation or other conditions that will 
limit the validity of informed consent to participate in the study or the potential 
compliance to study procedures.  
21. Additional medication: Use of an investigational device or investigational drug 
within 30 days or 5 half-lives (whichever is longer) preceding the first dose of 
study medication.  
22. Use of the following medications is not permitted within the following time 
frames 
• Depot corticosteroids:  12 weeks 
• *Cytochrome P450 3A4 strong inhibitors including but not limited to 
antiretrovirals (protease inhibitors) (e.g., indinavir, nelfinavir, ritonavir, 
saquinavir, atazanavir); imidazole and triazole anti- fungals (e.g., 
ketaconazole, itraconazole, voriconazole); clarithromycin, telithromycin, 
troleandomycin, mibefradil, cyclosporin, nefazodone: 6 weeks 
• Grapefruit is allowed up to Visit 1, then limited to no more than one glass of 
grapefruit juice (250 mL/8 ounces) or one grapefruit per day 
• Systemic, oral, parenteral (intra-articular) corticosteroids: 30 days 
• Antibiotics: 30 days 
• Inhaled corticosteroids:  2 weeks 
• Inhaled ICS/LABA combination products:  2 weeks 
• Long-acting anticholinergics (e.g., tiotropium): 4 days 
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• PDE-4 inhibitors (e.g., roflumilast): 1 week 
• Oral leukotriene inhibitors (e.g., zafirlukast, montelukast, zileuton):  48 hours 
• Inhaled long acting β2-agonists (e.g., salmeterol):  48 hours 
• Oral beta-agonists: 48 hours 
• Inhaled sodium cromoglycate or nedocromil sodium: 24 hours 
• Ipratropium/albuterol (salbutamol) combination product:  6 hours 
• Oral Theophylline preparations 48 hours 
• Short-acting anti-cholinergics (e.g., ipratropium bromide):  6 hours 
(ipratropium will be supplied for rescue) during the study, in inhaled or 
nebulized form) 
• Inhaled short-acting β2-agonists:  6 hours (albuterol/salbutamol was supplied 
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